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Abstract 
 
Acute Myeloid Leukaemia (AML) and Multiple Myeloma (MM) are currently 
incurable malignancies which have devastating effects on patients who develop 
them. Chemotherapeutic regimens have remained largely unchanged over recent 
decades, it is therefore apparent that there is a need for novel therapeutic 
interventions. It is thought that these new treatments will come to fruition through 
a better understanding of the biological processes which underpin these 
diseases. Cancer cells have classically been thought to generate ATP through 
the non-mitochondrial based Warburg hypothesis, however it is becoming 
apparent that malignant cells are equally reliant on mitochondrial oxidative 
phosphorylation to fuel their rapid proliferation. Mitochondria were thought to 
remain in their somatic cell for their lifetime; however, ground-breaking research 
from the Gerdes laboratory has shown that mitochondria can move between 
somatic cells. In my thesis, I aimed to examine whether mitochondria were 
transferred between non-malignant bone marrow stromal cells (BMSC) and 
AML/MM cells. 
 
Mitochondria were shown to move from BMSC to AML blasts and MM cells, this 
process enhanced the proliferation of these malignancies. AML-derived NOX2 
superoxide was shown to stimulate mitochondrial biogenesis in BMSC, allowing 
mitochondria to move to AML blasts through tunnelling nanotubes. In the MM, it 
was found that CD38 expression on MM cells was able to form tunnelling 
nanotubes which facilitated the trafficking of mitochondria. Inhibition of NOX2 and 
CD38, in AML and MM respectively, reduced disease progression in vivo in part 
by reducing the quantity of mitochondria which move to the malignant cell.  
Furthermore, it was shown that AML/MM hijack this process from normal 
haematopoiesis as mitochondria move in vivo to haematopoietic stem cells in 
response to bacterial infection. Taken together I have presented a novel biological 
process in haematopoietic malignancies, which may be exploited to treat AML 
and MM. 
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MFI - Mean fluorescence intensity 
MGUS - Monoclonal gammopathy of unknown significance 
MIF - Macrophage inhibitory factor 
Miro1 - Mitochondrial Rho-GTPase  
MM - Multiple myeloma 
MMP-2 - Metalloproteinase-2  
MOI - Multiplicity of infection 
MPP - Multipotent progenitor 
MSC - Mesenchymal stem cells 
mtDNA - Mitochondrial DNA 
MYH - Myosin heavy chain gene 
NAC - N-Acetyl Cysteine 
NAD+ - Nicotinamide adenine dinucleotide 
NFκB - Nuclear factor-κB  
NGS - Next generation sequencing  
NK Cell - Natural killer cell 
NKP - Natural killer cell progenitor 
NNUH - Norfolk and Norwich University Hospital 
NOX2 - NADPH oxidase 2 
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NPM1 - Nucleophosmin 1 
NSG - NOD SCID Gamma 
OCR - Oxygen consumption rate 
OXPHOS - Oxidative phosphorylation 
PBS - Phosphate buffered saline 
PCL - Plasma cell leukaemia 
pCMV - Cytomegalovirus promoter 
PDK1 - Phosphoinositide-dependent kinase 1  
PGC-1α - Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PIP3 - Phosphatidylinositol-3,4,5-triphosphate  
PPR - PTH/PTH-related receptor  
PVDF - Polyvinyladine fluoride  
qRT -PCR - Quantitative real time polymerase chain reaction 
RANK - Receptor activator of nuclear factor κ-B  
RANKL -Receptor activator of nuclear factor κ-B ligand 
RIPA - Radioimmunoprecipitation assay  
RISC - RNA-induced silencing complex 
RNA - Ribose Nucleic Acid 
ROS - Reactive oxygen species 
RT- Room temperature 
RTK - Receptor tyrosine kinase 
SCF - Stem cell factor 
SCID - Severe combined immunodeficient  
shRNA - short hairpin RNA 
SMM - Smoldering MM 
SNP - Single nucleotide polymorphism 
ST-HSC - Short Term haematopoietic stem cell 
TAE - Tris acetate EDTA 
TAP - TNT-anchor point  
TCA cycle – Tricarboxylic acid cycle 
TCR - T cell receptor 
TET2 - Ten-eleven translocation oncogene family member 2  
TNT - Tunneling nanotube 
TSP - Thymus-seeding progenitor  
VCAM-1 - Vascular cell adhesion molecule 1  
VEGF - Vascular endothelial growth factor 
VIC - 2′-chloro-7′phenyl-1,4-dichloro-6-carboxy-fluorescein  
VSV-G - Vesicular stomatitis virus glycoprotein  
WHO - World Health Organisation 
5hmC – 5-hydroxymethylcytosine 
5mc - 5-methylcytosine  
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1 Introduction 
 
1.1 Haematopoiesis  
 
To understand haematopoietic malignancies such as Acute Myeloid Leukaemia 
(AML) and Multiple Myeloma (MM), it is of paramount importance to explore the 
development of normal blood cells. Haematopoiesis is a complex process which 
generates blood cells within the bone marrow (1). The blood is a highly 
regenerative tissue with approximately 1 x 106 mature blood cells generated every 
second (2). Haematopoiesis initiates from a pluripotent stem cell, the 
haematopoietic stem cell (HSC) (3). Despite its complexity, extensive animal 
experimentation means that haematopoiesis is the one of the best understood 
and described processes within the human body (4). Pioneering work by Till, 
McCulloch and colleagues in the 1960s paved the way for the discovery of the 
HSC (5). Mice treated with a lethal dose of irradiation, were rescued from death 
via the transplantation of bone marrow cells from a non-radiated mouse. 
Interestingly, small splenic lumps were observed in the irradiated mice following 
transplantation (6). Extensive analysis determined these colonies were formed 
from a single cell, capable of multi-lineage differentiation (7). The specific isolation 
of HSCs and other blood progenitor cells, using specific surface markers, allowed 
the complex hierarchical structure of haematopoiesis to be elucidated (8). In this 
system, mature blood cells are generated from a specific lineage multipotent 
progenitor cell which, in turn, have been derived from HSCs (9). Figure 1.1 
highlights the hierarchical structure of haematopoiesis which is further described 
below. 
 
1.1.1 Haematopoietic Stem Cell (HSCs) 
 
The work by Till and McCulloch demonstrated a single cell type had the ability to 
differentiate into and re-constitute all cells within the bone marrow (5, 7, 10). This 
cell was termed the HSC, a pluripotent stem cell with the ability to self-renew (9). 
Under basal conditions the number of HSCs remains relatively constant with the 
majority of cells residing in the G0 phase of the cell cycle (11). The HSC is a very 
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rare cell type - early studies that purified HSCs from mice found that only 0.05% 
of the total BM cells were HSCs (12, 13). These HSCs were isolated by the then 
relatively new technology fluorescence-activated cell sorting (FACS) using 
monoclonal antibodies, which revolutionised the field. Early HSCs were sorted 
using two surface markers; Thy-1low lineage marker (Lin) and Sca-1, with HSCs 
being Lin- and Sca-1+ (12, 13). These Lin-Sca-1+ HSCs were the only cells found 
to re-populate the entire haematopoietic system of irradiated mice (13), with 
Lin+Sca-1+ and Lin-Sca-1- cells unable to re-populate the bone marrow (14). More 
extensive purification, using additional surface markers CD117/c-Kit and CD34, 
highlighted that the HSC population isolated by Spangrude and colleagues (13) 
contained at least 3 multipotent populations; long term HSCs (LT-HSCs), short 
term HSCs (ST-HSCs) and multipotent progenitors (MPPs) (15). Through the use 
of additional surface markers, CD150 and CD48, these populations are now well 
defined (16).  
 
LT-HSCs are pluripotent and can undergo asymmetric cell division, differentiating 
into ST-HSCs in addition to self-renewing and maintaining the pool of HSC (17). 
ST-HSCs are multipotent and can differentiate into MPPs, which produce the 
common myeloid and lymphoid progenitors (see section 1.1.2 and 1.1.3). LT-
HSCs are able to sustain haematopoiesis for more than 11 months, compared to 
the relatively short time of 6-10 weeks of ST-HSCs (18).  
 
Mouse models have been critical in the evolution of our understanding of the 
human haematopoietic system. The development of mice lacking mature T and 
B cells has allowed the creation of xenograft models that incorporate human 
haematopoietic cells, which can specifically analyse human haematopoiesis in 
vivo (19). Using this model, it was found that human peripheral blood leukocytes 
were able to generate human T and B cells (20). More recently the specific 
transplantation of HSCs isolated from umbilical cord blood, into a modified SCID 
NOD-SCID-Gamma (NSG) mouse, has been used for the analysis of human 
haematopoiesis (21). Engraftment of human CD45+ cells was found in the bone 
marrow and spleen, along with mature human blood cells in the peripheral blood 
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(22). These experiments have resulted in the well understood hierarchical system 
of haematopoiesis (Figure 1.1). 
 
 
 
Figure 1.1. A schematic overview of the hierarchical system of haematopoiesis. 
The process of haematopoiesis starts with the pluripotent LT-HSC which differentiates into the 
ST-HSC whilst self-renewing to maintain the HSC pool. The ST-HSC then differentiates into the 
MPP, which gives rise to the CMP and CLP starting the myeloid and lymphoid lineages. Through 
a number of intermediate progenitors, the wide range of mature blood cells are generated. This 
figure is modified from Marlein and Rushworth 2017 (18). 
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1.1.2 Myeloid Lineage 
 
Haematopoiesis diverges into two distinct cell lineages; the myeloid and lymphoid 
lineages (23). The MPP has the ability to differentiate into either the common 
lymphoid progenitor (CLP) or the common myeloid progenitor (CMP), which is the 
first cell of the myeloid lineage and is capable to generating all of the cells that 
make up this lineage (24). The immediate differentiation step of the CMP is to 
create either the megakaryocyte-erythroid progenitor (MEP) or the granulocyte-
erythroid progenitor (GMP) (25). Through a range of intermediates, the GMP can 
generate basophils, neutrophils, eosinophils and macrophages via monocytes 
whereas the MEP can generate erythrocytes (red blood cells) and thrombocytes 
(platelets) (25).  There has also been recent evidence suggesting there is a 
progenitor, separate to the CMP/CLP lineage, which lacks the ability to generate 
cells of the MEP lineage (26).  
 
There are a number of different transcriptional regulators which cause the 
commitment to either the GMP or MEP lineage. For commitment to the GMP fate, 
the transcription factor CCAAT/enhancer-binding protein (C/EBPα) is crucial (27). 
HSCs express low levels of C/EBPα but levels increase upon differentiation of 
CMPs to GMPs (27). Artificially expressing C/EBPα in B cells of the lymphoid 
lineage causes them to differentiate into monocytes of the myeloid lineage (28), 
highlighting that this transcription factor is crucial for generation of cells 
downstream of the GMP. In addition, when C/EBPα is conditionally removed from 
mice, these mice lack the ability to generate GMPs from CMPs (29).   
 
There is also a key transcription factor involved in commitment of the CMP to the 
MEP lineage, this transcriptional factor is GATA-1 (30). Again GATA-1 expression 
levels are low in HSCs, with higher expression found in MEP and erythroid 
precursors. The importance of this transcription factor has been shown in mice 
lacking GATA-1, where these mice are unable to generate mature red blood cells 
(31). 
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1.1.3 Lymphoid Lineage 
 
As well differentiating into the CMP, MPPs also have the ability to generate the 
CLP. The CLP can then differentiate into the T cell, B cell and natural killer (NK) 
progenitor cells, which in turn creates mature T cells, B cells and NK cells (32). 
Mature T and B cells form the adaptive immune response (33, 34) whilst NK cells 
contribute to the innate immune system (35). T and B cells acquire a single 
antigen specific receptor through somatic DNA re-arrangements of T Cell 
Receptor (TCR) and Ig genes, creating a vast repertoire capability of recognising 
a wide range of antigens (36). Expression of the IL-7 receptor is critical for the 
commitment to the lymphoid lineage (37).  
 
The majority of B cell maturation takes place within the bone marrow, originating 
from the B cell progenitor which is irreversibly committed to the B cell lineage 
(38). Initiation of B-cell development requires two key transcription factors; E2A 
and early B cell factor (EBF). In the absence of either of these transcription 
factors, B cell development is arrested at the first stage of development (39, 40). 
On their surface, mature B cells have a specific B cell receptor (BCR) which is 
comprised of two heavy chains and two light chains (41). This receptor is capable 
of binding to specific antigens generating an immune response. The key step in 
creating this receptor is the re-arrangement of the heavy chain upon the activation 
of recombination-activating genes, which occurs between the pre-pro B cell and 
pro-B cell stage (42). Upon the generation of the late pre-B cell the light chain of 
the BCR is rearranged (V to J), if the resulting joints are in a continuous open 
reading frame the rearrangement is classed as “productive” (43).  
 
A fully functional follicular B cell (FoB) is made after a negative selection process, 
to remove autoreactive B cells (44). These cells can then migrate from the bone 
marrow to join the pool of circulating B cells. Upon activation by a foreign antigen, 
the FoB cell differentiates into an effector plasma cell which secretes specific 
antibodies to eliminate pathogens. Memory B cells are also created upon FoB cell 
activation, for use in subsequent exposure to the same antigen (45).  
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Contrary to B cell maturation, only a limited part of the T cell maturation occurs 
within the bone marrow with T cell progenitors migrating to the thymus for 
maturation (46). Bone marrow-derived thymus-seeding progenitors (TSPs), 
which include MPPs and CLPs (47), migrate to the thymus to differentiate into 
mature CD4+ (helper) and CD8+ (cytotoxic) T cells capable of mounting an 
immune response to pathogens. The number of TSPs in the peripheral blood is 
relatively small, with less than a total of 1000 found in the peripheral blood of mice 
(48).  
 
TSPs enter the thymus and differentiate into double negative cells (CD4-CD8-), 
which in turn generate double positive (CD4+CD8+) cells (49). After the re-
arrangement of the α and β chains of the TCR the double positive cells become 
single positive cells (either CD4+ or CD8+), which enter the cortex of the thymus 
for positive selection (50). Here single positive cells are selected on their ability 
to engage host MHC complexes (51). Upon the successful completion of positive 
selection, the single positive cells move to the medulla of thymus to undergo 
negative selection - here cells that recognise self-antigens are eliminated (52). A 
critical signalling pathway in the development of T cells is the Notch1 signalling 
pathway, activated by ligands of the Jagged family (53). Ectopic expression of the 
intracellular domain of the Notch1 receptor in haematopoetic progenitors resulted 
in T cell maturation in the bone marrow, which completely blocked B cell 
development (54).  
 
Unlike B and T cell development, NK cell development does not include the 
somatic rearrangement of genes encoding for antigen specific receptors. This is 
mainly due to their role in the innate immune whereby they secrete IFNγ and 
TNFα, rather than adaptive antigen sensing (55). The pre-NKP (natural killer 
progenitor) is the first committed cell to this lineage and IL-15 is crucial in the 
formation of this cell from the CLP (56). A key process in the maturation of the 
NK cell is the acquisition of CD56 and CD16 (57) along with the S1P5 receptor, 
which allows egress of the mature NK cell from the bone marrow (58).   
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1.2 Bone Marrow  
 
The bone marrow is the site of the majority of steps in haematopoiesis, whilst also 
being the location where malignant haematopoietic cells proliferate and 
accumulate. Therefore, it is important to discuss the anatomy and the complex 
microenvironment within the bone marrow. 
 
1.2.1 Bone Marrow Anatomy  
 
Human bone is composed of trabecular bone surrounded by a layer of cortical 
bone and a range of connective tissues (59), as shown in Figure 1.2. The 
trabecular bone is made up of four regions (endosteal, subendosteal, central and 
perisinusoidal) and is made up of a lattice filled with blood vessels, along with red 
and yellow bone marrow (60). In haematopoiesis, the most important region of 
trabecular bone region is the endosteal as it forms the point of contact between 
the bone marrow and bone (61). This region contains a range of non-
haematopoietic cells that are involved in the maintenance and regulation of both 
normal and malignant blood cell development (62). In addition, within the 
endosteal there are thin-walled blood vessels called sinusoids whose role is to 
aid blood cell migration away from the bone marrow (63).  
 
The bone marrow is made up of both haematopoietic red marrow and the fatty 
non-haematopoietic yellow marrow (64). All bone marrow at birth is composed of 
red marrow and is converted slowly to yellow marrow as we age. However, yellow 
marrow has been shown to be able to revert back to red marrow under certain 
stress stimuli such as severe blood loss (65). Red marrow contains the 
parenchyma, the location of haematopoietic stem cells and resultant progenitors, 
and the vascular component which comprises of supporting stromal cells (59). 
The yellow marrow is made up of fat cells, which serve as the energy reserve and 
can be used in times of severe starvation (66). 
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Figure 1.2. Schematic representation of the structure of the human bone. 
Human bone is made up of three regions; the epiphysis, metaphysis and diaphysis. Each region 
contains trabecular bone surrounded by cortical bone. The bone marrow is located within hollow 
regions of the trabecular bone, with the endosteum forming the divide between bone and bone 
marrow. Adapted from Marlein and Rushworth (18). 
 
 
1.2.2 Bone Marrow Microenvironment 
 
The expansion and differentiation of the HSC population occurs within a well-
controlled environment containing a number of different cell types and secretory 
molecules (62). Through the 3D imaging of mouse bone marrow, it was seen that 
there were high concentrations of HSCs in specific micro-domains or “niches” 
(67). The vascular component of the red bone marrow contains a vast array of 
stromal cells, which are present in HSC niches. These stromal cells arise from a 
multipotent stem cell, the bone marrow mesenchymal stem cell (BM-MSC), which 
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has the ability to differentiate into adipocytes, chondrocytes, osteoblasts, 
endothelial cells and myocytes (68, 69). The differentiation hierarchy of the BM-
MSC is schematically represented in Figure 1.3.  
 
There is still great debate as to the actual identity of BM-MSCs within the bone 
marrow. In 2006, the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy introduced a minimum criteria for the 
identification of BM-MSCs using cell surface marker expression. Under these 
guidelines, BM-MSCs must be positive for CD73, CD90 and CD105 whilst being 
negative for CD31, CD34 and CD45 (70). These criteria are not perfect in defining 
BM-MSCs (due to the difficulty in reliably characterizing the stemness of 
populations expressing the above surface markers (71)), however these 
parameters are utilized in my thesis to define the BM-MSC stromal population. 
The aim was to isolate the BM-MSC population from human bone marrow 
aspirates, however during in vitro culture the BM-MSC may differentiate into early 
multipotent progenitors. Therefore, I define the heterogeneous “stromal” 
population used in this study as bone marrow stromal cells (BMSC) (Figure 1.3). 
 
 
Figure 1.3. The vascular (stromal) component of the red bone marrow. 
BM-MSC have the ability to differentiate into osteoblasts, endothelial cells, chondrocytes, 
adipocytes and myocytes via intermediate mesenchymal stromal cells. BM-MSC were isolated 
from human bone marrow aspirates for this study, however during culture it is likely that this cell 
will differentiate. Therefore, the heterogeneous “stromal” cell population used in my thesis are 
defined as bone marrow stromal cells (BMSC). 
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1.2.3 Bone Marrow Stromal Cells (BMSC) 
 
Bone marrow stromal cells (BMSC) encompass the BM-MSC and early 
multipotent progenitors prior to mature differentiation. BMSC line the sinusoids 
within the endosteal region of the trabecular bone (72) and provide cytokines and 
chemokines that are required for the maintenance of the HSC pool (62). One such 
chemokine, CXCL12 (or SDF-1), stimulates the attraction and retention of HSCs 
within the niche via its CXCR4 receptor (73). Deletion of CXCL12 in BMSC (74), 
or CXCR4 on HSCs (75), can result in a drastic loss of HSC numbers within bone 
marrow niches - highlighting the crucial role of this chemokine in HSC 
maintenance. Recently, it has been found that circadian oscillations can control 
the secretion of CXCL12 by BMSC (76). In this study, noradrenaline was released 
by sympathetic nerve fibres, causing BMSC to downregulate their CXCL12 
secretion and results in HSC egress from the bone marrow.  
 
Another key cytokine in the regulation of the HSC niche is stem cell factor (SCF), 
which again is produced by BMSC (77). SCF has both membrane-bound and 
soluble forms which bind to the receptor tyrosine kinase c-KIT (CD117) on HSCs, 
regulating maintenance and proliferation (78, 79). The membrane-bound form is 
crucial in maintaining haematopoiesis, as mice which only express the soluble 
form (Sl/Sld mutant mice) are completely devoid of HSCs and resultant 
downstream haematopoietic cells (80). 
 
Recently, three distinct populations of highly CXCL12-expressing perivascular 
BMSC have been identified; CXCL12-abundant reticular (CAR) cells, nestin-
GFP+ stromal cells and leptin receptor+ stromal cells (77). These populations 
were identified by transgene expression using stromal promoters; GFP was 
knocked into the CXCL12 locus and the Nestin promoter to identify CAR cells and 
nestin-GFP+ stromal cells respectively (81, 82). The Leptin receptor+ stromal cells 
were identified using lineage mapping using Cre-recombinase expressed under 
the control of leptin receptor elements (83). CAR cells are mesenchymal 
progenitors which have the ability to differentiate into adipocytes and osteoblasts, 
removal of these cells results in depleted HSC numbers associated with a 
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reduction of CXCL12 and SCF levels (84). Nestin-GFP+ cells express CXCL12 
and SCF at comparable levels, however, a reduction in these cells only caused a 
modest loss of HSC numbers (77). Finally, leptin receptor+ stromal cells also 
express CXCL12 and SCF whilst having the ability to differentiate into adipocytes, 
but lack the ability of osteoblastic differentiation (84). It is apparent that these 3 
distinct stromal cells types have commonalities, especially in SCF and CXCL12 
expression, therefore it is still widely accepted to class these distinct populations 
as BMSC. 
 
1.2.4 Osteoblasts 
 
BMSC have the ability to differentiate into bone forming osteoblasts (85). This 
differentiation process is controlled by the transcription factor Runx2 and is 
achieved through a pro-osteoblast intermediate (86). Heterozygous and 
homozygous Runx2 knockout mice have severely disrupted osteogenesis, with 
homozygous knockout animals dying at birth (87). Mature osteoblasts undergo a 
three-step process; proliferation, matrix maturation and mineralisation which 
results in the formation of bone (88).  
 
Like BMSC, there is evidence that osteoblasts contribute to the regulation of 
proliferation of HSCs. This was initially proposed after analysing the proximity of 
HSCs and mature haematopoietic progenitors to osteoblasts - HSCs were found 
close to osteoblasts with mature progenitors positioned further away (89). 
Conditional knockout of osteoblasts within the bone marrow resulted in the 
inability of the bone marrow to support normal haematopoiesis (90, 91). In a later 
study, the number of osteoblasts was increased through genetic manipulation of 
the PTH/PTH-related receptor (PPR) which is located on osteoblasts themselves 
(92). It was found that the increase in osteoblast number resulted in secretion of 
high levels of Notch ligand jagged 1. This caused an expansion of the HSC 
population within the bone marrow and this process can be reversed with the 
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administration of a γ-secretase inhibitor. Osteoblasts can also secrete CXCL12, 
albeit 1000-fold less than BMSC, but they lack the ability to secrete SCF (93). 
 
1.2.5 Bone Marrow Endothelial cells 
 
BMSC can differentiate into bone marrow endothelial cells, which also regulate 
the trafficking and homing of HSCs (94). Early studies using a conditional deletion 
of the gp130 receptor on endothelial cells resulted in a reduction of HSC numbers 
in bone marrow HSC niches (95). Like BMSC and osteoblasts, endothelial cells 
secrete CXCL12 – however this is at a level 100-fold less than BMSC and 10-fold 
greater than osteoblasts (96). Stimulation of endothelial cells with IL-1 or TNFα 
results in the production of cytokines (including G-CSF, GM-CSF and IL-6) that 
are crucial in the maintenance of the HSC pool (97). Endothelial cells also express 
the vascular cell adhesion molecule 1 (VCAM-1) (98) which binds to VLA-4 on 
HSC, enabling HSC retention within preferable bone marrow niches. 
Furthermore, endothelial cells synthesise soluble and membrane bound forms of 
SCF - knockout of this factor results a depletion of HSC numbers (83). 
 
1.2.6 Adipocytes 
 
Adipocytes present within the bone marrow also originate from BMSC and form 
marrow adipose tissue (MAT) (99). These cells make up approximately 15% of 
the bone marrow and are shown to increase in number during aging, reaching up 
to 60% by the age of 65 (100). Differentiation of adipocytes from BMSC is an 
intricate process controlled mainly by the PPARγ transcription factor (101) - 
PPARγ knockout mice were shown to lack terminally differentiated adipose tissue 
(102). In addition, the C/EBPα transcription factor is crucial in forming adipocytes 
with C/EBPα knockout mice lacking the ability to generate MAT (103). Adipocytes 
have been shown to produce and secrete SCF (104) whilst having the ability to 
produce CXCL12, IL-8 and IL-3 (105); which contributes significantly to the 
maintenance of the HSC niche.  
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1.2.7 Chondrocytes and Myocytes 
 
Another cell type which is formed from the differentiation of BMSC are 
chondrocytes, which in turn forms cartilage (106). Chondrocytes are metabolically 
active and can generate large quantities of extra cellular matrix (ECM) 
components including collagen, proteoglycans and glycoproteins. A major 
transcription factor involved in the generation of chondrocytes is Sox9, 
inactivation results in failure of chondrocyte differentiation (107). There is very 
little evidence to suggest that chondrocytes are involved in the maintenance of 
the HSC pool within the bone marrow, however downstream ECM components 
generated by chondrocytes make up key parts of the HSC niche.  
 
Myocytes form muscle tissue and are also formed by differentiation of BMSC - 
under the control of the transcription factor MyoD (108). As with chondrocytes, 
myocytes do not readily contribute to the maintenance of the HSC niche.  
 
1.2.8 Osteoclasts 
 
Although not part of the BMSC differentiation cascade, osteoclasts are a very 
important component of the bone marrow microenvironment. The process of bone 
formation is a highly dynamic remodeling process involving bone forming 
osteoblasts (see 1.2.4) and bone resorbing osteoclasts (109). Osteoclasts are 
generated in the haematopoietic component of the bone marrow from the GMP 
in the myeloid lineage (110).  Two haematopoietic factors are required for the 
formation of osteoclasts, the cytokine RANKL and CSF-1 (111).  Osteoclasts are 
crucial in generating the HSC niche; functional niches are not present in oc/oc 
mice (which lack osteoclasts) due to defects in HSC homing (112). Reduced 
osteoblasts are present in oc/oc mice, therefore the role of osteoclasts in HSC 
maintenance is likely to be indirectly through osteoblasts. Soluble and membrane 
forms of SCF are not synthesised by osteoclasts and only small quantities of 
CXCL12 are secreted.     
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1.2.9 Non-malignant Bone Marrow Disorders 
 
As with any other organ in the body errors can occur in the bone marrow which 
lead to disorders with varying degrees of severity. As haematopoiesis is the major 
process which occurs within the bone marrow, it is not surprising that the majority 
of non-malignant and malignant disorders arise from defects in this process.  
 
The most common non-malignant disorder of the bone marrow in which medical 
treatment is sought is anaemia. Anaemia is characterised by the reduction of 
functional erythrocytes in the bone marrow and peripheral blood, or by a decrease 
in the amount of haemoglobin in the erythrocyte (113). Errors in erythrocyte 
production or reduced functionality of haemoglobin synthesis can ultimately 
impact the ability of the blood to transport oxygen - the major symptom of anemia. 
Iron deficiency anaemia is a very common subtype which, as the name suggests, 
is caused by a lack of intake of iron in the diet (114). A more severe type of 
anaemia is aplastic anaemia where the bone marrow is unable to produce both 
functional red and white blood cells in addition to platelets (115). Here mature 
immune cells attack HSCs which inhibits haematopoiesis and increases the 
number of fat cells.  
 
Another non-malignant disorder of the bone marrow that affects cellular 
homeostasis is myelodysplastic syndrome (MDS) - however in this case MDS 
causes an increase in the number of cells. This disorder results in the 
overproduction of myeloid cells resulting in cytopenia lowering the number and 
production of normal blood cells. This disorder can manifest into a far more severe 
malignant disorder, acute myeloid leukemia (AML), if not managed properly (116).  
 
1.2.10 Malignant Bone Marrow Disorders 
 
Although non-malignant disorders of the bone marrow have profound effects on 
individuals who suffer from them, they are very manageable in the clinic. 
However, malignant disorders of the bone marrow are by far more severe and 
are very difficult to treat by clinicians. There are multiple malignant disorders that 
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can arise in the bone marrow, whereby blood cells generated at various points 
can become cancerous and proliferate without control.  
 
Haematological cancers are classed into three groups; Leukaemia, Myeloma and 
Lymphoma (although lymphoma is not present in the bone marrow) (117). The 
incidence of these cancers can be seen in Figure 1.4. The term leukaemia can 
be further split into four sub-types; acute myeloid leukaemia (AML), chronic 
myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL) and chronic 
lymphoblastic leukaemia (CLL). As the names suggest AML and CML effect cells 
of the myeloid lineage and ALL and CLL effect the lymphoid lineage, with the fast 
progressing acute conditions being more severe than the slower chronic 
conditions. Leukaemia of the lymphoid lineage has a favourable survival outcome 
compared to leukaemia of myeloid lineage (118).  
 
Myeloma is a clonal chronic malignancy that specifically effects the plasma cell 
of the lymphoid lineage (119). Leukaemia and myeloma are liquid malignancies 
that are present within the bone marrow and peripheral blood, whereas lymphoma 
is a solid tumour which resides within the lymphatic system and comprises of 
lymphocytes. This malignancy can be split into Hodgkin and Non-Hodgkin 
lymphoma; Hodgkin lymphoma is characterised by the cancerous Reed-
Sternburg cells whilst Non-Hodgkin encompasses the remainder of lymphomas 
(120). My thesis is focused on AML and multiple myeloma and these 
malignancies will be discussed further in sections 1.3 and 1.4. 
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Figure 1.4. National Cancer Institute Incidence Statistics 2018. 
The estimated incidence of specific cancers in 2018 is presented as a percentage of total cancers 
diagnosed. (A) Shows an overview of all types of cancers diagnosed, of note haematological 
malignancies make up 10% of total cancers diagnosed. (B) Shows a breakdown of the specific 
haematological subtypes. In relation to my thesis the most important values are that AML and 
Myeloma make up 12 and 18% of the haematological malignancies diagnosed in 2018. This data 
was accessed on August 2018 from the Surveillance, Epidemiology, and End Results Program 
statistics generated by the National Cancer Institute; https://seer.cancer.gov/statfacts/. 
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1.3 Acute Myeloid Leukaemia (AML) 
 
1.3.1 Overview of AML 
 
AML is an aggressive neoplasm characterised by the accumulation of immature 
haematopoietic myeloid progenitor cells (blasts) in the bone marrow (121). These 
blasts increase their proliferative rate whilst halting their differentiation capacity. 
AML disease is maintained by a small pool of leukaemic stem cells (LSCs), which 
have the ability to survive chemotherapy and cause disease relapse (minimal 
residual disease) (122). AML is a very heterogeneous disease due to the fact that 
there are multiple differentiation points down the myeloid lineage (from CMP to 
mature myeloid cells) where the blast can arrest differentiation and start to 
proliferate. In addition, there are various chromosomal translocations present in 
AML (123). Therefore, specific subtypes of AML have been classified to aid 
diagnosis and treatment, these will be discussed in section 1.3.3.  
 
 
Figure 1.5. Comparison of new cases to deaths in Leukaemia and Myeloma. 
This figure shows the number of new US cases of leukaemia and myeloma compared to the 
number of deaths, highlighting the less treatable diseases. The lowest case/death ratio, which 
highlights poor prognosis, is AML followed by myeloma. The highest case/death ratio, showing 
good survival, is CML. This graph was generated from data from the Surveillance, Epidemiology, 
and End Results Program statistics, accessed August 2018; https://seer.cancer.gov/statfacts/. 
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AML is a disease of the elderly with the median age of patients at diagnosis being 
71 - it is very uncommon to be diagnosed in patients less than 45 years of age 
(124). The survival rate of patients with AML is poor, with only 27.4% of patients 
surviving 5 years post diagnosis (125). In addition, the number of US deaths 
expected in 2018 (10670) compared to number of new cases (19520) is elevated 
compared to other leukaemias, this is shown graphically in Figure 1.5. The 
incidence of AML is higher in males, with 5.2 cases per 100,000 in men compared 
to 3.6 cases per 100,000 in women (125). It has also been reported that AML is 
more common in Caucasian populations compared to populations of African 
descent. The incidence of AML is lower in Asian populations followed by Hispanic 
and American Indian populations. The frequency of AML is increasing in 
developed countries such as the Canada and Australia (126), in addition to the 
UK where the number of AML cases has increased by 8% over the last decade 
(127). However, this increase is most likely due to a combination of an aging 
demographic and the development of more sophisticated detection techniques. 
Within the UK, AML incidence is more common in males living in deprived areas 
whereas there is no link in females (127).  
 
1.3.2 Symptoms, Diagnosis and Treatment 
  
Like any other disease, the symptoms of AML vary from patient to patient. A 
recent study compared a cohort of AML patients to determine the frequency of 
known AML symptoms. It was found that the most common symptom was fatigue 
followed by bruising, weakness, dizziness, shortness of breath and bleeding 
(128). Due to the un-specific nature of these symptoms there is a need for a 
diagnostic procedure to confirm the presence of AML.  
 
The initial procedure for diagnosing leukaemia used by clinicians is a blood test - 
where a high abnormal white blood cell count or very low blood count could 
indicate the presence of leukaemia (129). A bone marrow aspirate is then 
conducted where a small sample of bone marrow is taken from the patient and 
analysed for the presence and sub-type of leukaemia (130). Flow cytometry and 
Wright-Giesma staining are used to diagnose AML (131). AML blasts are myeloid 
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cells therefore they express the myeloid markers CD13 and CD33; secondly AML 
blasts have large nuclei with very little cytoplasm in addition to containing 
azurophilic granules, which can be determined using Wright-Giesma staining. To 
fully diagnose AML, greater than 20% of the total cells in the bone marrow must 
be AML blasts (132). Non-malignant MDS may be diagnosed if there are less than 
20% blasts in the bone marrow.  
 
The treatment of AML has not changed in over 40 years and involves an intense 
regime of chemotherapy, the primary goal is to induce remission where blast 
levels are reduced to less than 5% (133). This chemotherapy regimen is called 
7+3 and involves a continuous infusion of cytarabine (Ara-C) for 7 days, with an 
anthracycline such as daunorubicin given on days 1, 2 and 3 (134). There are 
variations in this procedure; at the Norfolk and Norwich University Hospital 
(NNUH) 10+3 is used, where Ara-C is given for 10 days with daunorubicin given 
at days 1, 3 and 5 (Information provided by Dr Charlotte Hellmich, NNUH 
Haematology Registrar). While over 70% of patients treated with intense 
chemotherapy enter remission, a number enter disease relapse (131). Therefore, 
there is a need for consolidation/curative therapy, which is most commonly an 
allogenic haematopoietic stem cell transplant (HSCT). In this process donor 
HSCs with the same human leukocyte antigen (HLA) are administered to AML 
patients after myeloablative conditioning of the bone marrow usually with 
cyclophosphamide (135). In this process, the patient’s bone marrow is ablated 
and replaced with the donors haematopoietic system, thereby reducing the 
chance of relapse. A side effect of this process is graft vs host disease (GVHD), 
whereby T cells differentiated from donor HSCs can attack non-haematopoietic 
host cells within the bone marrow. This can be managed using 
immunosuppressant medication such as cyclosporine (136), therefore HSCTs 
remain a common treatment regime in the treatment of AML. Autologous 
transplants are also used if an appropriate donor is not found, although this is 
rare. 
 
The current treatments of AML are highly aggressive and consequently they are 
not well tolerated by the elderly patients that generally develop AML and results 
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in the poor 5-year survival rate. Therefore, new research into the biology of the 
disease is needed to develop new treatments which are tolerable to the 
demographic of the disease, which may increase patient survival duration. 
 
1.3.3 Classification of AML 
 
As AML is a very heterogeneous disorder, the French-American-British (FAB) 
classification was developed in 1976 based on the type of cell which the 
leukaemia developed and the degree of maturity, with AML initially split into six 
subtypes (M0-M6) (137). Updates to this system were introduced in 1985 and 
1987, which added two more classifications the M7 and M0 respectively (138, 
139). Acute basophilic leukaemia was proposed as M9 in 1999, however this has 
not been widely accepted (140). Table 1.1 presents the FAB AML classification 
system. 
Table 1.1. FAB classification of AML. 
Data from (141). 
 
 
More recently (2002) the World Health Organization (WHO) proposed an 
alternate classification system, which could be more clinically useful and produce 
more meaningful prognostic information that the FAB system (142). This included 
4 major classifications of AML with specific subtypes located within these major 
classifications. An updated version of this classification was published in 2008 
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(143) and currently the WHO classifications are used interchangeably with FAB 
classifications. The current WHO classification of AML is presented in Table 1.2. 
 
Table 1.2. World Health Classification of AML. 
 
 
1.3.4 Molecular basis of AML 
 
Nonrandom cytogenetic chromosomal translocations have been identified in 
roughly 52% of total cases of AML and have long been considered the genetic 
events that drive the formation of the disease (144). The first chromosomal 
translocation identified was the t(8;21)(q22;q22), which fuses AML1 (RUNX1) on 
chromosome 8q22 with ETO (MTG8) on chromosome 21q22 (145). This 
alteration is one of the most frequent, found in approximately 6% of patients with 
AML (144), and forms the AML1-ETO protein which interferes with the tumour 
repressor p14(ARF) (146). Another common translocation that occurs in AML is 
the inv(16)(p13;q22) which fuses the myosin heavy chain (MYH) gene at 16p13 
with the core binding protein β (CBPβ) gene at 16q22 (147) - this fusion protein 
has been shown to impair neutrophil development (148). These two 
translocations have a good prognostic outcome, whereas translocations which 
involve the 11q23 (MLL) gene have poor prognosis (149). A specific example is 
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the t(9;11)(p22;q23), which produces the MLL-AF9 fusion protein resulting in 
aberrant transcription of MLL target genes (150). 
 
40-50% of diagnosed AML cases are deemed cytogenetically normal (CN) when 
assessed using conventional band analysis (151); therefore it is important to 
analyse the effect of alternate molecular events. With the advent of next 
generation sequencing (NGS) the genetic landscape of CN AML patients has 
been more clearly defined, leading to the discovery of mutations which contribute 
to AML disease progression. Each CN AML case is seen to have an average of 
13 mutations - 5 of which are driver mutations and 8 being random passenger 
mutations (152). Key driver mutations found in AML patients will be discussed in 
more detail below. 
 
The most common mutation in AML are mutations of Nucleophosmin 1 (NPM1), 
which occurs in between 25 and 30% of patients diagnosed with AML (153). 
These mutations result in the aberrant expression of the NPM1 protein in the 
cytoplasm (which usually resides in the nucleus) promoting myeloid proliferation 
and the development of AML (154). Patients with NPM1 mutations have a 
favourable prognosis due to the sensitivity of the AML blasts to intense 
chemotherapy (155). NPM1 mutations are often associated with other key 
mutations that are involved in the development and progression of AML, including 
DNA Methyltransferase 3A (DNMT3A), Fms-Like Tyrosine Kinase 3 (FLT3) and 
Isocitrate Dehydrogenase (IDH) mutations (156).  
 
Missense mutations affecting the arginine codon 882 of the DNMT3A gene are 
present in approximately 18 to 22% of AML cases and result in a defect in normal 
haematopoiesis and proper methylation (157). These mutations have recently 
been identified as pre-leukaemic mutations and are persistent at times of 
remission, therefore the prognostic outcome of these mutations is adverse (158). 
FLT3 was found in 1993 to be strongly expressed in haematopoietic cells and 
important for cell survival and proliferation (159). Internal tandem duplications 
(ITD) in the juxtamembrane domain of FLT3 are present within 20% of all AML 
cases and results in the constitutive activation FLT3 signaling promoting blast 
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proliferation (160). FLT3-ITD mutations have been associated with increased 
chance of relapse (161). Gain-of-function mutations of the IDH1/2 genes are 
oncogenic and result in the loss of normal enzyme function, creating a new ability 
of the enzyme to convert α-ketoglutarate into 2-hydroxyglutarate. Mutations of the 
highly conserved arginine residue at codon 132 in IDH1 and codon 140 of IDH2 
have been identified in around 15-20% of AML patients (162). IDH1/2 mutations 
are found more frequently in older patients and confer a poor overall survival 
(163).   
 
In addition to the most frequent mutations described, there are other mutations 
that are present in AML patients which contribute to disease progression. One of 
these is a mutation of the ten-eleven translocation oncogene family member 2 
(TET2), which is found to be mutated in around 9-13% of AML cases (164). TET2 
is an enzyme involved in DNA methylation where it converts 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC) in DNA; the role of loss of function 
mutations (in regard to overall AML patient survival) are not clear and still debated 
(165). The runt-related transcription factor (RUNX1 or AML1) is crucial in normal 
haematopoiesis and is frequently involved in the AML1-ETO chromosomal 
translocation leading to AML disease progression (166). In addition to 
chromosomal translocations, mutations of RUNX1 are present and are found in 
5-13% of AML cases and are found to be resistant to conventional induction 
chemotherapy regimens (167). Other mutations involving the CCAT enhancer 
binding protein α (CBPα), additional sex comb-like 1 (ASXL1) and p53 have also 
been described as driver mutations within AML cases (165).  
 
1.3.5 Key Signaling Pathways in AML 
 
Chromosomal translocations and genetic mutations (described in 1.3.4) can lead 
to the aberrant activation of key intracellular signaling pathways – resulting in 
leukaemogenesis. In addition, the overexpression of key secretory cytokines 
within the bone marrow microenvironment (BMM) can have a similar effect on 
signaling cascades. The majority of intracellular signaling cascades that are 
aberrantly activated in AML originate from a receptor tyrosine kinase (RTKs), 
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which are significant components in the pathogenesis of this malignancy (168). 
The most commonly affected RTK in AML is FLT3, which as discussed previously, 
is mutated in approximately 20% of cases and causes constitutive activation of 
this specific RTK (169). Other members of this class of receptor exist (c-kit, c-
fms, vascular endothelial growth factor (VEGF) receptor and Brutons tyrosine 
kinase (BTK)) and all are implicated in AML progression, where mutations again 
cause the aberrant constitutive expression of the receptor (170-172).  
 
The MAPK/ERK pathway is a key process in cellular homeostasis that links 
extracellular stimuli with proliferation, differentiation and survival of the cell (173). 
In this process, the receptor tyrosine kinase activity of the epidermal growth factor 
receptor (EGFR) is activated by external stimuli promoting Ras to bind to GTP 
causing activation. Ras then activates RAF kinase, which phosphorylates and 
activates MEK which in turn phosphorylates and activates mitogen-activated 
protein kinase (MAPK). MAPK can then activate transcription factors (such as c-
myc and c-Jun) which promote protein synthesis and cell cycle progression. This 
signaling process is constitutively activated in AML blasts, resulting in disease 
progression (174). FLT3-ITD mutations have also been shown to activate MAPK 
in AML blasts (175). In addition, AML blasts have been shown to be susceptible 
to small molecule MAPK inhibitors (176).  
 
Another key intracellular signaling pathway that is abnormally activated in AML is 
the PI3K/AKT/mTOR pathway, this pathway is crucial to many aspects of cell 
growth and survival (177). Activation of growth factor receptor protein kinases 
results in the auto-phosphorylation and recruitment and activation of 
phosphatidyl-inositol-3-kinases (PI3Ks) (178). Activation of PI3K causes the 
production of the second messenger phosphatidylinositol-3,4,5-triphosphate 
(PIP3) which in turn activates phosphoinositide-dependent kinase 1 (PDK1) and 
Akt/protein kinase B (PKB) (179). Akt has the ability, through mTOR and glycogen 
synthase kinase-3 (GSK3), to regulate several cell processes which result in cell 
survival and cell cycle progression. This pathway is over-activated in over 50% of 
patients with AML and AML blasts have been shown to be susceptible to PI3K 
pathway inhibitors (180). 
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The JAK/STAT (Janus associated kinase-signal transducer and activator of 
transcription) signaling pathway has also been implicated in AML disease 
progression. This pathway includes four tyrosine kinases (JAK1-3 and Tyk2) 
(181) and upon the binding of its ligand, the receptor activates through 
dimerization and phosphorylation of its cytoplasmic domain (182). Activated JAK-
cytokine receptor complexes recruit specific cytoplasmic transcription factors 
called STAT proteins (183). STAT proteins dimerize and translocate to the 
nucleus, where they regulate the transcription of a wide range of genes controlling 
cell division and cell cycle progression. A strong expression of JAK/STAT proteins 
is observed in AML blasts along with constitutive expression of this signaling 
pathway (184). Inhibitors of the JAK/STAT pathway have been shown to 
decrease the proliferation of AML blasts (185).  
 
The three major signaling pathways implicated in AML disease progression have 
been discussed. Other pathways are also aberrantly expressed in AML, including 
the Wnt/ β-catenin (186) and NF- κB pathways (187). The combination of all these 
pathways result in the aberrant expression of genes that increase protein 
synthesis, cell cycle progression and cellular survival - subsequently this could 
simulate the formation and progression of AML.  
 
Although these pathways may provide a novel therapeutic window for disease 
intervention, it is also important to note that there is a vast amount of cross-talk 
between the pathways. Therapies targeting a single cellular pathway in AML may 
be ineffective, as other compensatory pathways may still generate the same pro-
tumoral aberrant activation of key genes. 
 
1.3.6 Current clinical trials 
 
As discussed earlier the treatment of AML has not changed in over 40 years, 
therefore new therapies are required as the overall survival of patients with AML 
is poor. There are current clinical trials ongoing which are analysing the 
effectiveness of therapies that target some of the ideas discussed in this section, 
along with other novel therapeutic targets. An overview of the current clinical trials 
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occurring in AML is presented in Table 1.3. In my opinion, one of the most 
promising new therapeutics in clinical trials for AML is Venetoclax (ABT-199), 
which targets the anti-apoptotic Bcl-2 protein within the mitochondria (188). 
Venetoclax has achieved a durable response in elderly AML patients ineligible for 
induction therapy, with 73% reaching complete remission (189). 
 
Table 1.3. An overview of current clinical trials ongoing for the treatment of AML. 
Data in the table is from a combination of (190) and from https://clinicaltrials.gov/ct2/home 
 
 
 
1.4 Multiple Myeloma (MM) 
 
1.4.1 Overview of MM  
 
The second haematological malignancy my thesis will focus on is Multiple 
Myeloma (MM) which is a neoplastic disorder of plasma cells, the terminal 
differentiation stage of a B cell. This disease is characterised by the accumulation 
and proliferation of monoclonal plasma cells within the bone marrow and 
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accounts for approximately 10% of all diagnosed haematological disorders (191, 
192). In addition, MM is the second most commonly diagnosed haematological 
malignancy behind lymphoma (see Figure 1.4). In MM malignant plasma cells are 
unable to produce functional antibodies, instead producing monoclonal or light 
chain only (Bence Jones protein) immunoglobulins (193). There are numerous 
clinical stages of this disease, which will be discussed in 1.4.3. 
 
Looking back at Figure 1.5, it can be seen that MM has the second worst 
prognostic outcome behind AML. The number of US MM deaths predicted in 2018 
(12770) compared to number of new cases (30770) is elevated compared to other 
haematological malignancies (125). Like AML, this disease affects primarily the 
older demographic with the average age at diagnosis being 66 (194) and only 
50.7% of patients survive 5 years (125). When analysing the likelihood of 
developing MM in various geographic locations, it appears that the frequency of 
MM cases is far greater in the western world (such as North America and Europe) 
compared to traditionally weaker economic countries (such as Africa) (195). 
However, it is important to consider the predicted life expectancies in these 
countries - on average people are only expected to live to about 50-year-old in 
weaker economic countries. Therefore, as MM patients are generally diagnosed 
at around 66, the chance of developing MM is lower in these younger populations 
in developing countries. When analysing the prevalence of MM in those of African 
descent compared to Caucasians, MM is twice as common in those of African 
descent compared to Caucasians (196). When these results were normalized 
with economic factors the difference is still observed, implying there is a biological 
difference for the observed results (197). In addition, MM is 40-50% more 
commonly diagnosed in males compared with females (198).  
 
1.4.2 Clinical Stages of MM 
 
Plasma cell disorders cover a plethora of disease states ranging from the 
asymptomatic premalignant proliferation of plasma cells (monoclonal 
gammopathy of unknown significance (MGUS)) and asymptomatic MM 
(smoldering MM (SMM)) to symptomatic malignant disease (MM and plasma cell 
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leukaemia) (199). Research has determined that almost all cases of MM evolve 
from MGUS (200), however only around 1% of MGUS cases progress to 
malignant disease (201).  
 
Abnormal immunoglobulin protein (paraproteins) are found in the blood of MGUS 
patients, first noted by Waldenström in 1960 when abnormal gamma-globulin 
bands were found when carrying out protein electrophoresis on the serum from 
healthy patients (202). There are three distinct clinical subtypes of MGUS 
depending on the abnormal monoclonal protein secreted; non-IgM, IgM and light-
chain MGUS (203). In 2003, the International Myeloma Working Group (IMWG) 
developed a diagnosis classification for known monoclonal gammopathies (204). 
For MGUS to be diagnosed there must be <30g/L monoclonal immunoglobulin in 
the patient’s serum, with fewer than 10% monoclonal plasma cells in the bone 
marrow. An update of these criteria in 2010 added the absence of end stage 
organ damage to the classification of MGUS (205). There are vast variations in 
the speed of progression from MGUS to malignant MM, with some progressing 
swiftly and others not at all. The risk of progression is effected by a number of 
factors including type of monoclonal Ig that is secreted (206). Patients with MGUS 
are monitored yearly and there are currently no therapeutic interventions for this 
stage of the disease. 
 
The progression of MGUS disease can lead to SMM, which is the intermediate 
stage to malignant MM. SMM is also a disease with elevated monoclonal plasma 
cells which produce paraproteins. It is diagnosed when the number of monoclonal 
plasma cells in the bone marrow increases to over 10%, paraprotein 
concentration in patient serum exceeds 30g/L and there is no sign of end organ 
damage (207). The risk of developing malignant MM from SMM is far greater 
compared with MGUS, 10% of patients diagnosed with SMM will develop MM 
within 5 years (208). SMM is biologically heterogeneous as it contains a subset 
of late MGUS patients and early MM patients who have not developed end organ 
damage (209). As this is the case, treating patients in the SMM stage provides 
an opportunity to decrease the cases of MM - although currently there are no 
treatment regimens for this condition. A recent study showed that treating SMM 
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patients with approved MM therapeutics (Lenalidomide and Dexamethasone) 
increased the 5-year MM progression free time from 30 to 77% compared to no 
treatment (210).  
 
 
 
Figure 1.6. The clinical stages of Multiple Myeloma disease progression. 
 
SMM can lead to symptomatic MM upon the detection of tissue damage using the 
CRAB criteria; Calcium, Renal insufficiency, Anaemia and/or Bone lesions (211). 
The symptoms, diagnosis and treatments of symptomatic MM will be described 
in section 1.4.3. The rare disorder of plasma cell leukaemia (PCL) can arise from 
Symptomatic MM (212). This condition is very aggressive and is characterised by 
the presence of circulating monoclonal plasma cells in the peripheral blood. PCL 
is diagnosed when there are more than 20% monoclonal plasma cells in the 
peripheral blood and an absolute plasma cell count of greater than 2x109/L (213). 
There are two types of PCL (primary and secondary) where primary PCL is 
diagnosed in patients with no history of MM, whereas secondary PCL is observed 
as a leukaemic transformation of relapsed or refractory MM disease in MM 
patients (204). The incidence of primary PCL is greater than secondary PCL - 60-
70% compared to 30-40% respectively. 
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1.4.3 Symptoms, Diagnosis and Treatment 
 
Symptomatic MM is diagnosed when CRAB criteria have been reached, as 
mentioned above. Of the CRAB criteria, the most common symptoms in MM are 
fatigue (often caused by anaemia) and bone pain (119). 90% of MM patients 
present with bone disease at some point during the MM progression (214), 
ultimately due to an imbalance of osteoblast and osteoclast production (215). The 
bone damage can often lead to hypercalcemia resulting in renal failure in around 
50% of all MM patients (216).  
 
To diagnose MM numerous clinical procedures are carried out - one of these is a 
test to detect paraprotein levels in serum/urine. To achieve this either a serum 
protein electrophoresis assay, serum immune-fixation assay or serum FLC assay 
is carried out in parallel to a 24-hour urinary protein electrophoresis (217). The Ig 
type of the paraproteins can be detected using these methods: 50% of MM 
patients are IgG, 20% are IgA, 20% are light chain only, 2% are IgD and 0.5% 
are IgM (194). In rare cases (2-3% of patients) no detectable paraprotein is 
detected and these patients are deemed non-secretory MM (218). Bone marrow 
biopsies are also carried out in patients suspected of having MM, this test will 
determine the number of monoclonal plasma cells in the bone marrow. Additional 
tests, such as FDG-PET (fluorodeoxyglucose positron emission tomography) and 
CT scans of the entire skeleton, are utilised to diagnose bone lesions. MRI scans 
are sometimes carried out when it is difficult to distinguish between SMM and MM 
(219).  
 
The first case of MM was first described in 1844 (220), however the first working 
treatment was not discovered until 100 years later. The nitrogen mustard 
alkylating agent melphalan was the first drug shown to have beneficial effect on 
MM patient survival - 50% of patients treated showed improved survival (221). 
Melphalan was then combined the corticosteroid prednisone, which increased 
MM patient survival by 6 months compared to patients treated with melphalan 
alone (222). This treatment was used as a MM core therapy for decades until a 
study presented the idea that thalidomide, used very famously for morning 
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sickness in the 1950s, had anti-MM properties reducing bone marrow plasma cell 
number along with reducing levels of paraproteins (223). Thalidomide was 
approved for use in MM, commonly in combination with melphalan and 
prednisone, along with the thalidomide derivative lenalidomide. The proteasome 
degradation pathway is very important for MM survival (see section 1.4.6), 
therefore the anti-MM effect of proteasome inhibitors such as bortezomib and 
carfilzomib was studied. 35% of patients treated with bortezomib had complete or 
partial response to bortezomib (224), and when combined with melphalan and 
thalidomide the median patient survival increased from 16 months to 24 months 
(225).  
 
The most important phases of MM therapy are the initial therapy, stem cell 
transplant and consolidation/maintenance therapy.  Initial therapy depends on the 
risk factor of the patient, but all contain a regimen of three drugs: a proteasome 
inhibitor, a thalidomide derivative and a corticosteroid (119). Patients with low or 
medium risk are given 4 cycles of bortezomib, lenalidomide and dexamethasone 
- followed by an autologous stem cell transplant (ASCT). Patients at high risk are 
given a slightly modified 4 cycles of carfilzomib, lenalidomide and dexamethasone 
- followed by an ASCT. Maintenance therapy for low, medium and high-risk 
patients is lenalidomide, bortezomib or carfilzomib respectively. Only around 50% 
of MM patients survive 5 years after diagnosis as they become refractory and 
resistant to treatments - there is therefore a need for alternate therapeutic 
interventions. It is envisaged that these will arise from a better understanding of 
the biology of MM pathogenesis. 
 
1.4.4 Plasma Cell Immunoglobulins 
 
The most important function of a non-malignant plasma cell is to its ability to 
produce immunoglobulins in response to encountering foreign pathogens (226). 
These immunoglobulins can be secreted or bound to the cell membrane and are 
composed of two heavy (α, γ, δ, ε or μ) and two light chain (κ or λ) peptides that 
form a tetrameric complex (Figure 1.7) (227). Based on the specific peptide 
sequence in the heavy chain, the immunoglobulin can be sub-divided into 5 
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different classes; IgA, IgG, IgD, IgE and IgM. Monoclonal plasma cells in MM 
secrete large quantities of one specific type of immunoglobulin and, as discussed 
in 1.4.3, there is variation in the percentage of patients with each type of Ig heavy 
chain. Each type of heavy chain Ig confers a different prognostic outcome; with 
the rare IgD having a poor prognosis (21 months) and IgG patients having a more 
favourable prognosis (61.8 months) (194, 228).  
 
 
Figure 1.7. Schematic representation of an immunoglobulin (Ig). 
The structure of an immunoglobulin is presented that is either secreted or present on the cell 
surface of a normal or malignant plasma cell. MM cells secrete large quantities of monoclonal 
immunoglobulins with a specific heavy chain peptide sequence, these are defined as 
paraproteins. 
 
 
1.4.5 Molecular Basis of MM 
 
Multiple myeloma is classified as a single disease, however within this disease 
there are various different cytogenetically distinct plasma cell neoplasms (229). 
Using fluorescence in situ hybridization studies, 40% of all MM cases were shown 
to have the presence of trisomies in the malignant cell (230). In the majority of the 
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remaining cases, chromosomal translocations were found involving the 
immunoglobulin heavy chain (IgH) on chromosome 14q32 (231). In a small 
number of cases both trisomies and chromosomal translocations were found, 
along with a minimal number of cases having no genetic abnormalities. These 
trisomies and chromosomal translocations (highlighted in Table 1.4) are 
considered primary cytogenetic abnormalities’ and are present from the 
development of MGUS (119). Other cytogenetic abnormalities can occur 
throughout the progression of MM are defined secondary cytogenetic 
abnormalities. A number of key MM driver mutations have also been found in key 
proto-oncogenes and tumour suppressors, including KRAS, NRAS, BRAF and 
TP53, which promote MM cell proliferation and survival (232).  
 
Table 1.4. Genetic abnormalities present in MM and their associated prognostic outcome. 
Table modified from (119). 
 
 
 
1.4.6 Key Signaling Cascades in MM 
 
There is much overlap in key signaling cascades that are promoted in AML and 
MM disease progression. Pathways include the PI3K/AKT/mTOR, MAPK/ERK 
and JAK/STAT (described in 1.3.5), whose aberrant activation also leads to an 
increased proliferative drive and survival of MM (233). These pathways are also 
able to stimulate osteoclast production and suppress osteoblasts, leading to the 
bone lesions observed in MM pathogenesis (234). Inhibitors of the PI3K, MAPK 
	 50	
and JAK/STAT pathways have been shown to reduce MM disease progression 
(235-237); however, like AML these have not translated to the clinic as there are 
multiple compensatory mechanisms which can recover the observed phenotype. 
 
One current therapy used in the treatment of MM, however, does target a key 
signaling pathway that is aberrantly activated in MM disease pathogenesis - the 
nuclear factor-κB (NFκB) pathway. This pathway is a major regulator of immune 
and inflammatory responses within the cell and it’s activation leads to the 
expression of genes such as IL-6 and TNFα (238). The NFκB pathway is activated 
by external signals including VEGF (which is in some cases secreted by 
supporting cells in the BMM), but more importantly by A proliferation-inducing 
ligand (APRIL) and B-Cell-Activating Factor (BAFF) which are two of the most 
crucial survival factors for healthy plasma cells and MM cell alike (239, 240). TACI 
and BCMA are the common receptors that these factors bind to activating the 
NFκB pathway, however BAFF can also activate an alternate pathway through 
the BAFF-R receptor.  
 
The NFκB transcription family composes of a number of transcription factors 
including NFKB1 (p50 and p105), NFKB2 (p52 and p100), RelA (p65), RelB and 
c-Rel (241). The transcription factors are held in their inactive form by their 
inhibitory protein IκBα and after stimulation of TNFR-associated factors, IκBα is 
activated by phosphorylation leading to its degradation by the proteasome (242). 
This results in the accumulation of homodimers and heterodimers of NFκB 
transcription factors within the nucleus, leading to the expression of genes 
including those involved in cell survival and cell cycle progression. Inactivation of 
the NFκB pathway, via the inhibition of IκBα degradation, can cause dividing cells 
to be more susceptible to apoptosis (243). Proteasome inhibitors (such as 
bortezomib and carfilzomib) can exploit this mechanism and have shown to be 
successful in treating MM. Proteasome inhibitors were approved by the FDA in 
2003.  
 
Another key molecule in the pathogenesis of multiple myeloma is CD38, also 
known as cyclic ADP ribose hydrolase, which is found uniformly of the surface of 
	 51	
MM cells (244). CD38 is a multi-functional 48 kDa type II glycoprotein discovered 
by Reinhertz and colleagues in 1980 (245), and it plays a role in the activation 
and proliferation of mature lymphocytes as well as malignant plasma cells (246). 
CD38 is presently known to have two main functions, firstly as an ectoenzyme 
catalysing the conversion of nicotinamide adenine dinucleotide (NAD+) to cyclic 
adenosine diphosphate-ribose (ADPR) - which is a potent intracellular calcium 
releaser (247). Secondly, CD38 functions as a receptor which mediates leukocyte 
migration through the endothelium via its co-receptor CD31 (248). Preclinical 
studies of CD38 inhibition shows that it mediates MM cytotoxicity in the presence 
of the protective bone marrow (249). More recently early phase clinical trials of 
Daratumumab (a CD38 targeting antibody) in MM patients has demonstrated a 
favourable safety profile and encouraging efficacy in patients with heavily pre-
treated and refractory disease (250, 251). Daratumumab has now been FDA 
approved for the treatment of relapse refractory myeloma in combination with 
bortezomib or lenalidomide (252). Although highly promising in the treatment of 
MM, the actual mechanism of MM cytotoxicity through inhibition of CD38 is 
relatively unknown.  
 
1.4.7 Current Clinical Trials in MM 
 
The treatment of multiple myeloma has progressed over the last 20 years, 
however due to the still relatively poor 5-year survival rate other novel therapies 
are required. It is envisaged that survival rates will improve due to the FDA 
approval of the CD38 monoclonal antibody Daratumumab, however this is only 
used in relapse MM patients and is not currently a front-line treatment. Having 
said this there is always a need for new therapeutics and there are a number of 
clinical trials ongoing in the treatment of MM. In my opinion, the most promising 
novel therapeutic for the treatment of MM is Daratumumab. Although already 
approved for the treatment of relapsed/refractory patients, I believe this drug will 
become a front-line therapy in the years to come. 
 
Table 1.5 summarises the current clinical trials ongoing in MM. It can be seen that 
the majority of clinical trials ongoing are focusing on the relapsed/refractory 
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patients, most probably due to the high rates of relapse within MM patients after 
successful front-line treatments described in 1.4.3. 
 
Table 1.5. An overview of current clinical trials occurring in Multiple Myeloma. 
Clinical trial data was collected from https://clinicaltrials.gov/ct2/home accessed August 2018. 
 
 
1.5 Malignant Bone Marrow Microenvironment 
 
It is envisaged that novel therapeutics in the treatment of AML and MM will arise 
from a better understanding of the biology that underpins disease pathogenesis 
and proliferation. A key factor that requires further investigation is the interaction 
the malignant haematopoietic cell has with its microenvironment and how this 
interaction promotes the survival and proliferation of the disease. The “seed and 
soil” hypothesis was first postulated in 1889 (253) and describes how metastatic 
tumours only grow in a distant organ if that organ offers the correct “soil” or 
microenvironment. This theory was largely forgotten until the last couple of 
decades (254), and due to revised interest we now know that the “seed and soil” 
hypothesis may be true for tumour initiation and proliferation itself (255). Not only 
does the microenvironment play a role in disease initiation and proliferation, it is 
also a key player in the development of chemo-resistance and disease relapse 
(256) - two major concerns in haematopoietic malignancies. The vast majority of 
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chemotherapeutics used today to treat a plethora of cancers target the malignant 
cell itself, rather than the microenvironment in which the malignancy resides. The 
BMM is a highly specialised niche that comprises of a variety of cell types 
including BMSC, osteoblasts and endothelial cells which are comprehensively 
reviewed in section 1.2.   Finely elucidating the complex interactions between 
tumour “seed” and microenvironment “soil” will hopefully give rise to novel 
therapeutic interventions and increase the survival of patient with AML and MM. 
 
1.5.1 AML 
 
Isolated AML blasts undergo high levels of apoptosis when cultured ex vivo, 
signifying the important role that the bone marrow microenvironment has on the 
survival of AML (257). AML patients have high levels of relapse caused by 
minimal residual disease, where small numbers of AML blasts are sequestered 
within the bone marrow. Compared with the understanding of the genetic 
abnormalities that contribute to AML disease progression (see section 1.3.4), little 
is understood about the complex interactions between the AML blasts and its 
BMM. The role of the microenvironment first came to the forefront when the level 
of apoptosis within AML blasts was shown to reduce when cultured with a layer 
of BMSC ex vivo (258). This was followed by a study that showed culturing the 
AML blasts with the BMSC cell line HS-5, provided protection against 
chemotherapy treatments (259).  
 
Our understanding of how the BMM confers chemo-resistance and protects 
against apoptosis is increasing as we elucidate the complex mechanisms 
involved. It has been found that AML blasts can shape their own 
microenvironment to favour their survival and proliferation (260, 261), which 
involves direct contact or stimulating cells of the BMM to secrete key soluble 
factors.  
 
As discussed in section 1.2.3, BMSC secrete high levels of CXCL12. AML blasts 
express CXCR4 and hijack the CXCR4/CXCL12 axis – allowing homing to 
favourable niches within the BMM (262). After the migration of AML blasts to 
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these niches, they are able to manipulate cells of the BMM to their advantage. 
BMSC continue to secrete CXCL12 in the BMM and this chemokine has been 
shown to activate the PI3K/Akt signaling pathway, promoting the survival and 
proliferation of AML blasts (263). The direct co-culture of AML blasts with BMSC 
was shown to up-regulate the master transcription factor c-Myc in BMSC, which 
contributed to chemo-resistance via the downregulation of apoptosis related 
genes (264). Furthermore, this chemo-resistance was overcome upon the 
addition of a small molecule inhibitor of c-Myc. BMSC have increased levels of 
IL-6 secretion in the presence of AML blasts which has been shown to protect 
AML blasts through activation of the JAK/STAT pathway, through the IL-6 
receptor (265). In another example of AML manipulating the BMM; AML blasts 
have been shown to secrete the macrophage inhibitory factor (MIF), which in turn 
stimulates BMSC to secrete IL-8 (266). IL-8 can activate the PI3K/Akt and MAPK 
signaling pathways to promote survival and proliferation (267). 
 
Other cells within the BMM can contribute to the survival and proliferation of AML 
blasts. Endothelial cells express VCAM-1, which binds to the VLA-4 on AML cells 
and maintains their retention within favourable niches (268). The matrix 
metalloproteinase-2 (MMP-2) is an endopeptidase-like enzyme which remodels 
the ECM and has been shown to contribute to tumour progression (269). 
Endothelial cells and fibroblasts express MMP2 and are activated by the 
extracellular metalloproteinase inducer (EMMPRIN), also known as CD147, 
located on AML blasts (270). The interaction of receptor activator of nuclear factor 
κ-B ligand (RANKL) and receptor activator of nuclear factor κ-B (RANK) is 
important in osteoblast regulation of osteoclasts (271). AML blasts express RANK 
and utilise RANKL (secreted by osteoblasts) to activate the NFκB pathway and 
impair NK cell anti-leukaemic immunosurveillance (272). Finally, adipocytes have 
been shown to transfer free fatty acids (FFA) to AML blasts (273), through CD36 
(274) - increasing fatty acid oxidation (FAO). As a result, AML blasts have been 
shown to be susceptible to the FAO inhibitor Avocatin B (275).  
 
Comparable with the non-malignant HSC niche, AML resides in a 
microenvironment with low oxygen (<1%) levels defined as hypoxic (276). 
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Residing in hypoxic environments minimises the exposure to chemotherapeutic 
drugs as well as activating key signaling cascades such as the PI3K/Akt/mTOR 
pathway (277). AML blasts generate high levels of reactive oxygen species 
(ROS), which contribute to the hypoxic niche, through the overexpression of 
NADPH oxidase 2 (NOX2) (278). NOX2 is an enzyme present on the surface of 
myeloid cells and catalyses the conversion of molecular oxygen to superoxide - 
used by phagocytic cells to neutralise pathogens (279). In the context of AML, the 
overexpression of NOX2 has been shown to increase AML disease progression 
through the activation of the MAPK pathway (278). 
 
Taken together, the BMM plays a significant role in the progression of the AML 
and may provide favourable places of therapeutic intervention. The BMM 
protection of AML is summarised schematically in Figure 1.8. 
 
1.5.2 MM 
 
Multiple myeloma is also a disease heavily reliant on its bone marrow 
microenvironment for migration, survival, proliferation and drug resistance. Many 
of the aspects of the AML BMM are also apparent in the microenvironment of MM. 
Direct contact between BMSC and MM cells, or through BMSC derived soluble 
factors, has been shown to aid MM cells evade chemotherapeutic drugs (280). 
MM cells migrate to favourable niches very similarly to AML blasts, whereby they 
exploit the CXCR4/CXCL12 axis (281) and remain in these niches due to the 
VLA-4/VCAM-1 interaction (282). The adhesion of MM cells to BMSC stimulates 
the Notch signaling pathway in both cell types, subsequently stimulating the 
production of IL-6 and VEGF (283). VEGF promotes angiogenesis which has 
been shown to be crucial for MM disease progression (284). This interaction also 
promotes the NFκ-B pathway in BMSC and again leads to the production of IL-6, 
which stimulates MM cells to produce VEGF (284). Recently, BMSC have been 
shown to release exosomes containing miRNA which can be sequestered by MM 
cells, promoting disease progression (285).  
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Of the factors released by BMSC, IL-6 is most arguably the most crucial for MM 
cell proliferation and survival. Also produced by osteoblasts, IL-6 paracrine 
production by BMSC has been shown to be reliant on MM stimulation. The 
cytokine IL-1β, released by MM cells, has been shown to stimulate the production 
of IL-6 within BMSC (286). In addition, the secretion of MIF by MM cells results in 
the same increase in BMSC IL-6 secretion (287). Upon IL-6 binding to the IL-6 
receptor, many key signaling pathways (such as PI3K/Akt, MAPK, and 
JAK/STAT) are activated - leading to MM proliferation and survival (288). 
Increased IL-6 levels in the serum of patients with MM has been shown to confer 
a poor overall prognosis (289).  
 
Other cells within the BMM are also crucial in MM disease progression. The 
increased number of osteoclasts in MM patients leads to characteristic bone 
lesions found in the disease. Activation of osteoclasts occurs through the RANK 
ligand which is produced upon MM cells binding to BMSC; blocking of the RANK 
receptor on osteoclasts can result in reduced tumour burden (290). In addition, 
osteoclasts can constitutively release proangiogenic factors, such as VEGF 
(291). MM cells express the MMP-2 inducer EMMPRIN which causes endothelial 
cells and fibroblasts to remodel the ECM to the advantage of MM cells (292). 
More recently, MM cells have also been shown to release microvesicles which 
contain high levels of EMMPRIN (293). Osteoblasts have the ability to secrete IL-
6 (294), however the suppression of osteoblast function is found in MM patients. 
This is achieved through the Wnt signaling antagonist DKK-1 secreted by MM 
cells, which inhibits osteoblast differentiation promoting osteoclast generation 
(295). The interactions the MM cell has with its BMM, described in this section, 
are summarised schematically in Figure 1.8. 
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Figure 1.8. The bone marrow microenvironment of AML and MM. 
A schematic representation of how the BMM provides protection from chemotherapeutics and 
promotes proliferation of survival of AML and MM cells. AML blasts are shown in blue and MM 
cells in orange, with cells of the BMM in the centre of the schematic. 
 
 
 
1.6 Metabolism 
 
1.6.1 Metabolism Overview 
 
Metabolism is defined as the sum of the biochemical processes (more than 8,700 
reactions and 16,000 metabolites) which transduce or consume ATP (296). Core 
metabolism involves the utilisation of nutrients such as carbohydrates, fatty acids 
and amino acids through numerous biochemical processes defined in the “Golden 
Age of Biochemistry” (1920s to 1960s). Cells require energy in the currency of 
ATP to function and maintain cellular homeostasis. The vast majority of this ATP 
is generated through aerobic respiration, using glucose as the energy source 
(297). The first stage in this process is glycolysis, whereby glucose is converted 
into two molecules of pyruvate - which yields two molecules of ATP. Pyruvate is 
then fed into the tricarboxylic acid cycle (TCA) cycle within mitochondria (after 
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conversion to acetyl-coA) which reduces nicotinamide adenine dinucleotide 
(NAD+) to NADH and flavin adenine nucleotide (FAD) to FADH2 (298). Only one 
ATP molecule is generated in the TCA cycle, however 3 molecules of NADH and 
one molecule of FADH2 are produced - which provide electrons for the next stage 
of the process. As the TCA cycle occurs twice per glucose molecule, these values 
can be doubled. 
 
The final stage of glucose metabolism is oxidative phosphorylation which involves 
the transfer of electrons (from NADH and FADH2) along four protein complexes 
(I, II, III and IV) located on the inner membrane of mitochondria (297). Electrons 
are passed from Complex I (NADH/ubiquinone oxidoreductase), which removes 
electrons from NADH, to Complex II (Succinate dehydrogenase), which removes 
electrons from FADH2, to ubiquinone. This reduces ubiquinone to ubiquinol, which 
in turn transfers electrons to cytochrome C via Complex III 
(ubiquinone/cytochrome c oxidoreductase). The final complex electrons are 
transferred to is cytochrome c oxidase - here electrons are passed to oxygen 
reducing it to water. As the electrons are moved through the four protein 
complexes, protons are transported into the inner membrane space of 
mitochondria - generating a difference in electrical potential (299). This creates a 
proton motive force which drives protons across the mitochondrial inner 
membrane through the ATP synthase, triggering a rotation of the F0 subunit to 
produce ATP (300).  
 
The 1978 and 1997 Nobel Prize in Chemistry were awarded for the elucidation of 
chemiosmosis and the underlying enzymatic mechanisms of ATP synthase 
respectively.  The number of protons required to generate one molecule of ATP 
is highly debated, one study suggested four protons are required (301). This study 
however did not examine the mammalian ATP synthase, this is an important point 
as there are likely to be species variations in regard to the number of protons 
required to produce ATP molecules. One NADH molecule has the ability of 
releasing 10 protons to the inner membrane space; four by Complex I, four by 
Complex III and two by Complex IV (297). FADH2 only releases 6 protons as it 
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skips Complex I. Therefore, a large number of ATP molecules can be generated 
from the metabolism of each glucose molecule.  
 
1.6.2 Mitochondria  
 
During aerobic respiration, the TCA cycle and electron transport chain both occur 
in a specialised organelle - the mitochondrion. Mitochondria evolved as the result 
of a symbiotic relationship between aerobic bacteria and eukaryotic cells, where 
ancient bacterial symbionts were acquired by eukaryotic cells enabling the 
utilisation of aerobic respiration (302). Mitochondria are double membraned 
organelles, which are capable of highly efficient ATP production.  The inner 
membrane forms cristae, which enhance the surface area of the electron 
transport chain allowing enhanced ATP production. The structure of the 
mitochondrion is presented in Figure 1.9, with an overview of the process of 
aerobic respiration.  
 
As mitochondria originated from bacteria they contain a unique genome 
(mitochondrial DNA (mtDNA)) that is distinct from nuclear genomic DNA (gDNA) 
and inherited on the maternal line (303). The mitochondrial genome is made up 
of a 16 kilobase circular mtDNA which contains 37 genes, 12 of which encode 
protein subunits of the electron transport chain proteins (304). The remaining 
proteins encoded are made up of mitochondrial tRNAs and rRNAs; in addition, 
there are still 900 proteins encoded on gDNA. The biogenesis of new 
mitochondria is a tightly controlled process, facilitated by the master transcription 
factor peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) (305).  
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Figure 1.9. The structure of the mitochondrial organelle. 
A schematic representation of the structure of the mitochondrial organelle with key biochemical 
pathways involved in aerobic glycolysis highlighted. These include glycolysis, the TCA cycle and 
OXPHOS. The electron transport chain is also highlighted (enlarged image) showing the 
movement of protons across complex I, III and IV into the intermembrane space, followed by the 
generation of ATP through ATP synthase (shown in the schematic as S). 
 
1.6.3 Cancer Metabolism 
 
Cancer cells have been shown to have atypical respiration whereby they utilise 
the non-mitochondrial based process of aerobic glycolysis to generate ATP. This 
mechanism was first discovered by Otto Warburg and is deemed the Warburg 
effect (306). In this process cancer cells generate pyruvate from glucose (as with 
aerobic respiration), however they use fermentation to generate lactate from 
pyruvate rather than generate acetyl-CoA. This effect results in the increased 
consumption of glucose, as glycolysis is far less efficient than oxidative 
phosphorylation (OXPHOS) at generating ATP. The increased glucose 
consumption has proved a valuable tool in cancer diagnosis; FDG-PET scans can 
detect the increased glucose consumption of a cancer cell (307).  
 
The reason why cancer cells utilise aerobic glycolysis is highly debated. Initially it 
was thought that mitochondria within cancer cells are defective and this resulted 
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in an impairment of OXPHOS, therefore non-mitochondrial ATP generation 
methods were employed. However, it was later found that the OXPHOS capacity 
of cancer mitochondria is intact (308). The reason for the switch to aerobic 
glycolysis is therefore more likely to be due to a number of other factors including 
the tumour microenvironment and activation of oncogenes. As the tumour 
increases in size, the tumour microenvironment becomes hypoxic - leading to the 
stabilization of hypoxia inducible factor (HIF). As the dependence on aerobic 
respiration becomes less, there is a switch in metabolism towards glycolysis 
(309). In addition, the activation of certain oncogenes including Ras drive a 
change in tumour metabolism; Ras activates mTOR, which in turn induces HIF 
which promotes glycolysis (310).  
 
Not all tumours, however, are dependent on the Warburg hypothesis: for 
example, AML blasts require OXPHOS for survival. The THP-1 AML cell line has 
been shown to be more sensitive to OXPHOS inhibitors compared to glycolysis 
inhibitors (311). Also, there are AML blasts which have a high OXPHOS gene 
signature and these cells are less sensitive to the chemotherapeutic Ara-C when 
compared to low OXPHOS AML cells (312). In another study, AML blasts were 
shown to utilise OXPHOS to generate an antioxidant response (313). 
Furthermore, AML blasts have been shown to have increased mitochondrial 
levels compared to HSCs (314), which makes them more susceptible to the 
mitochondrial translation inhibitor tigecycline (315). 
 
Multiple myeloma appears to be a “Warburg cancer” relying predominantly on 
glycolysis. MM is susceptible to glycolysis inhibitors such as dichloroacetate 
(DCA) (316) and has an elevated glycolysis gene profile (317). However, these 
studies were conducted solely on MM cells and did not take into account the effect 
of the protective microenvironment. MM cells do however have the ability to utilise 
OXPHOS under ritonavir treatment (318) and HIF-1a suppression (319). 
 
 
 
	 62	
1.6.4 The Transfer of Mitochondria between Somatic Cells 
 
The mitochondrion organelle was classically thought to reside in its somatic cell 
for its lifetime, where they undergo fission and fusion to generate mitochondrial 
networks and are ultimately turned over by the specific type of autophagy - 
mitophagy (320). However, recently it was found that this was not the case - 
mitochondria were found to move between cells. In a landmark paper by the 
Gerdes Lab in 2004, intercellular mitochondrial transfer was first shown to occur 
between PC12 rat pheochromocytoma cells, normal rat kidney cells and HEK239 
human embroyonic kidney cells (321). This study opened up the idea that 
intercellular mitochondrial transfer could occur in a range of non-malignant and 
malignant settings, an overview of which is shown in Table 1.6.  
 
Table 1.6. Overview of intercellular mitochondrial systems described in literature. 
 
 
The use of cells devoid of mtDNA (rho0 cells) has been a useful tool in studying 
intercellular mitochondrial transfer, as restoration of mtDNA within the rho0 cell 
highlights the acquisition of external mitochondria. These cells can be generated 
in cell lines using long term culture with ethidium bromide (322). Ethidium bromide 
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specifically intercalates with mtDNA (over genomic DNA) causing shearing and 
degradation. Using these cells, mitochondrial transfer was seen to occur from 
mesenchymal stem cells (MSC) to a number of difference malignancies both in 
vitro and in vivo. Mitochondria have been seen to move to both A549 (lung 
adenocarcinoma) (323) and 143B (osteosarcoma) (324) rho0 cells in vitro from 
MSCs. In vivo, B16 (melanoma) and 4T1 (breast cancer) rho0 cells were shown 
to acquire mitochondria from MSCs (325). The latter study used single nucleotide 
polymorphisms (SNP) in mtDNA to determine the host origin of mitochondria 
acquired by the malignant cells. 
 
The intercellular transfer of mitochondria has been shown to occur from MSC to 
other cancer cells, including SKOV3 cells (ovarian cancer) and MCF7 (breast 
cancer); however, in this study the authors found increased mitochondrial transfer 
occurred from endothelial cells over MSCs (326). Mitochondria have also been 
shown to be transferred within cancer cell populations and not from a specific 
mitochondrial donor such as MSCs. This was seen to occur between human 
mesothelioma cells populations (327) and between human laryngeal squamous 
cell carcinoma populations (328). Mitochondria were also found to move between 
T24 and RT4 bladder cancer cells (329). To date there has been no literature 
describing intercellular mitochondrial transfer within a haematological setting. 
 
This biological phenomenon is not unique to malignancies - intercellular 
mitochondrial transfer has also been shown to occur in non-malignant settings. A 
study by Islam and colleagues in 2012 described the transfer of mitochondria from 
airway instilled BMSC to lung epithelial cells under lipopolysaccharide (LPS) 
treatment (330). In a separate study mitochondria were observed to move from 
astrocytes to injured neurons in a CD38 dependent mechanism (331).  
 
Mitochondria have been shown to move between cells in various independent 
ways. Firstly, and most commonly, mitochondria have been shown to move 
between cells via tunneling nanotubes (TNT). TNTs are continuous cellular 
projections of the cytoskeleton, which are actin based and also contain 
microtubules (332). Mitochondria have been shown to move via TNTs from MSCs 
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to lung adenocarcinoma (323), ovarian and breast cancer cells (326); in addition 
to between pheochromocytoma PC12 cell (321, 333), bladder cancer cells (329) 
and mesothelioma cell populations (327). The mitochondrial Rho-GTPase (Miro1) 
aids in the coupling of mitochondria to the actin cytoskeleton and overexpression 
results in increased mitochondrial transfer. Mitochondria have also been shown 
to move through connexin43 gap junctions (330) and extracellular vesicles (331). 
Apart from the methods of mitochondrial movement, little is known about the 
underlying mechanisms that control this biological process.  
 
There have been numerous biological consequences of intercellular 
mitochondrial transfer described. Firstly, the transfer of mitochondria has been 
shown to rescue cells from stress induced apoptosis (333). Furthermore, chemo-
resistance has been shown to occur in malignant cells that have acquired 
mitochondria (326). Restoration of tumourigenic potential has also been shown 
in cancer cell lines that lack mtDNA (rho0 cells) in which mitochondrial transfer 
has occurred. This was mainly through reinstatement of the ability to utilise 
aerobic respiration to generate ATP (323, 334) - which is evidence to suggest that 
the Warburg effect may not occur in all cancers. In addition, intercellular 
mitochondrial transfer between bladder cancer cell populations increases 
invasiveness of the recipient cell (329). Finally, mitochondrial transfer occurs in 
non-malignant settings to protect against disease; mitochondria moved to lung 
epithelial cells from BMSC to protect against lipopolysaccharide induced acute 
lung injury (330), whereas mitochondria moved from astrocytes to recover injured 
neurons after stroke (331). Overall it can be seen that there are many biological 
consequences of mitochondrial transfer, all of which benefit the recipient cell and 
ultimately lead to cell survival.  
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1.7 Research Rationale and Objectives/Aims 
 
1.7.1 Rationale 
 
AML and MM are incurable diseases with the two poorest survival rates within 
haematological malignancies. Treatment of these cancers has hardly changed 
over recent decades, accounting for the lack of improvement in patient survival 
compared to other malignancies. Therefore, novel therapeutic interventions are 
required to improve overall survival of patients. It is envisaged that these new 
therapies will evolve from a better understanding of the biological processes that 
underpin the malignancies. AML and MM have been shown to rely heavily on their 
BMM to develop, proliferate and evade current chemotherapy regimens - this may 
be therapeutically targetable in combination with low-dose chemotherapy.  
 
This study aims to further dissect underlying mechanisms within the BMM that 
contribute to the protection of AML and MM. Research will focus on whether 
intercellular mitochondrial transfer occurs within AML and MM – aiming to 
elucidate mechanisms which may control this biological phenomenon. 
 
1.7.2 Objectives/Aims 
 
1. Investigate intercellular mitochondrial transfer within AML. Establish the 
underlying mechanisms that stimulate and facilitate the transfer. 
 
2. Determine the metabolic state of MM within the BMM, analyse intercellular 
mitochondrial transfer and determine control mechanisms. 
 
3. Determine whether intercellular mitochondrial transfer is tumour specific or 
a process hijacked by cancer to fuel its metabolic requirements. 
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2 Materials and methods 
 
2.1 Materials 
 
Materials and reagents used in my thesis will be highlighted in the experimental 
procedures described in the methods below and in Table 2.1. All reagents were 
sourced from Sigma Aldrich (St Louis, MO, USA), unless otherwise stated.  
 
Table 2.1. Reagents used in my thesis, with the manufacturer and catalogue number. 
Agilent (Santa Clara, CA, USA), BioLegend (San Diego, CA, USA), Cell Signaling Technologies 
(Danvers, MA, USA), Clontech Takara Bio, Saint-Germain-en-Laye, France), Detroit R&D 
(Detroit, MI, USA), Fisher Scientific (Hampton, New Hampshire, USA), GE Healthcare (Little 
Chalfont, UK), Machery-Nagel, Duren, Germany), Merck Millipore (Burlington, MA, USA), 
Miltenyi Biotec (Bergisch Gladbach, Germany), New England BioLabs (Ipswich, MA, USA), PCR 
Biosystems (London, UK), Promega (Madison, WI, USA), Qiagen (Hilden, Germany), Santa 
Cruz Biotechnology (Dallas, TX, USA), Sigma Aldrich (St Louis, MO, USA) and ThermoFisher 
(Waltham, MA, USA). 
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2.2 Cell culture 
 
All cells described below were cultured in a humidified culture incubator 
(ThermoFisher, Waltham, MA, USA) at 5% CO2 and 37 ˚C. 
 
2.2.1 Cell lines 
 
AML cell lines; OCI-AML3, MV4-11, THP-1 and U937 were obtained from the 
American Type Culture Collection (ATCC) and were maintained in RPMI-1640 
medium, supplemented with 10% foetal calf serum (FCS), 2mM L-glutamine, 
100U/ml penicillin and 10µg/ml streptomycin (pen-strep). Cells were cultured at a 
concentration of 0.5 x106 cells/ml and split accordingly on a weekly basis. The 
MM cell lines; MM1S, MM1R, U266, RPMI and H929 were obtained and cultured 
as per the AML cell lines (335).  
 
293T cells were provided by Dr Ariberto Fassati (University College London, UK), 
which were derived from human embryonic kidney (HEK) 293 cells. These cells 
are a highly transducable cell line used in lentiviral production. 293T cells were 
cultured in 10mm tissue culture dishes at a 50-90% confluency, in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% FCS and without pen-
strep as previously described (336). Cells were split 1:3 when they reached a 
90% confluency. Briefly, 0.25% Trypsin was diluted 1:3 using PBS and 7.5ml was 
added to the 293T cells. The cells were incubated at room temperature for 2-3 
minutes before gently swirling the dish to remove the cells. 5ml of DMEM was 
added to inactivate the trypsin and the cell suspension was transferred to a 50ml 
falcon tube, where a vigorous mixing step occurred to ensure no clumps of 293T 
cells remained. The suspension was topped up to 32ml and aliquoted into 3 fresh 
10mm plates. 
 
2.2.2 Primary cell isolation 
 
Bone marrow aspirates from patients with AML and MM were obtained by 
haematology registrars at the NNUH, following informed consent under approval 
	 71	
from the UK NHS Health Research Authority (LCREref07/H0310/146) as 
previously described (273). Primary cell isolation was achieved using Histopaque 
density centrifugation. Briefly 10ml of Histopaque-1077 was added to a 50ml 
falcon tube and 15-20ml of bone marrow was layered on top. This was centrifuged 
at 1400rpm for 20 minutes with brakes and acceleration removed, which ensured 
successful separation of the different blood components. The mononuclear cells 
formed a “buffy coat” on top of the Histopaque layer and were isolated using a 
Pasteur pipette. A schematic overview of the density separation can be seen 
below in Figure 2.1. 
 
 
Figure 2.1. Schematic of the Histopaque density centrifugation of primary bone marrow. 
Bone marrow aspirate was layered on Histopaque-1077 and centrifuged to produce the “buffy 
coat” containing AML/MM cells along with BMSC. 
 
 
PBS was added to the isolated buffy coat to a final volume of 15ml and centrifuged 
at 1400rpm for 5 minutes, with the acceleration and brakes turned on. Any 
remaining red blood cells were removed by the addition of 1X red cell lysis buffer 
(1ml) (ThermoFisher, Waltham, MA, USA) to the cell pellet for 5 minutes, prior to 
the addition of 14ml of PBS. Pelleted mononuclear cells, after centrifugation, were 
cultured for 24 hours in DMEM supplemented with 10% FCS and penstrep. 
Suspension cells were removed at this time and fresh DMEM was added to the 
remaining adherent cells in the flask. 
 
Malignant AML and MM cells were located in the suspension cell fraction after 
the 24-hour incubation. AML samples with <90% purity were purified using CD34 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and magnetic-
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activated sorting (MACS). All MM samples were purified using CD138 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) with MACS. Up to 
200 million AML/MM cells were centrifuged at 1400rpm for 5 minutes and re-
suspended in MACS buffer (PBS pH 7.4 supplemented with 0.5% BSA and 1mM 
EDTA). Magnetically labelled CD34/CD138 antibodies were added to the AML 
and MM cell suspension respectively and incubated at 4˚C for 30 minutes. After 
another centrifugation step, as above, the cells were re-suspended in MACS 
buffer and added to a MS column (Miltenyi Biotec, Bergisch Gladbach, Germany) 
attached to a magnet. Three column washes in MACS buffer were carried out 
before CD34/CD138+ cells were eluted by removal of the MS column from the 
magnet. 
 
Non-malignant BMSC were located in the adherent fraction. Fresh DMEM 
medium was added to the flask twice weekly until patches of adherent BMSC 
were visible. At this point the BMSC were removed from tissue culture plastic 
using the serine protease trypsin. Briefly, medium was removed from the flask 
and cells were washed with 10ml of PBS followed by the addition of 3ml 0.25% 
Trypsin. After a short incubation in a humidified culture incubator, the flask was 
lightly tapped to remove the adherent cells followed by the addition of 5ml DMEM 
medium to inactivate the Trypsin. 20ml of DMEM was added to the cell 
suspension and was placed back in the incubator, allowing the cells to re-adhere 
to the tissue culture plastic.  This formed of a uniform layer of BMSC which were 
expanded for around 2 weeks until 80% confluency then passaged again prior to 
use in experiments. BMSC were characterised by the expression of surface 
markers CD73, CD90 and CD105 whilst being negative for the myeloid marker 
CD45. 
 
Non-malignant CD34+ HSCs were isolated from peripheral blood venesections 
from haemochromatosis patients at the NNUH. One pint of blood was initially 
centrifuged in multiple 15ml falcon tubes for 20 minutes at 1400rpm, with brakes 
and acceleration turned off. This allowed the separation of the red blood cells 
from the serum, shown in Figure 2.2. A small buffy coat of cells, including HSCs, 
formed on top of the red cells and was removed with a Pasteur pipette and pooled 
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together obtaining ~50ml per pint of blood. This cell solution was diluted 2-fold in 
PBS and 25ml was layered on top of 15ml of Histopaque-1770. A further buffy 
coat of cells was obtained using Histopaque density centrifugation, as described 
above, and these cells were washed in PBS twice before suspension in MACS 
buffer. CD34+ cells were then isolated using CD34 microbeads and MACS, as 
per AML primary samples. These cells were used in experimental procedures at 
the time of purification.  
 
CD34+ HSC were also isolated from umbilical cord blood of babies born via 
caesarean section, using an adapted protocol by Hogan and collegues (337). 
Cord blood was isolated by Dr Charlotte Hellmich and Dr Genevra Pillinger at the 
NNUH. Roughly 50ml of cord blood was layered onto 2 x 15ml of Histopaque-
1770 and density separated using centrifugation as described above. CD34+ 
cells were isolated using MACS as per the venesection blood. Purified cord blood 
CD34+ HSC were injected into NSG mice to create “humanised” NSG mice (22) 
to analyse in vivo non-malignant mitochondrial transfer.  
 
 
Figure 2.2. Schematic representation of CD34+ HSC isolation from venesection blood. 
The buffy coat generated is then taken and purified by CD34+ MACS, resulting in a pure 
population of CD34+ HSCs. 
 
 
2.2.3 Cryopreservation of primary cell and cell lines 
 
Aliquots of primary AML and MM samples were frozen at the point of extraction 
prior to CD34/CD138 MACS purification. Total mononuclear cells (buffy coat) 
were frozen at a 5x106 cells/ml concentration in FCS supplemented with 10% 
DMSO. Cells were slowly frozen in a cryo-freezing container (ThermoFisher, 
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Waltham, MA, USA) to a temperature of -80˚C. AML and MM cell lines were also 
frozen in this way. 
 
To thaw the aliquots, the vial of cells was removed from the -80˚C freezer and 
placed in a 37˚C incubator to defrost. The cells were then transferred into a 15ml 
falcon tube and topped up to 15ml with fresh culture medium to dilute the DMSO 
concentration, which ensured maximum cell viability after thawing. Cells were 
centrifuged at 1400rpm for 5 minutes, supernatant was discarded and the cells 
were re-suspended in 15ml of fresh DMEM (primary samples) or RPMI-1640 (cell 
lines). Primary samples were then cultured as per fresh primary samples; removal 
of suspension cells and purification of the malignant cell along with expansion of 
the adherent BMSC.  Cell lines were cultured for 1 week prior to splitting and 
maintenance at a 0.5 x106 cells/ml concentration.  
 
2.2.4 Counting cells via Trypan Blue exclusion 
 
Trypan Blue exclusion was used to determine cell concentrations. Briefly, 10µl of 
cell suspension was mixed with 10µl Trypan Blue and 10µl of this solution was 
pipetted onto a haemocytometer. Healthy living cells did not take up the Trypan 
Blue stain as their cell membrane was intact; however, dead or dying cells took 
up the stain as their cell membrane was fractured. The number of healthy cells in 
the four outer quadrants of the haematocytomer were counted and the cell 
concentration (cells/ml) was calculated, see Figure 2.3.  
 
 
  
Figure 2.3. Determining cell concentrations using Trypan Blue exclusion. 
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The calculated cell concentration was used throughout my thesis to calculate the 
number of cells needed per experimental procedure. The equation below was 
used to determine this. 
 Number	of	cells	requiredCell	concentration = Volume	of	cell	suspension	required	(ml) 
 
2.2.5 Generation of a cell line depleted of mitochondria (rho0 cells) 
 
To assess mitochondrial transfer to AML cells, I attempted to generate a cell line 
that was severely depleted of mitochondria, as per the protocol by Tan and 
colleagues (325). Here the OCI-AML3 cell line was cultured in RPMI-1640 
medium (10% FCS and penstrep) supplemented with 50ng/ml ethidium bromide, 
100µg/ml sodium pyruvate and 50µg/ml uridine. The ethidium bromide was used 
to specifically intercalate with and deplete mtDNA, the addition of pyruvate and 
uridine allowed the cell line to enhance glycolysis to generate the ATP required 
for cell survival. The medium was changed twice weekly by centrifuging the cells, 
discarding the supernatant and adding fresh medium. After a 40-day culture the 
mtDNA content in these cells was analysed by qPCR. 
 
2.3 Cell culture assays 
 
Primary and cell line AML and MM (along with BMSC) were cultured as above 
prior to use in the cell culture assays described below.  
 
2.3.1 Co-cultures of AML/MM and BMSC 
 
Co-culture systems were used to show that mitochondrial transfer occurred 
between BMSC and AML/MM cells. Primary BMSC were plated on 6, 12 and 24 
well plates at a density of 2x105, 5x104 and 2x104 respectively. The medium was 
replaced 24 hours after plating, BMSC were ready to use after 48 hours. At this 
point primary or cell line AML/MM cells were added to BMSC in a volume of 2, 
1.5 and 1ml for 6, 12 and 24 well plates respectively. AML/MM were added to 
BMSC in a ratio of 5 malignant cells per BMSC. At various time points, the two 
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cell types were separated by gentle mixing (as BMSC are adherent cells and 
AML/MM are suspension cells) and analysed independently.  
 
2.3.2 MitoTracker based mitochondrial transfer assay 
 
Mitochondrial transfer was shown to occur between BMSC and AML/MM using 
three independent methods. Firstly, a MitoTracker based staining method was 
developed to show the specific movement of BMSC mitochondria to malignant 
AML/MM. The specific mitochondrial stain MitoTracker Green FM (ThermoFisher, 
Waltham, MA, USA) was utilised for this method. BMSC plated on 24 well plates 
were stained for 1 hour with 200nM MitoTracker, in 500µl FluoroBrite DMEM 
medium (ThermoFisher, Waltham, MA, USA) supplemented with 10% FCS. After 
the incubation, BMSC were washed 3 times with PBS to remove any un-bound 
probe. AML/MM were then added to the stained BMSC for 24 hours and levels of 
MitoTracker in AML/MM cells were then analysed by flow cytometry, compared 
with mono-cultured cells.  
 
Naïve un-labelled AML/MM cells were initially added to stained BMSC, however 
results were un-convincing as very large increases in MitoTracker fluorescence 
were observed in AML/MM cells. I found this was due to MitoTracker dye leaking 
from BMSC and staining AML/MM mitochondria. To eliminate this, I additionally 
stained AML/MM cells with 200nM MitoTracker Green for 30 minutes before they 
were added to BMSC. This saturated AML/MM mitochondria with MitoTracker, 
therefore any dye leakage will have a negligible effect on the MitoTracker 
fluorescence within the malignant cell. This change achieved more believable 
increases in MitoTracker fluorescence in the AML/MM, which was attributed to 
BMSC derived mitochondria moving into AML/MM cells. 
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Table 2.2. Pharmacological agents used to assess mitochondrial transfer levels. 
 
 
This method was also used to quantify levels of mitochondrial transfer. Stained 
AML/MM in mono-culture were compared to when they were cultured with stained 
BMSC, this achieved a baseline level of transfer. The effect of pharmacological 
compounds (seen in Table 2.2) on mitochondrial transfer levels could then be 
determined by comparing mitochondrial transfer between drug treatment and 
baseline transfer.  
 
2.3.3 rLV.EF1.mCherry mitochondrial transfer assay 
 
For the second method, I used a stable lentiviral transfection of BMSC 
mitochondria with a red mCherry fluorescence in order to track BMSC 
mitochondria. A rLV.EF1.mCherry-Mito-9 lentivirus was purchased from Clontech 
and was used to transduce human BMSC. 0.5µl of the virus (0.5x106 virus 
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particles) was added to 5x105 BMSC in 500µl of penstrep free 10% FCS DMEM 
medium. 1ml of DMEM medium was added after 24 hours, BMSC were then 
cultured for a further week. At this point, successful transduction was assessed 
by the detection of mCherry fluorescence in the BMSC using fluorescent 
microscopy. If successful transduction was observed, AML/MM cells were added 
to BMSC for 1 week. Mitochondrial transfer was observed by acquisition of the 
Mito-9 mCherry fluorescence in AML/MM cells using fluorescent microscopy. 
Microscopy with AML blasts was carried out with live cells, the protocol was 
however optimised with MM. The co-culture was carried on tissue culture 
coverslips, with the cells fixed in 4% Paraformaldehyde and mounted with 
ProLong™ Gold Antifade Mountant containing DAPI (ThermoFisher, Waltham, 
MA, USA).  
 
2.3.4 Visualisation and quantification of tunnelling nanotubes 
 
To visualise TNTs formed between BMSC and AML/MM cells, the 1,1'-
Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DiI) stain 
(ThermoFisher, Waltham, MA, USA) was utilised. DiI is a lipophilic membrane 
stain that diffuses laterally staining the whole cell. 1x106 AML/MM cells in a 
volume of 1 ml were stained with a DiI concentration of 5µg/ml for 15 minutes. 
The cells were washed thrice in PBS and incubated for 30 minutes in culture 
medium. BMSC were also stained with MitoTracker Green FM (200nM) for 1 hour 
before washing thrice in PBS. The stained AML/MM were combined with the 
BMSC for 24 hours before fixing with 4% Paraformaldehyde. Cells were imaged 
by confocal microscopy. 
 
A second method was utilised for the MM study, whereby MM cell plasma 
membranes were labelled with GFP using stable lentiviral transduction. The 
rLV.EF1.AcGFP1-Mem-9 lentivirus was purchased from Clontech. 0.5µl of the 
virus (0.5x106 virus particles) was added to 5x105 MM1S/U266 MM cell lines in 
500µl of penstrep free RPMI medium supplemented with 10% FCS. After 
confirmation of lentiviral transduction, these cells were added to BMSC stained 
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with 200nM MitoTracker Red CMXRos (ThermoFisher, Waltham, MA, USA) as 
above. TNT visualisation was carried out using confocal microscopy. 
 
Only a very small number of TNTs were visualised as they form and dissociate 
very rapidly. To quantify TNTs formed between AML/MM cells and BMSC I 
utilised the TNT-anchor points (TAPs) formed on the BMSC. These TAPs were 
residual DiI stain remaining after AML/MM derived TNTs had dissociated. These 
TAPs were not present on BMSC when AML/MM cells were cultured in a 0.4µM 
trans-well system, they are therefore specific to the cell-cell contacts observed. 
 
2.4 Cell viability assays 
 
2.4.1 CellTitre-Glo 
 
The viability of AML, MM and BMSC was assessed using the CellTite-Glo assay 
(Promega, Fitchburg, WI, USA), as previously described (338).  Addition of the 
CellTitre-Glo substrate causes cell lysis and a luminescent signal proportional to 
the amount of ATP present, which is a representation of the number of 
metabolically active cells (summarised in Figure 2.4). For the reaction, 5x104 cells 
were plated on a white 96 well plate in a 50µl volume. 50µl of CellTitre-Glo 
substrate was added, followed by a 10-minute incubation in the dark. 
Luminescence at an emission wavelength of 560nm was detected using the 
LUMIstar Omega microplate reader (BMG LABTECH, Ortenberg, Germany). This 
assay was also used to determine the levels of ATP produced by AML/MM after 
co-culture with BMSC.   
 
 
Figure 2.4. An equation showing the CellTitre-Glo reaction. 
In the presence of ATP, the CellTitre-Glo substrate is converted to Oxyluciferin. This reaction 
produces light which can be detected by luminescence at a wavelength of 560nm. 
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2.4.2 Annexin V/PI 
 
Cell viability was also assessed using the eBioscienceTM Annexin V/PI detection 
kit (ThermoFisher, Waltham, MA, USA), as previously described (339). The 
annexin V FITC antibody binds to phosphatidylserine externalised on apoptotic 
cells. Propidium iodide (PI) stains DNA of necrotic and apoptotic cells, healthy 
cells are not stained as PI cannot cross their membrane. To perform the assay, 
2x104 AML/MM cells were centrifuged and re-suspended in 800µl of 1X 
annexin/PI binding buffer containing 2µl of annexin V FITC antibody and 4µl of 
PI. The cells were incubated in the dark for 15 minutes before washing in ice-cold 
PBS. The cells were then run on the Sysmex Cube 6 flow cytometer and results 
analysed using FCS Express 5 software (De Novo Software, Glendale, CA, USA). 
An example of a flow cytometry plot generated from this assay is shown in Figure 
2.5.  
 
 
Figure 2.5. Representative flow cytometry plot of an Annexin V/PI viability assay. 
Cells were stained with PI and Annexin V and analysed by flow cytometry. Live cells (PI- Annexin 
V-), Apoptotic (PI- Annexin V+) and Dead (PI+ Annexin V+) cells can be determined. 
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2.5 Detection of reactive oxygen species 
 
2.5.1 DCFDA / H2DCFDA (DCF) assay 
 
To determine ROS levels in BMSC the DCF assay (ThermoFisher, Waltham, MA, 
USA) was utilised as per the manufacturers protocol. For this assay H2DCFDA 
was added to the cell of interest which is taken up and deacetylated by cellular 
esterases to a non-fluorescent compound H2DCF. This compound is oxidised in 
the presence of ROS to the highly fluorescent compound 2’, 7’ –dichlorofluorescin 
(DCF). This compound has an emission wavelength of 529 nm and can be 
detected by flow cytometry in the FITC channel. A schematic overview of this 
reaction is shown in Figure 2.6. 
 
 
Figure 2.6. Overview of the DCF assay to detect ROS. 
The H2DCFDA reagent is taken up by cells and converted to H2DCF by cellular esterases. In the 
presence of ROS H2DCF is oxidised to form the fluorescent DCF. 
 
To perform the reaction 1x105 BMSC were stained with 10µM H2DCFDA in 500µl 
FluoroBrite DMEM medium (ThermoFisher, Waltham, MA, USA) - supplemented 
with 10% FCS for 15 minutes at 37 °C. BMSC were removed from tissue culture 
plastic with trypsin prior to staining. The cells were washed three times in PBS 
after staining, the cells were then run through the Sysmex Cube 6 flow cytometer. 
Results were analysed using FCS Express 5 software.  
 
2.5.2 AmplexTM Red superoxide detection assay 
 
The DCF assay described above has the capability of measuring total ROS in 
cells – which includes superoxide, peroxide, hydroxyl radicals and hydroxyl ions. 
In the AML study superoxides were of interest as NOX2 on the surface of the 
AML blasts generates large amounts of superoxide. The AmplexTM Red 
superoxide detection assay (ThermoFisher, Waltham, MA, USA) was used to 
specifically measure superoxide levels generated (as per the manufacturers 
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protocol). This assay is a one-step reaction where (in the presence of horseradish 
peroxidase (HRP)) the Amplex Red reagent (10-acetyl-3,7-
dihydroxyphenoxazine) reacts with superoxide forming Resurfin. This product 
fluoresces at an emission wavelength of 585nm and is designed to be detected 
in a 96 well plate format. This reaction was carried as per the manufacturer’s 
specifications.  
 
Figure 2.7. Overview of the AmplexTM Red reaction used to detect superoxides. 
In the presence of superoxides the Amplex Red Reagent to converted to the fluorescent 
compound Resurfin. 
 
To perform the reaction 2x105 AML blasts were plated on a black 96 well plate 
with a transparent base in a volume of 50µl FluoroBrite DMEM medium 
supplemented with 10% FCS. A master mix was created by mixing 0.5µl Amplex 
Red reagent, 1µl HRP and 48.5µl 1X reaction buffer per sample. 50µl of this 
master mix was added to the cell suspension and fluorescence was measured 
using the FLUOstar Omega microplate reader (BMG LABTECH, Ortenberg, 
Germany). A hydrogen peroxide standard curve was performed on each 96 well 
plate measured to determine an accurate superoxide concentration in the 
samples tested. 
 
2.6 Microscopy 
 
2.6.1 Confocal Microscopy 
 
To visualise TNT formations between BMSC and AML/MM cells (along with TAPs 
on BMSC) confocal microscopy was carried out using a Zeiss LSM 800 Axio 
Observer.Z1 confocal microscope with 40X and 63X water objectives (Carl Zeiss, 
Oberkochen, Germany). Cells were prepared as described in section 2.3.4. Fixed 
cells on 24 well black walled imaging plates (Ibidi, Munich, Germany) were placed 
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on the microscope using a plate holder. ZEN Blue imaging software (Carl Zeiss) 
smart setup was used to define fluorophore wavelength acquisition parameters 
of DiI stain and MitoTracker Green FM or GFP and MitoTracker CMXRos. TNT 
formations were infrequently observed, TAP formation on BMSC was therefore 
used to quantity the number of TNT formation per culture. Multiple images were 
taken for TAP quantification. ImageJ software was used to achieve accurate 
quantification and for image processing. Confocal microscopy was also used to 
detect CD38 expression on BMSC after MM co-culture, whether CD38 localised 
to TAPs and whether CD38 was found on TNTs. Cells were prepared as per 
section 2.3.4 with the addition of 2µl of anti CD38-Alexa Fluor 647 antibody prior 
to fixing (Miltenyi Biotec, Bergisch Gladbach, Germany). Another smart setup was 
carried out in ZEN Blue imaging software to incorporate the extra fluorophore. 
ImageJ was used for image processing. 
 
2.6.2 Fluorescent microscopy 
 
Fluorescent microscopy was carried out on a Zeiss Axio Vert.A1 microscope with 
20X and 40X air objectives (Carl Zeiss, Oberkochen, Germany). This microscope 
was used to detect mCherry-Mito-9 in AML/MM cells after co-culture with 
rLV.EF1.mCherry-Mito-9 transduced BMSC. Cells were prepared on 24 well 
black walled imaging plates (or coverslips as described in 2.3.3) and placed on 
the plate/slide holder on the microscope. ZEN Blue imaging software was used 
to acquire fluorescent and light images. Image processing was achieved using 
ImageJ software. 
 
2.7 Flow Cytometry 
 
Flow cytometry was used in my thesis for a number of different applications: 
• To analyse mitochondrial levels in AML/MM/BMSC in addition to 
mitochondrial transfer levels (using MitoTracker Green Fluorescence). 
• To detect cell surface receptors with antibodies conjugated to a 
fluorophore. 
• To sort a specific cell population based on its cell surface receptors. 
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To achieve the above applications a range of flow cytometers were used based 
on the number of fluorophores they can detect in a single sample and whether 
they had cell sorting capabilities. Table 2.3 shows a comparison of the flow 
cytometers capabilities. Table 2.4 shows all antibodies used in the analysis, 
purchased from Miltenyi Biotech (Bergisch Gladbach, Germany) and BioLegend 
(San Diego, CA, USA). 
 
2.7.1 Sysmex Cube 6 
 
The Cube 6 flow cytometer (Sysmex, Gorlitz, Germany) is a multi-channel flow 
cytometer with 2 lasers - the blue 488nm and red 633nm. This laser combination 
can detect the following fluorophores: FITC, PE, PERCP and APC. The Cube 6 
flow cytometer was used in my thesis for single colour flow cytometry only, due 
to the lack of sophisticated colour compensations - cross-over of emission spectre 
therefore could not be controlled and accounted for. The MitoTracker based flow 
cytometry assay was performed on this cytometer as only the FITC channel (in 
which MitoTracker Green is detected) was required. 
 
Prior to use an automated priming sequence was performed to ensure no 
blockages or air bubbles were present in the system. To run the samples, ~1x105 
cells were re-suspended in 1ml of PBS and transferred into a flow cytometry 
analysis tube. The flow cytometry tube was attached to the cytometer and the 
analysis was started through the FCS software - 1x104 cells were analysed in a 
pre-defined gated region. An automated cleaning cycle was carried out after all 
sample tubes had been analysed. Sample data was exported as an FCS file and 
analysed using FCS Express 5 software. For the MitoTracker based staining 
assay this analysis determined the mean fluorescence intensity (MFI) of 
MitoTracker Green in AML/MM cells.  
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2.7.2 Beckman Coulter CytoFLEX 
 
The Beckman Coulter CytoFLEX flow cytometer (Brea, CA, USA) also is a two-
laser flow cytometer (488 and 633nm) capable of detecting FITC, PE, PERCP 
and APC (as per the Cube 6 flow cytometer). This cytometer is however more 
sophisticated as bandpass filters allows the further detection of PE-cy5, PE-cy7 
and APC-cy7. Colour compensation also allows the detection of up to four 
fluorophores within the same sample tube. In my thesis, this flow cytometer was 
used when multiple fluorophores were assessed (<4) in the same sample tube. 
An example of this is the confirmation of CD34+ HSC engraftment into NSG mice, 
whereby human CD45-FITC and mouse CD45-APC were used to detect human 
and mouse cells in the peripheral blood of mice. 
 
Prior to use the automated daily clean process was carried out to ensure the flow 
cytometer was cleaned and primed. A compensation matrix was calculated by 
running single stained samples and a dual/tri/quad stained sample. This matrix 
determined the level of spectre cross over and created a compensation to account 
for the overlap in future samples tested. This compensation was applied prior to 
running the “real” test samples. 1x105 cells were stained with the antibodies of 
interest (along with appropriate isotype controls) in 50µl PBS for 15 minutes 
before the addition of a further 300µl of PBS. These stained samples were 
transferred to a flow cytometry tube and placed in the CytoFLEX for analysis. 
1x104 cells were analysed in a pre-defined region. Data analysis was performed 
using the CytExpert 1.2 software. 
 
2.7.3 BD FACSCanto II 
 
The FACSCanto II flow cytometer (BD, Franklin Lakes, NJ, USA) is a three-laser 
flow cytometer (405, 488 and 633nm) capable of assessing up to 7 different 
fluorophores within the same sample. These fluorophores included FITC, PE-
Cy5, PE-Cy7, APC, APC-Cy7, BV421 and BV510. A colour compensation (for 
each antibody panel used) was carried out using single stained samples to 
calculate fluorophore emission cross-over. This compensation was applied to 
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each experiment prior to running the samples. In addition, fluorescence minus 
one (FMO) controls for each fluorophore were carried out to determine the 
positive and negative gates for each marker. This flow cytometer was used to 
detect mitochondrial levels in various cell populations within mouse bone marrow 
- antibodies panels used can be seen in Table 2.5. This flow cytometer was 
located in the Pathology Laboratory at the NNUH and was maintained by Dr 
Allyson Tyler and Dr Ian Thirkettle.  
 
To perform the analysis 5x106 mouse bone marrow cells were stained for 15 
minutes with 200nM MitoTracker in 500µl Flurobrite DMEM - with 10µl Lineage 
depletion cocktail bound to biotin (Miltenyi Biotec, Bergisch Gladbach, Germany). 
The cells were centrifuged at 1400rpm for 5 minutes and re-suspended in 50µl of 
PBS. A master mix of antibodies was made (where a 1X mix contained 2µl of 
each antibody) and was added to the cells. After a subsequent 15-minute 
incubation, 300µl of PBS was added and the cells were transferred to a flow 
cytometry tube. The samples were run on the FACSCanto II using the automated 
carousel function. Sample data was analysed using a combination of FCS 
Express 5 and FlowJo software. 
 
2.7.4 BD FACSAria II 
 
The FACSAria II (BD, Franklin Lakes, NJ, USA) has the same flow cytometry 
abilities as the FACSCanto II with the additional capability of cell sorting. This flow 
cytometer was used to sort a pure population of OCI-AML3, MV4-11, MM1S, and 
U266 luciferase cells used for in vivo studies. Cell sorting was carried out by Dr 
Zhigang Zhou. 
 
2.7.5 BD FACSMelody 
 
The FACSMelody (BD, Franklin Lakes, NJ, USA) also has the same capabilities 
as the FACSCanto II and has the sorting capabilities of the FACSAria II. This flow 
cytometer was located at the Earlham Institute and was used to sort human HSCs 
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from the bone marrow of “humanised” NSG mice. This sorting was carried out by 
Dr Iain Macaulay and Dr Laura Mincarelli.  
 
Table 2.3. Capability comparison of the flow cytometers used. 
 
 
Table 2.4. Antibodies used in flow cytometry assays. 
 
 
Table 2.5. Antibody panels used to detect human and mouse HSCs. 
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2.8 Seahorse Extracellular Flux Assay 
 
To analyse the metabolic activity of AML and MM cells the Seahorse XFp 
Analyzer (Agilent Technologies, Santa Clara, CA, USA) was used with the 
Seahorse XFp Cell Mito Stress Test Kit (as per the manufacturers protocol). 
Levels of OXPHOS (mitochondrial respiration) and glycolysis (non-mitochondrial 
respiration) in a cell of interest can be determined using this method, through the 
analysis of oxygen consumption rates (OCR) and extracellular acidification rates 
(ECAR) respectively. In my thesis, this method was used primarily to observe the 
changes in mitochondrial respiration between mono and co-cultured AML and 
MM cells, along with respiration dynamics in BMSC post culture with malignant 
cells. Not only can this assay determine basal mitochondrial respiration rates it 
can also determine the maximum respiration, spare capacity of a cell, proton leak 
and ATP production (Figure 2.8). This was achieved using periodic injections of 
Oligomycin (inhibiting ATP synthase reducing OCR), FCCP (increases H+ ion 
permeability of the lipid bilayer facilitating H+ transport across the hydrophobic 
mitochondrial inner membrane independently of ATP synthase - increasing OCR) 
and Rotenone/Antimycin A (targeting complex 1 and 3 reducing OCR).  
 
 
Figure 2.8. The Mito Stress test experimental profile. 
Periodic injections of Oligomycin, FCCP and Rotenone/Antimycin A allowed basal and maximum 
respiration to be determined using oxygen consumption rate (OCR). ATP production, spare 
capacity and proton leak were also able to be analysed. Source: Agilent Technologies, 
https://www.agilent.com/cs/library/flyers/public/5991-7118EN.pdf, accessed May 2018. 
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To run the assay AML and MM cells were first cultured for 72 hours with or without 
BMSC. Specific numbers of cells were then plated on Seahorse XFp cell culture 
plates (coated with Poly-D-Lysine) in Seahorse XFp Base Medium supplemented 
with 2.5mM Glucose, 2mM Glutamine and 1mM Pyruvate. To analyse BMSC, 
these cells were plated on coated seahorse plates prior to AML co-culture. 1x105 
AML/MM cells were plated in triplicate in 50µl volumes, followed by centrifugation 
at 1400rpm for 5 minutes to ensure a confluent mono-layer of cells is achieved. 
24 hours prior to the assay the Seahorse Extracellular Flux analyser was switched 
on to allow it to equilibrate at 37˚C. Seahorse XFp sensor cartridges were also 
hydrated in XFp Calibrant overnight at 37˚C. To run the assay Oligomycin, FCCP 
and Rotenone/Antimycin A were loaded into the pre-calibrated sensor cartridge 
in 1µM, 1µM and 0.5µM concentrations respectively. The sensor was loaded into 
the extracellular flux analyser and the pre-defined MitoStress protocol was run.  
After a 20-minute sensor equilibration the cell plate (with wells topped up to 180µl 
of Seahorse Base Medium) was loaded into the analyser. Results obtained were 
analysed using Graphpad and Microsoft Excel.  
 
2.9 Genetic knockdown of AML, MM and BMSC 
 
To analyse the effect of NOX2, PGC-1α and CD38 on mitochondrial transfer 
genetic knockdown was carried out with short hairpin RNA (shRNA) targeted to a 
gene of interest (GOI) using a lentiviral system. The cell type of interest is 
transduced with a lentivirus containing RNA which encodes shRNA targeting a 
GOI. This RNA is incorporated into the genome of the cell resulting in shRNA 
being transcribed by RNA polymerase III machinery. This shRNA mimics pri-
miRNA and is modified by Drosha and Dicer enzymes to produce double stranded 
RNA, removing the short hairpin. This is then loaded into the RNA-induced 
silencing complex (RISC) where the sense strand (passenger) is degraded by 
Argonaute-2. The remaining anti-sense strand leads the RISC to mRNA 
complementary to itself, resulting in mRNA cleavage by RISC - silencing the GOI. 
The process of lentiviral preparation is explained below. The protocol was 
designed by Dr Lyubov Zaitseva, as previously described (340). 
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2.9.1 Lentiviral production 
 
2.9.1.1 Plasmid preparation 
 
Escherichia coli (E. coli) glycerol stocks (containing pLKO.1-amp vectors 
encoding shRNA specific for a GOI) were purchased from Sigma Aldrich’s 
MISSION® shRNA library (see Table 2.6 for details). 
 
Table 2.6. pLKO.1-amp vectors containing shRNA targeting a GOI 
 
 
The initial step in the preparation of a lentivirus is the generation of pLKO.1-amp 
plasmids from E. coli stocks. Luria Bertani (LB) agar plates, containing 50µg/ml 
ampicillin, were made and left to set at room temperature. Using a stringent 
aseptic technique, the MISSION® glycerol stocks were streaked on these plates 
and incubated upside down at 37˚C for 16 hours. Single E. coli colonies were 
then picked with a sterile pipette tip and transferred into a 10ml tube containing 
5ml of sterile LB broth supplemented with 50µg/ml ampicillin. This tube was then 
incubated at 37˚C on shaking platform set at 240rpm.  
 
After incubation, bacterial growth caused the LB broth to turn cloudy and plasmid 
purification could now take place. The bacterial culture was centrifuged at a high 
speed for 10 minutes to pellet the bacterial cells - the supernatant was discarded. 
Plasmid DNA was then purified from the E. coli cells using the NucleoSpin® 
Plasmid kit (Macherey-Nagel, Duren, Germany), as per manufacturer’s 
instructions. Briefly, E. coli cells were lysed and neutralised prior to loading onto 
a plasmid DNA binding spin column. Plasmid DNA was washed and eluted from 
the column. Purified plasmid DNA was quantified using a Nanodrop 
spectrophotometer (ThermoFisher, Waltham, MA, USA) - with purity confirmed 
using A260/230 and A260/280 ratios.  
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2.9.1.2 Plasmid precipitation 
 
A total plasmid concentration of 180ng/µl or greater was required to proceed with 
lentiviral production. If a lower concentration was generated a precipitation step 
was carried out to increase the plasmid concentration. Here 3M sodium acetate 
was added at a ratio of 1:10 to the total plasmid volume, followed by the addition 
of ice cold absolute ethanol (greater than two times the total plasmid volume). 
The solution was then frozen at -80˚C for several hours, then centrifuged at a high 
speed for 5 minutes at 4˚C. The supernatant was discarded and 1ml of ice cold 
70% ethanol was added and another centrifugation step was carried out as 
above. As much of the ethanol was removed as possible and the plasmid pellet 
was dried out in a tissue culture hood. The plasmid pellet was finally re-
suspended in water to achieve the desired plasmid concentration of >180ng/µl. 
 
2.9.1.3 Transfection of packaging cells 
 
293T packaging cells were cultured as described in 2.2.1 and split 1:2 prior to 
transfection. To create a functional lentivirus encoding shRNA targeted to a GOI, 
three different plasmids were required along with a transfection reagent. The 
pLKO.1-amp plasmid generated in 2.9.1.1 was the first plasmid used. In addition, 
Vesicular stomatitis virus glycoprotein (VSV-G) and cytomegalovirus promoter 
(pCMV) were also required as envelope proteins and packaging protein promoter 
respectively. The latter two plasmids were made from glycerol stocks as per the 
pLKO.1-amp plasmid. The transfection reagent used was FuGENE® 6 (Promega, 
Fitchburg, WI, USA). 
 
For each 10mm tissue culture dish of 293T cells a master mix of plasmids and 
transfection reagent was made as follows: 1µg of VSVG and pCMV plasmids 
were mixed with 1.5µg of pLKO.1-amp plasmid in a total volume of 15µl TE buffer. 
This DNA mixture was added to 200µl of Opti-MEM medium (ThermoFisher, 
Waltham, MA, USA) along with 18µl of FuGENE® 6. The medium was removed 
from the plate of 293T cells and replaced with 7.5ml of fresh 293T DMEM medium 
before the addition (in a dropwise manner) of the Opti-MEM medium containing 
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plasmid and transfection reagent. After a 24-hour incubation, the medium was 
removed and discarded from the 293T cells and replaced with fresh medium. This 
was repeated at 48, 72 and 96-hour time points, however at these times the 
medium removed was collected and stored at -80˚C - as it contained the lentivirus. 
 
2.9.1.4 Lentivirus titre 
 
Small 70µl aliquots from each virus collection time point were kept aside from the 
bulk collection - these were used to determine the lentivirus titre. Viral RNA was 
isolated from the 3-pooled lentiviral time point collections using the Nucleospin® 
Dx Virus kit (Machery-Nagel, Duren, Germany). 150µl of the 210µl total pooled 
volume was taken aside, 600µl of RAV1 buffer was added and vortexed 
thoroughly. After a 5-minute incubation, 600µl of absolute ethanol was added and 
vortexed for 30 seconds. The solution was then loaded into a Nucleospin® Dx 
Virus column and centrifuged at 8000 x g for 1 minute discarding the waste. The 
column was placed in a new collection tube, before the addition of 500µl of RAW 
buffer and a further centrifugation step using the above parameters. The column 
was then washed with RAV3 buffer twice (600 and 200µl respectively) using 1 
minute centrifugation steps at 8000 and 11000 x g. RNA was then eluted into 
clean and sterile Eppendorfs using 50µl of nuclease free water (warmed to 70˚C).  
Any remaining contaminating DNA was removed using a DNase step - 12.5µl of 
viral RNA was added to 10µl of DNase and 2.5µl DNase1 buffer. The solution 
was incubated in a thermocycler for 30 minutes at 30˚C followed by a 5-minute 
incubation at 70˚C.  
 
The RNA genome copy number was then calculated using the Lenti-X qRT-PCR 
titration kit (Clontech Takara Bio Europe, Saint-Germain-en-Laye, France). 
Briefly, a master mix was generated (detailed in Table 2.7) on ice, with 10% extra 
volume to account for pipetting errors. The RT enzyme mix was added last. A 
standard curve was made in 8-well PCR strips using a known concentration of 
5x107 copies/µl as the top concentration, which was diluted down to 5x103 in 
EASY dilution buffer. Viral RNA samples were also diluted using a 10-fold serial 
dilution method resulting in 4 concentrations. 2µl of the control template, viral 
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RNA and negative control were added in duplicate to a 96 well Lightcycler PCR 
plate (Roche, Basel, Switzerland) - containing 18µl of the master mix detailed in 
Table 2.7 The plate was sealed and run on a Lightcycler LC480 (Roche, Basel, 
Switzerland) using the following program: 
 
• RT Reaction – 5 minutes at 42˚C, 10 seconds at 95˚C (1 cycle) 
• Amplification – 5 seconds at 95˚C, 30 seconds at 60˚C (40 cycles) 
• Melting Curve – 15 seconds at 95˚C, 30 seconds at 60˚C (1 cycle) 
 
Table 2.7. Master mix for Lenti-X lentiviral titration qPCR 
 
 
A standard curve was generated using cycle threshold (Ct) values of the known 
copy number dilutions - enabled by the Roche Lightcycler software. This was 
used to determine the raw copy number of the viral RNA. Actual copy numbers 
per ml was determined using the equation below: 
 
 Copies	per	ml = Raw	copy	number	×1000	µl/ml	×DNAse	dilution	factor	×	Viral	RNA	elution	volumeDEFGFHI	JHKLIM	NOIPKM	 LQM	NFQHI	RST	MUGQHVGFOE 	×	WHKLIM	NOIPKM	HXXMX	GO	YZR 
 
For example, a raw copy number of 2 x 107 would give the following copy 
numbers per ml: 
 Copies	per	ml = 20000000		×	1000	×	2	×	50150	×	2  =	6.66	x	109		
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If a concentration of above 1 x 108 copies per ml was obtained the process was 
continued, if not the 293T packaging cells were transfected once again as per 
Section 2.9.1.3.  
 
Next, the copies per ml was translated into transducing units per ml (TU/ml) using 
the following equation: 
 TUml = 	Copies	per	ml100000  
 
The qPCR based lentiviral titration method was compared to a traditional 
fluorescent microscopy method for titrating lentiviral vectors, which obtained the 
above division factor of 100,000. This experiment was performed by Dr Lyubov 
Zaitseva.  
 
The volume of prepared virus needed to infect a given cell number with a 
particular number of viral particles (multiplicity of infection (MOI)) was generated 
using the equation below: 
 Volume	of	prepared	virus = 	Number	of	cells	to	be	infectedTU/ml 	×desired	MOI 
 
The volume of prepared virus was concentrated (30-40 fold) using Amicon® Ultra-
15 centrifugal filters (Merck Millipore, Burlington, MA, USA). During this process, 
lentivirus from the 3-time point collections was pooled on ice, and centrifuged at 
15,000rpm for 15 minutes at 4˚C. This was continued until the full volume was 
added to the centrifugal filter and concentrated to approximately 1ml. Upon 
completion of the concentration step a new TU/ml was generated and used for 
MOI calculations. The lentivirus was stored at -80˚C until use. 
 
2.9.2 Lentiviral knockdown 
 
AML/MM/BMSC were infected with the lentivirus prepared in 2.9.1. 5 x 105 cells 
were seeded on 24 well plates in 500µl of pen-strep free medium. 0.5µl of 
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hexadimethrine bromide (Polybrene) was added to aid the uptake of lentivirus into 
cells. The volume of virus calculated to give the required MOI was added to the 
cells. Empty construct virus (ShE) was also added to other wells of cells as 
controls - to rule out any non-specific viral effects. 24 hours after infection, 1ml of 
fresh medium was added and the cells were cultured for a further 48 hours. 
Knockdown (KD) was tested using qPCR after 72 hours (detailed in section 
2.10.4). If knockdown was successful the control and GOI KD cells were used in 
mitochondrial transfer based experiments. 
 
MM and BMSC were transduced with a lentivirus purchased from Clonetech 
(rLV.EF1.mCherry-Mito-9 and rLV.EF1.AcGFP1-Mem-9) and were used as per 
the above method - with the exception of no ShE control used.  
 
2.10 Molecular biology techniques 
 
2.10.1 RNA extraction 
 
Gene expression levels in AML/MM/ BMSC were analysed using RT-qPCR. The 
first step in this process was the extraction of RNA from these cells. RNA was 
extracted using the ReliaPrep™ RNA Cell Miniprep Kit (Promega, Fitchburg, WI, 
USA) as per manufacturer’s instructions. Briefly, cells were collected and washed 
in PBS and 250µl of BL+TG buffer was added and mixed thoroughly - followed 
by the addition of 85µl Isopropanol. The lysate was vortexed thoroughly before it 
was loaded into a ReliaPrep™ minicolumn - the column was then centrifuged at 
13000 x g for 30 seconds. 24µl of Yellow Core Buffer was mixed with 3µl of 0.09M 
MgCl2 and 3µl of DNase I enzyme (in that order) and was added to the column. 
The column was incubated for 15 minutes at RT before the addition of 200µl of 
column wash solution and a further centrifugation step using the above 
parameters. 500µl of RNA wash solution was added to the column and was 
centrifuged again at 13000 x g for 30 seconds - the minicolumn was then placed 
in a fresh collection tube. A further 300µl of RNA wash solution was added and 
the column was centrifuged for 3 minutes at 16000 x g. The minicolumn was then 
placed in an elution tube, 20µl of nuclease free water was added and the tube 
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was centrifuged for 1 minute at 13000 x g to elute the RNA. RNA was stored at -
20˚C until further use. 
 
2.10.2 DNA extraction 
 
To detect inter-species mitochondrial transfer DNA was isolated from human AML 
and MM cells - mouse mitochondrial DNA was then detected using qPCR. DNA 
was extracted using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma 
Aldrich, St Louis, MO, USA) using the manufacturer’s instructions. Briefly, cells 
were harvested and washed in PBS and the suspended in 200µl of Resuspension 
solution. To lyse the cells 20µl of Proteinase K was added followed by 200µl of 
Lysis Solution C. This lysate was vortexed and incubated at 70˚C for 10 minutes. 
After incubation 200µl of absolute ethanol was added to the lysate, followed by 
loading the lysate onto the column. The column was centrifuged at 12000 x g for 
1 minute - discarding the waste. 500µl of Wash Solution was added to the column 
and a further centrifugation step was carried out as above. A further 500µl of 
Wash Solution was then added to the column, this time however the centrifugation 
time and speed were increased to 3 minutes and 16000 x g respectively. Finally, 
100µl of Elution Solution was added directly to the column and centrifuged for 1 
minute at 12000 x g, which eluted the DNA from the column. DNA was stored at 
-20˚C until further use.   
 
2.10.3 Quantification of extracted RNA/DNA 
 
Once extracted, RNA and DNA was quantified using the NanoDrop 
spectrophotometer (ThermoFisher, Waltham, MA, USA). The apparatus was 
blanked using 1µl of elution buffer (water for RNA and Elution Solution for DNA). 
1µl of sample was then loaded onto the NanoDrop and RNA/DNA concentration 
(ng/µl) was determined. Sample purity was determined using the A260/230 ratio 
- a sample was deemed pure between 1.7 and 2.3.  
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2.10.4 cDNA synthesis 
 
In order to analyse the gene expression levels in AML/MM/BMSC, cDNA was 
synthesised from RNA extracted in 2.10.3. This was achieved using reverse 
transcription with the qPCRBIO cDNA synthesis kit (PCR Biosystems, London, 
UK), as per the manufacturers protocol. For a 10µl reaction, 2µl of 5X cDNA 
Synthesis Mix was mixed with 0.5µl of 20X RTase and 300ng of RNA. The 
remaining volume was made up to 10µl with nuclease free water. PCR tubes were 
placed in a Thermocycler (Bio-Rad, Watford, UK) and a pre-defined program 
involving a 42˚C incubation for 30 minutes and an 85˚C incubation for 10 minutes 
was run. The cDNA samples were then held at 4˚C for up to 3 hours before a 5-
fold dilution in nuclease free water. The samples were stored at -20˚C until further 
use. 
 
2.10.5 Real time qPCR 
 
The Roche Lightcycler 480 (Roche, Basel, Switzerland) was used to carry out 
real time quantitative PCR (qPCR). This method was used for gene expression 
analysis along with human and murine mtDNA analysis. 
 
2.10.5.1 Gene Expression 
 
cDNA synthesised in section 2.10.4 was used to perform qPCR to determine gene 
expression levels. The qPCRBIO SyGreen Mix (PCR Biosystems, London, UK) 
was used to carry out qPCR on 96 and 384 well Roche Lightcycler reaction plates 
(287). Briefly, a master mix was created containing 4µl of SyGreen Mix, 1µl of 
10µM forward and reverse primer mix (see Table 2.8 and 2.9) and 1µl nuclease 
free water. 4µl of the diluted cDNA was added to the PCR wells along with 6µl of 
the appropriate master mix. PCR plates were then sealed and centrifuged briefly 
before loading into the light cycler. qPCR was run using a pre-programmed 
method described below. Upon amplification, SybrGreen was incorporated into 
newly synthesised DNA which could be detected by fluorescence. 
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• Pre-amplification (95˚C for 2 minutes). 
• Amplification over 45 cycles (95˚C 15 seconds, 60˚C for 10 seconds and 
72˚C for 10 seconds). 
• Melting curve analysis to confirm PCR product specificity (95˚C for 5 
seconds, 65˚C for 1 minute and 97˚C continuous).  
• Cooling (40˚C for 30 seconds). 
 
Cycle threshold (Ct) values were determined for each GOI, along with a 
housekeeping gene (Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
β-actin) as their expression does not change with the treatment or genetic 
alteration of cells. ΔCt values for GOIs were determined (Ct GOI – Ct 
housekeeping gene) and ΔΔCt was determined (ΔCt control – ΔCt test). The 
change in expression was expressed as a fold change of treated cells compared 
to untreated control cells (2-ΔΔCt). 
 
Table 2.8. KiCqStart® SybrGreen Primers (Sigma Aldrich) used in qPCR analysis. 
 
 
Table 2.9. QuantiTect Primers (Qiagen) used in qPCR analysis.  
Primer sequences were not disclosed by the manufacturer. 
 
 
 
2.10.5.2 SybrGreen based mtDNA analysis 
 
To detect cross species mitochondrial transfer SybrGreen based qPCR using 
human and mouse specific primers was utilised. Two kits were purchased, the 
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human mitochondrial DNA (mtDNA) monitoring primer set (Clontech, Clontech 
Takara Bio Europe, Saint-Germain-en-Laye, France) and the mouse 
mitochondrial DNA copy number kit (Detroit R&D, Detroit, MI, USA). The human 
kit contained a human mtDNA primer (ND1) and a human genomic DNA (gDNA) 
primer (SLCO2B1) whilst the mouse kit contained mouse mtDNA and gDNA 
primers (specific genes not disclosed). DNA (extracted in 2.10.2) was diluted to 
2ng/µl in water and 4µl was loaded onto a Lightcycler PCR plate. Human and 
mouse mtDNA and gDNA master mixes were created as follows: 4µl SybrGreen, 
1µl of 10µM forward/reverse primer mix and 1µl water. 6µl of the appropriate 
master mix was added to the 4µl of DNA and the plate was sealed and centrifuged 
briefly. The mouse and human qPCR were run using different methods which are 
highlighted below: 
 
Human mitochondrial kit: 
• Pre-amplification (98˚C for 2 minutes). 
• Amplification over 30 cycles (98˚C for 10 seconds, 61˚C for 15 seconds 
and 68˚C for 30 seconds). 
• Melting curve analysis (95˚C for 5 seconds, 65˚C for 1 minute and 97˚C 
continuous). 
• Cooling (40˚C for 30 seconds). 
 
Mouse mitochondrial kit: 
• Pre-amplification (95˚C for 10 minutes). 
• Amplification over 30 cycles (95˚C for 15 seconds and 60˚C for 60 
seconds). 
• Melting curve analysis (95˚C for 5 seconds, 65˚C for 1 minute and 97˚C 
continuous). 
• Cooling (40˚C for 30 seconds). 
 
PCR products obtained were ran on agarose gel electrophoresis gels, explained 
in section 2.10.6. 
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2.10.5.3 Taqman® based mtDNA analysis 
 
To show the cross-species mitochondrial transfer from BMSC to HSCs (under 
lipopolysaccharide (LPS) treatment in vivo), a qPCR was carried out using 
Taqman® chemistry compared to SybrGreen chemistry. In this method, a 
sequence specific probe containing both a 2′-chloro-7′phenyl-1,4-dichloro-6-
carboxy-fluorescein (VIC)/ 6-Carboxyfluorescein (FAM) fluorophore and a 
TAMRA® quencher binds to the GOI. Upon amplification of the DNA the probe is 
cleaved releasing both the fluorophore and quencher allowing for the detection of 
the fluorophore. 
 
Pre-designed Taqman® assays were obtained from ThermoFisher (see Table 
2.10), encompassing both human and mouse mtDNA and gDNA. Cell lysate was 
loaded onto a PCR plate (2µl). The human and mouse mtDNA Taqman® assays 
were run in duplex reactions due to the difference in fluorophore (VIC and FAM). 
Human and mouse gDNA Taqman® assays were run in simplex reactions. 
Simplex and duplex master mixes were generated. For the simplex master mix 
0.5µl of Taqman® assay (containing primers and probe) was mixed with 5µl of 
TaqPath ProAmp enzyme (ThermoFisher, Waltham, MA, USA) and 2.5µl water. 
For the duplex master mix 0.5µl of each Taqman® assay (total 1µl) was mixed 
with 5µl of TaqPath ProAmp enzyme and 2µl water. This master mix (8µl) was 
then added to the cell lysate on the PCR plate. The PCR plate was sealed and 
centrifuged at 1000rpm for 1 minute before it was loaded into the Lightcycler - 
qPCR was run using the following pre-programmed method: 
 
• Pre-amplification (60˚C for 30 seconds and 95˚C for 5 minutes). 
• Amplification over 50 cycles (95˚C for 15 seconds and 60˚C for 1 minute). 
• Cooling (40˚C for 30 seconds). 
 
From the Ct values obtained, human and mouse mitochondrial copy numbers in 
human HSCs were generated. Human and mouse mtDNA Ct values were 
normalised against the human gDNA Ct to obtain the ΔCt (Ct human/mouse 
mtDNA – Ct human gDNA). The ΔCt value was used to generate the 
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mitochondrial copy number (2-ΔCt). This method was adapted from the Takara 
Clontech human mitochondrial DNA (mtDNA) monitoring primer set protocol 
(http://www.clontech.com/GB/Products/Stem_Cell_Research/Pluripotency_and_
Differentiation/qPCR_Primer_Sets/ibcGetAttachment.jsp?cItemId=90270&fileId=
7220863&sitex=10030:22372:US. Accessed June 2018). The mouse mtDNA 
assay was used to ensure no mouse cell contamination. Mitochondrial copy 
numbers were used to determine the percentage of mouse mitochondria in 
human HSCs after isolation from “humanised” NSG mice - using the equation 
below. 
 
 
 
Table 2.10. Taqman® assays used for mouse and human copy number assessment. 
 
 
2.10.6 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to analyse qPCR products - 1.25% 
agarose gels were cast containing SYBR Safe (ThermoFisher, Waltham, MA, 
USA). For 60ml of agarose gel, 0.75g of agarose was diluted in 60ml of 1X Tris 
Acetate EDTA (TAE) buffer with 6µl of SYBR Safe. The solution was microwaved 
on full power for 60 seconds to dissolve all agarose and was cooled slightly before 
pouring into gel casts. A lane dividing well comb was added to allow the loading 
of samples. After the gel had set it was loaded into a DNA gel running tank with 
the comb removed - 1X TAE was added to the gel tank to submerge the gel. PCR 
products (10µl) were prepared by adding 2µl of 6X Orange G loading dye- 10µl 
of the sample was loaded into appropriate wells on the gel along with 5µl of 100 
base pair DNA ladder (New England Biolabs, Ipswich, MA, USA) to determine 
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PCR product size. The gel was run for 1 hour at 100V and was imaged using the 
UV function (filter 1) of the Chemdoc-It2 Imager (UVP, LLC, Upland, CA, USA). 
Images were edited using ImageJ software. 
 
2.10.7 Protein extraction 
 
To analyse protein levels within BMSC, protein was extracted and Western 
blotting analysis was carried out - as per (266). The first step in this process was 
protein extraction - both whole cell protein along with cytoplasmic and nuclear 
components. To extract whole cell protein radioimmunoprecipitation assay (RIPA) 
buffer supplemented with protease and phosphatase inhibitors was used. This 
buffer lyses the cells allowing the isolation of total protein. 50µl of RIPA buffer 
was added to cell pellets (~1x106 cells) and incubated on ice for 15 minutes. After 
the incubation, the cell lysate was centrifuged at maximum speed for 15 minutes 
at 4ºC. The supernatant was collected and stored at -20ºC until use - the cell 
pellet was discarded. 
 
To extract nuclear and cytoplasmic protein fractions the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents kit (ThermoFisher, Waltham, MA, USA) was 
utilised. Cell pellets were re-suspended in 100µl of CER I buffer, vortexed for 30 
seconds and incubated on ice for 10 minutes. 5.5µl of CER II buffer was 
subsequently added and vortexed once again for 30 seconds and incubated on 
ice for 1 minute. The cell lysate was then centrifuged at maximum speed for 5 
minutes and the supernatant was collected as it contained the cytoplasmic 
component. The pellet (containing nuclei) was re-suspended in 50µl of NER 
buffer and vortexed for 30 seconds. The nuclei containing lysate was incubated 
on ice for 50 minutes with a brief vortex carried out every 10 minutes. Finally, the 
lysate was centrifuged on the highest setting for 10 minutes - the nuclear 
containing supernatant was collected. Both fractions were stored at -20˚C until 
use. 
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2.10.8 Western Blotting 
 
12.5% polyacrylamide gels were made using 30% Polyacrylamide/Bis Solution 
(BioRad, Hercules, CA, USA). The gel mixture contained 10% SDS, 1.5M Tris pH 
8.8, 10% ammonium persulphate and TEMED (detailed volumes are seen in 
Table 2.11). Protein samples were prepared (from 2.10.7) by adding 4X sample 
loading buffer (containing β-mercaptaethanol and bromophenol blue) and 
denatured at 100˚C for 5 minutes.  
 
Table 2.11. Recipe for making 12ml of 12% polyacrylamide gel mix (enough for 1 gel). 
 
 
After the polyacrylamide gels were set protein samples (10µl) were loaded into 
the wells on the gel. 5µl of Precision Plus Protein All Blue Prestained Protein 
standard ladder (BioRad, Hercules, CA, USA) was also added to determine 
protein size. The gels were run at 200V for 45 minutes in running buffer containing 
10% SDS, 20µM glycine and 157µM Tris-Base. After completion of the run, the 
protein was transferred from the gel onto polyvinyladine fluoride (PVDF) 
membranes pre-treated with methanol. The gel and PVDF membrane were 
placed in transfer casts and added to a transfer tank containing transfer buffer 
(20µM Glycine and 157µM Tris-Base) - with an ice pack to lower the temperature 
generated by the electric current. The transfer took place at 100V for 1 hour, after 
which the membranes were blocked at RT in 5% bovine serum albumin (BSA) for 
1 hour.  
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To detect the protein of interest the blocked membrane was added to a tube 
containing primary antibody and was incubated overnight at 4˚C. Antibodies used 
in this study can be found in Table 2.12. Following an extensive washing step in 
TBST buffer (1X PBS and 0.01% Tween) the membranes were incubated for 1 
hour at RT with horseradish peroxidase (HRP) conjugated secondary antibodies. 
The same membrane was also probed for β-actin (total and cytosolic fractions) 
and SAM-68 (nuclear fractions) as above for loading controls.  
 
Table 2.12. Antibodies used in Western Blot analysis. 
 
 
The membranes were imaged using enhanced chemiluminscence (ECL) reagent 
(GE healthcare, Little Chalfont, UK). A 1:1 ratio of solutions A and B were mixed 
and 500µl was added to the membrane for 30 seconds. Excess solution was 
removed and the membrane was imaged using the Chemdoc-It2 Imager (UVP, 
LLC, Upland, CA, USA) - with the filter set to position 3. Images were edited and 
densitometry was determined using ImageJ software. 
 
2.11 Animal procedures 
 
All animal experiments used in this study were carried out in accordance with the 
UK Home Office regulations - under project license 70/8814 (Prof. Kristian 
Bowles) and 70/8722 (Dr Stephen Robinson). All work was carried out by myself 
(under UK Home Office personal license IBB43C002) with the assistance of Dr 
Rachel Piddock (ICC440663) and Dr Stuart Rushworth (ICD3874DB). Before 
carrying out the techniques outlined below, full training was conducted by Mr 
Richard Croft (IGEBEFB87) and Mrs Anja Croft (L8A2ACED). All animals were 
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housed in a containment level 3 laboratory (pathogen free) in the Disease 
Modelling Unit (DMU) at the University of East Anglia.  
 
2.11.1 Maintenance of animal colonies 
 
Two mouse strains were used in this study the non-obese diabetic (NOD) severe 
combined immunodeficiency (SCID) Il2rg knockout 
(NOD.Cg.PrkdscidIL2rgtm1Wji/SzJ or NSG) mice and the C57BL/6J mice. Colonies 
of NSG (originally purchased from the Jackson Laboratory, Bar Harbour, ME, 
USA) and C57BL/6J (originally purchased from stock at the DMU, UEA, UK) were 
maintained and bred in the “barn” area of the DMU. Breeding trios (1 Male and 2 
Females) were housed together for 6 months before separation. All offspring were 
weaned from their parents 3 weeks after birth and used in experiments at 4-12 
weeks of age.  
 
2.11.2 Xenograft Models 
 
The NSG mouse model was used in xenograft experiments whereby human 
AML/MM cell lines and primary AML blasts were transplanted. Human cells can 
engraft in the bone marrow of these mice as they are severely 
immunocompromised - lacking mature T, B and Natural Killer cells. The mice 
were not irradiated prior to transplantation, the animals were therefore in good 
health.  
 
AML and MM cell lines injected into the NSG were lentivirally modified with a 
pCDH-luciferase-T2A-mCherry construct (kindly gifted by Prof. Irmela Jeremias, 
Helmholtz Zentrum München, Germany). The luciferase construct allowed for the 
detection of human AML and MM cells in vivo using bioluminescence. Luciferase 
AML/MM cells were sorted prior to injection by Dr Zhigang Zhou using a 
FACSAria II cell sorter.  
 
To analyse mitochondrial transfer to normal CD34+ HSCs, a humanized mouse 
was created. Briefly, 3-4-week-old NSG mice were treated with 25mg/kg Busulfan 
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twice over a 48-hour time period. 2x105 primary human cord blood CD34+ HSCs 
were then injected into the tail vein. Engraftment of HSCs was determined through 
the analysis of human and mouse CD45+ cells in the peripheral blood. These 
animals were then treated with 1mg/kg LPS or PBS control for 2 hours to analyse 
mitochondrial transfer.   
 
2.11.3 Wild type C57BL/6J Models 
 
The C57BL/6J mice were used in this study to analyse the levels of mitochondria 
in LT and ST-HSC. 1mg/kg LPS or PBS control were injected by intraperitoneal 
(IP) injection (341) and after a 2-hour incubation the mice were sacrificed and 
bone marrow was isolated for flow cytometry analysis. These mice were also 
administered with live salmonella by oral gavage injection.  
 
2.11.4 Intravenous injections 
 
AML, MM and HSCs were administered into NSG mice through intravenous (IV) 
tail vein injection. To dilate the tail vein, mice were placed in a 37˚C hot box for 
10 minutes prior to injection. The mice were then placed in a benchtop restrainer 
and injected with a 26G needle into the lateral tail vein. After a short recovery time 
they were returned to their home cage. Cells were suspended and injected in a 
total volume of 200µl PBS - containing 0.5x106 and 2x105 cells for malignant and 
non-malignant cells respectively. 
 
2.11.5 Intraperitoneal injections 
 
Drug compounds and D-luciferin were administered to mice using an IP injection. 
Mice were manually restrained in a “scruff” and injected (with a 26G needle) into 
the peritoneum with a volume of 200µl. In cases where daily IP injection was 
required, alternate flanks of the animal were injected. 
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2.11.6 Subcutaneous injections 
 
Combinations of AML and BMSC were administered to mice using a 
subcutaneous injection. The mice were manually restrained and 200µl of cells 
were injected (using a 26G needle) under the skin on the hind flank. To compare 
the effect of PGC-1α knockdown in BMSC on the progression of AML, both flanks 
of the animal were utilised (see Figure 2.9).   
 
 
Figure 2.9. Schematic overview of the experimental set up for the subcutaneous model. 
 
Combinations 1 and 2 contained a mix of AML cells and BMSC. BMSC were modified lentivirally 
to analyse AML disease progression compared to a control viral modification. 
 
2.11.7 Blood Sampling 
 
Blood was taken from the tail vein of mice for flow cytometry analysis. Animals 
were placed in the 37˚C hot box for 10 minutes to dilate the vein. Mice were then 
placed in a benchtop restrainer and up to 200µl of blood was collected in a 1.5ml 
Eppendorf tube (using a 26G butterfly needle). 25µl of monosodium citrate was 
added to Eppendorf tubes prior to collection to ensure the blood did not clot. 
Antibodies of interest were then added to the blood for 15 minutes, the red cells 
were lysed using 1X red blood cells lysis buffer (ThermoFisher, Waltham, MA, 
USA) and then analysed using flow cytometry. 
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2.11.8 Live animal imaging using Bioluminescence  
 
To analyse tumour burden and location, bioluminescent imaging of live mice was 
carried out (342). This was enabled as AML and MM cells expressed the 
luciferase construct described in 2.11.2. 150mg/kg D-luciferin was IP injected and 
the mice were incubated at RT for 15 minutes to allow for maximum luciferase 
signal to be detected. During the last 5 minutes of the incubation the mice were 
anaesthetised in a chamber of isoflurane using a flow rate of 3%. Mice were 
imaged by the Bruker In-Vivo Xtreme (Bruker, Coventry, UK) using a pre-defined 
method (30 seconds exposure bioluminescent image, x-ray and light image). 
Mice were recovered in their home cage after imaging. Tumour burden and 
location was visualised by the detection of light produced by the formation of 
Oxyluciferin from luciferin, which is catalysed by the luciferase in the modified 
AML/MM cells. Images obtained were edited using ImageJ - bioluminescent 
images were merged with X-Ray images. Densitometry was also carried out using 
ImageJ software. 
 
2.11.9  Oral gavage 
 
To administer live Salmonella enterica to C57BL/6J mice an oral gavage injection 
was utilised - this procedure was carried out by Dr Devina Divekar. 100µl of 
salmonella (containing 1x109 bacteria) was loaded into an oral gavage needle. 
The mouse was restrained in a “scruff” and the salmonella was administered 
down the oesophagus directly into the stomach of the mouse. 
 
2.11.10 Schedule 1  
 
At the end point of the experiment (whether at a specific time point or during signs 
of animal disease) the mice were humanely sacrificed using schedule 1 killing. 
Signs of animal disease were piloerection, hunched posture and hind limb 
paralysis. Animals were sacrificed by exposure to a rising CO2 gradient followed 
by dislocation of the neck.  
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2.11.11 Isolation of mouse bone marrow 
 
The bone marrow was extracted from mice to allow for ex vivo analysis. The femur 
and tibia were isolated and stripped of soft tissue, the bone caps were removed 
and each individual bone was placed in a 0.5ml Eppendorf tube which was 
perforated to allow the removal of the bone marrow. This tube was placed in a 
1.5ml Eppendorf and was centrifuged on full power for 20 seconds to remove the 
bone marrow. The 4 bone marrow portions from each mouse were pooled and 
washed in PBS. Engraftment of AML cells was determined by staining the bone 
marrow with human CD45 and CD33 antibodies. Engraftment of MM cells was 
determined using the human CD45 antibody only (see Figure 2.10). AML/MM 
were deemed to have engrafted if the engraftment percentage was greater than 
1%. Human CD45 AML/MM cells were sorted from the mouse bone marrow using 
MACS with CD45 microbeads (as per 2.2.2). These cells were used to determine 
mitochondrial content using flow cytometry and metabolic capabilities using the 
Seahorse extracellular flux assay.  
 
 
Figure 2.10. Gating strategy to determine AML/MM engraftment in mouse bone marrow. 
 
Live cells were gated from the forward and side scatter plots. Human CD45 and CD33 expression 
is determined for the AML xenograft. Human CD45 expression is determined for the MM 
xenograft.   
	 110	
2.12 Statistical Analysis 
 
All data produced in my thesis was analysed by Prism software (Version 7.0, 
GraphPad Software, San Diego, CA, USA). The Mann-Whitney U test was used 
to analyse non-paired test groups, whereas the Wilcoxon signed-rank test was 
used to analyse paired test groups. Correlation data was analysed using the 
Pearson’s correlation co-efficient. Animal survival data was analysed by the 
Kaplan-Meier log-rank test. Results were considered significant where P<0.05 (*), 
P<0.01 (**) and P<0.005 (***). Results represent the mean ± standard deviation 
of 4 or more independent experiments.  
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3 AML derived NOX2 superoxide drives pro-tumoral 
mitochondrial transfer.  
 
3.1 Introduction 
 
Warburg stated in the 1920s that cancers utilise aerobic glycolysis (non-
mitochondrial based) to generate ATP rather than OXPHOS (306). However, 
AML appears to contradict this hypothesis as the malignancy is susceptible to 
OXPHOS inhibitors (311). In addition, primary AML blasts which have an 
OXPHOS gene signature are less susceptible to Ara-C (312). AML blasts have 
also been shown to have increased mitochondrial levels compared to normal 
CD34+ cells (314). This chapter of my thesis will determine how and why AML 
blasts have extra mitochondria. 
 
3.2 Results 
 
3.2.1 Mitochondria are transferred from BMSC to AML blasts 
 
Prior to determining how AML blasts acquire an increased mitochondrial mass, 
it’s important to confirm that primary AML blasts obtained from patients at the 
NNUH also had increased mitochondrial levels compared to normal CD34+ cells. 
AML blasts were indeed found to have on average a 4-fold increase in 
mitochondrial levels compared to CD34+ cells (Figure 3.1A), which is comparable 
to previously published literature.  
 
Taking this further, mitochondrial levels in primary AML blasts were assessed 
after they were cultured with BMSC. AML (suspension cells) and BMSC (adherent 
cells) were cultured in a 5:1 ratio for given time periods, followed by separation 
by gently mixing and mtDNA analysis. Mitochondrial levels in AML blasts were 
increased after a 72-hour (3-fold) and 1 week (6-fold) co-culture, compared with 
AML blasts cultured alone (Figure 3.1B). These results suggest that culture with 
BMSC caused an increase in mitochondrial levels within the AML blast.  
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Figure 3.1. Mitochondrial levels are elevated in AML blasts compared to CD34+ cells, and 
after co-culture with BMSC. 
Mitochondrial levels were calculated using qPCR with extracted DNA, ultilising a species specific 
mtDNA monitoring primer set. (A) Mitochondrial levels in “normal” CD34+ cells were compared to 
AML blasts. (B) The levels of mitochondria in AML blasts were determined after co-culture with 
BMSC over a 72-hour and 1 week time period. AML (suspension cells) and BMSC (adherent cells) 
were cultured in a 5:1 ratio for given time points, prior to separation by gentle mixing and 
independent mtDNA analysis. This experiment was performed by Dr Lyubov Zaitseva. 
 
To determine if intercellular mitochondrial transfer occurred between BMSC and 
AML blasts, three experiments were designed to specifically analyse the 
movement of mitochondria. The first of these utilised a specific mitochondrial dye 
(MitoTracker Green FM) which allowed labelled mitochondria to be detected by 
flow cytometry. BMSC pre-stained with MitoTracker were cultured with primary 
AML blasts for 24-hours, resultant MitoTracker MFI in AML blasts was examined 
by flow cytometry. In this assay AML blasts were also pre-stained with 
MitoTracker to eliminate dye leakage. An increase in MitoTracker MFI was 
observed in AML blasts (n=11) co-cultured with BMSC compared to AML blasts 
cultured alone - highlighting the specific movement of MitoTracker labelled 
mitochondria from BMSC to AML blasts (Figure 3.2). No significant change in 
MitoTracker MFI was observed in CD34+ cells (n=7) when co-cultured with 
BMSC, therefore mitochondrial transfer does not occur between BMSC and 
CD34+ cells under normal conditions (Figure 3.2).  
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Figure 3.2. MitoTracker Green MFI is increased in AML blasts but not in CD34+ cells after 
co-culture with BMSC. 
BMSC and AML blasts/CD34+ cells were pre-stained with 200nM MitoTracker Green FM. BMSC 
were then cultured with either AML blasts or CD34+ cells for 24-hours. MitoTracker MFI was 
measured by flow cytometry in AML blasts/CD34+ cells after co-culture with BMSC and in cells 
cultured alone.  
 
 
Figure 3.3. mCherry tagged BMSC mitochondria move to primary AML blasts. 
BMSC mitochondria were tagged with a mCherry fluorophore using the rLV.EF1.mCherry-Mito-9 
lentivirus. Un-labelled primary AML blasts (n=3) were cultured on these BMSC for 72-hours and 
imaged using fluorescence microscopy. Scale bar = 10µm. Experiment performed by Dr Lyubov 
Zaitseva. 
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In the second method, mitochondria in BMSC were specifically tagged with an 
mCherry fluorophore using the rLV.EF1.mCherry-Mito-9 lentivirus purchased 
from Clontech. Un-labelled primary AML blasts were cultured on these BMSC for 
72 hours and live cell fluorescence microscopy was used to image the co-
cultures. BMSC labelled mitochondria were seen to move to AML blasts, 
visualised by the acquisition of the mCherry fluorescence by AML blasts (Figure 
3.3).  
 
The third method I used was an in vivo xenograft model, enabled by sequence 
differences between human and murine mtDNA which can be detected by PCR. 
Four primary AML blast samples were injected into the tail vein of NSG mice, 
three weeks post administration the animals were sacrificed and bone marrow 
was extracted. Human AML blasts were seen to engraft into the bone marrow of 
NSG mice (using human CD45 and CD33 flow cytometry) at levels greater than 
50% (Figure 3.4A). Human AML blasts were purified from the bone marrow using 
MACS with human CD45 microbeads - the purity of human AML blast sample 
was determined again using flow cytometry (Figure 3.4B). PCR was carried out 
on extracted DNA using species specific mtDNA and gDNA primers, PCR 
products were visualised using agarose gel electrophoresis. In AML blasts grown 
in vitro only human mtDNA was detected, whereas in AML blasts purified from 
mouse bone marrow, murine mtDNA was detected with no murine gDNA (Figure 
3.5). Therefore, murine mitochondria moved from the BMM to human AML blasts 
in vivo.  
 
One possible limitation of this experiment was the purity of AML blasts sorted 
from the mouse bone marrow. A purity of 98.96% human CD45+CD33+ was 
achieved, there was therefore a possibility of 1.04% mouse contamination. To 
examine the potential consequence of murine mtDNA in the assay I deliberately 
spiked human DNA (98.96%) with mouse DNA (1.04%) and repeated the PCR. 
The spiked sample did not create the same result as my mitochondrial transfer 
assay (Figure 3.6) and excluded contamination as the cause of murine mtDNA 
detection. 
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Figure 3.4. Engraftment and purification of primary AML blast xenografts. 
Four primary AML blast samples were injected into NSG mice. After 3 weeks the animals were 
sacrificed and bone marrow was extracted. (A) shows the engraftment of AML blasts in the bone 
marrow using human CD45 and CD33 expression. (B) shows a representative flow cytometry plot 
of the purity of AML blast samples before and after MACS sorting. 
 
 
Figure 3.5. Murine mtDNA is detected in AML blast xenografts. 
PCR was carried out with DNA extracted from purified AML blast xenografts, using species 
specific mtDNA and gDNA primers. The figure presents an agarose gel on which PCR products 
were run.  
 
 
Figure 3.6. PCR trace of purified AML xenograft and a spiked DNA sample. 
A qPCR was run using the murine mtDNA primer with 100% murine DNA, the purified AML 
xenograft (98.96% pure) and a spiked human DNA sample with 1.04% murine DNA. The figure 
presents the PCR trace showing cycle threshold (Ct) values of the samples with the difference 
between xenograft and spiked sample (containing the same murine DNA percentage) highlighted.  
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Taken together, these three methods show that mitochondria are transferred from 
BMSC to AML blasts. The observation that AML blasts have increased 
mitochondrial levels (after culture with BMSC and compared with normal CD34+ 
cells) may therefore in part be a result of intercellular mitochondrial transfer. 
 
Previous studies analysing intercellular mitochondrial transfer utilised rho0 cells 
(devoid of mitochondria as described in Section 1.6.4), I therefore tried to 
generate AML rho0 cells to analyse mitochondrial transfer further. This was rather 
unsuccessful and took up a large amount of my PhD research time - due to the 
40-day culture required to generate these cells. During culture (in ethidium 
bromide, pyruvate and uridine) the growth rate of the OCI-AML3 cells used was 
severely reduced and I constantly battled bacterial infections in my cultures. 
Through increasing the penstrep concentration 3-fold, I managed to generate one 
batch of OCI-AML3 rho0 cells which had severely reduced mitochondrial levels 
(Figure 3.7A). I cultured these cells on human BMSC for 24 hours and found only 
a small increase in mtDNA copy number from ~0 to 2 copies per cell (Figure 3.7B). 
I attempted to engraft the remaining cells from this batch into NSG mice, 
unfortunately they were not seen to engraft as NSG mice showed no sign of 
disease after 3 months - as a result no further rho0 cells were generated for use 
in this study. 
 
 
Figure 3.7. OCI-AML3 cells cultured in ethidium bromide have reduced mtDNA content. 
OCI-AML3 cells were cultured in ethidium bromide, pyruvate and uridine for 40-days to generate 
rho0 cells (which are devoid of mtDNA). qPCR with a human mitochondrial monitoring kit was 
carried out to determine mtDNA content in WT and rho0 cells (A), and in rho0 cells after culture 
with human BMSC for 24 hours (B). 
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3.2.2 Mitochondria are transferred from BMSC to AML through TNTs 
 
How the mitochondria move from BMSC to AML blasts was next examined. From 
previous literature describing mitochondrial transfer it can be seen the most 
prominent transfer mechanism is through TNTs - these were examined in the 
context of mitochondrial transfer to AML blasts. First, I assessed the levels of 
mitochondrial transfer when AML blasts were directly and indirectly cultured with 
BMSC. This was achieved using the MitoTracker based assay which can quantify 
levels of transfer. As per the previous experiment there was a significant increase 
in MitoTracker MFI in AML blasts (n=4) cultured directly with BMSC, however 
there was no increase when AML blasts were cultured in a 0.4µm transwell 
system (Figure 3.8A). This shows that direct cell culture is required to facilitate 
mitochondrial transfer from BMSC to AML blasts.  
 
Figure 3.8. Mitochondrial transfer requires direct contact and is inhibited by CytoB. 
The MitoTracker based assay was used to assess mitochondrial transfer levels when primary 
AML blasts (n=4) were cultured with BMSC in direct and indirect culture (A). (B) CytoB and 
Dansylcadavarine were added to the AML/BMSC co-culture and mitochondrial transfer levels 
were assessed (n=4). Mitochondrial transfer levels in (B) are presented as ΔMitoTracker 
Fluorescence (MFI) between mono-cultured and co-cultured AML blasts. 
 
 
Furthermore, I analysed mitochondrial transfer levels upon the addition of 
Cytochalasin B (TNT inhibitor) and Dansylcadavarine (Endocytosis/Microvesicle 
inhibitor). Cytochalasin B (CytoB) was seen to inhibit mitochondrial transfer 3-
fold, whereas there was no change upon the addition of Dansylcadavarine (Figure 
3.8B). These results show that TNTs are the likely mechanism in which 
mitochondria move from BMSC to AML blasts.   
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CytoB is commonly used as a TNT inhibitor, however this compound is an actin 
inhibitor so therefore not specific to inhibiting TNT formations. Ergo, it was 
important to actually visualise TNTs that form between AML and BMSC to confirm 
that mitochondria move via this mechanism. TNTs are projections of the plasma 
membrane, therefore a plasma membrane dye (Vybrant DiI) was used to visualise 
AML plasma membrane projections. BMSC were stained with MitoTracker Green 
to label mitochondria and Vybrant DiI stained AML blasts were cultured with these 
for 24 hours. Confocal microscopy was used to visualise TNTs - however initially 
none were found. TNTs are highly dynamic which form and dissociate readily, 
therefore a fixation step was added to the protocol prior to visualisation. Using 
this method TNTs were visualised between AML blasts and BMSC (Figure 3.9), 
these TNTs were AML derived and contained mitochondria of BMSC origin.  
 
 
Figure 3.9. Visualisation of a TNT formed between AML blasts and BMSC.  
Primary AML blasts were stained with Vybrant DiI and cultured with MitoTracker Green stained 
BMSC. Fixed cell confocal microcopy was used to visualise TNT formations. A TNT formed by 
AML blasts can be seen containing BMSC derived mitochondria. Image taken by Dr Lyubov 
Zaitseva. 
 
 
I next aimed to quantify the number of TNTs which are formed during a co-culture 
between primary AML blasts and BMSC. During confocal microscopy, very few 
TNTs were observed however multiple Vybrant DiI dots were observed on BMSC 
- which remained after the dissociation of TNT formations (Figure 3.10A). These 
dots were called TNT-anchor points (TAPs) and were used to quantify the number 
of TNTs that formed between primary AML blasts and BMSC. TAPs were not 
found when AML blasts were cultured on BMSC in 0.4µm transwells (Figure 
3.10B). Examining four primary AML blasts, on average 300 TAPs were formed 
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over the 24-hour time period - per confocal image (Figure 3.10C). CytoB was 
found to decrease the number of TAPs by around 3.5-fold (Figures 3.10D).  
 
 
Figure 3.10. TAPs are formed by TNTs and can be used to quantify the TNT formations. 
TAPs are residual Vybrant DiI points where TNTs have formed and dissociated, shown in (A). (B) 
TAPs are only formed upon direct contact of primary AML blasts and BMSC. (C) The number of 
TAPs was quantified (per confocal image) between co-cultures of BMSC and four primary AML 
blast populations. (D) TAP formations were assessed upon the addition of CytoB (n=4).  
 
 
The results of these experiments have determined that one of the ways 
mitochondria move to AML blasts is through TNTs and the number of TNTs can 
be quantified using TAPs. 
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3.2.3 Mitochondrial transfer increases AML OCR and ATP production  
 
Next, the functional consequence of mitochondrial transfer was examined. Using 
the Seahorse Extracellular Flux Analyser (which measures the oxygen 
consumption rate (OCR) of cells - comparable with mitochondrial respiration 
levels within cells) it was found that AML blasts have increased OCR after co-
culture with BMSC (Figure 3.11). The maximum respiration and spare capacity 
was increased in AML blasts cultured with BMSC, with basal respiration and post 
oligomycin OCR increased in 1/2 AML blasts tested (Figure 3.12A). However, in 
this experiment oligomycin was not seen to have the expected effect on the 
respiration dynamics (should decrease OCR due to ATP synthase inhibition). This 
is likely due to the use of the wrong oligomycin concentration in the assay - the 
post Oligomycin result is therefore not reliable. In addition to the Seahorse data, 
the CellTitre-Glo assay revealed AML blasts cultured on BMSC had increased 
levels of ATP production (Figure 3.12B) – which suggested increased OCR in 
AML blasts results in increased ATP production.  
 
 
Figure 3.11. AML blasts have increased levels of OCR after co-culture with BMSC. 
Primary AML blasts (n=2) were cultured with and without BMSC for 24 hours and then OCR was 
analysed in AML blasts - using the Seahorse XFp Analyzer with the Mito Stress Test Kit. Data is 
represented as mean +/- standard deviation. Sequential injections of oligomycin (O), carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (F), and rotenone/antimycin A (R) were 
used to obtain respiration dynamics seen in Figure 3.12. 
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Figure 3.12. Elevated OCR in co-cultured AML cells results in enhanced ATP production. 
(A) Basal and maximum OCR rates were determined in AML blasts (n=2) (in addition to the post 
oligomycin (Post-O) OCR and spare capacity (S.C)) with and without BMSC culture. These values 
were determined using the respiration dynamics presented in 3.11 and as per 2.8 – and presented 
as % relative OCR. In all cases non-mitochondrial respiration (post rotenone/antimycin A) was 
subtracted from OCR values. (B) ATP production in AML blasts (n=4) +/-  BMSC culture was 
determined using the CellTitre-Glo ATP assay. 
 
3.2.4 Induction of oxidative stress promotes mitochondrial transfer 
 
In sections 3.2.1, 3.2.2 and 3.2.3 I have presented data which shows that 
mitochondria move from BMSC to AML blasts, that this transfer can occur through 
TNTs and that the transfer results in increased OCR and ATP production. This 
data is comparable with other published literature from other cancers where 
mitochondrial transfer has been described. Next, I aimed to take these results 
further by elucidating the stimulus mechanism of mitochondrial transfer in AML - 
which to date has not been described in any other cancer mitochondrial transfer 
system.   
 
Initially, a pharmacological screen was carried out using the MitoTracker based 
mitochondrial transfer assay to determine what effect different compounds have 
on the levels of mitochondrial transfer. It was found that compounds which induce 
oxidative stress (H2O2, Daunorubicin, CoCl2) increased mitochondrial transfer, 
whereas antioxidants (GSH and NAC) reduced the levels of mitochondrial 
transfer (Figure 3.13).  
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Figure 3.13. Pharmacological screen to assess mitochondrial transfer levels. 
Mitochondrial transfer levels were assessed between BMSC and AML blasts (n=1) upon the 
addition of a range of compounds which enhance or inhibit various key cell signalling pathways 
and processes. Details of the compounds used can be found in the methods section in Table 2.2.  
The levels of mitochondrial transfer are presented relative to a no drug control. H2O2 – hydrogen 
peroxide. DNR – daunorubicin. CoCl2 – cobalt chloride. JNKV – c-Jun N-terminal Kinase inhibitor. 
TNFa – tumour necrosis factor alpha. EX527 – selisistat. Met – metformin. Evero – everolimus. 
Len – lenalidomide. CBX – carbenoxolone. GSH – glutathione. DPI -  diphenyleneiodonium. NAC 
– N-acetyl cysteine.   
 
H2O2 was seen to increase mitochondrial transfer 3-fold whereas NAC was seen 
to reduce the process 4-fold. These results were replicated with an increased 
number of primary AML blast samples (n=8 for NAC and n=11 for H2O2) (Figure 
3.14).  
 
Figure 3.14. The effect of NAC and H2O2 on mitochondrial transfer levels. 
The MitoTracker based mitochondrial transfer assay was used to analyse the effect of NAC (A) 
(n=7) and H2O2 (B) (n=11) on the levels of transfer. The results are presented as ΔMitoTracker 
Fluorescence (MFI) between co-cultured and mono-cultured AML blasts, which corresponds to 
the level of mitochondrial transfer.   
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Normal CD34+ cells were not seen to acquire mitochondria from BMSC (Figure 
3.2). However, very interestingly the addition of H2O2 to the culture stimulated the 
transfer of mitochondria from BMSC to CD34+ cells (Figure 3.15). 
 
Figure 3.15. H2O2 promotes CD34+ cells to acquire mitochondria from BMSC. 
The levels of mitochondrial transfer were assessed between CD34+ cells (n=7) and BMSC with 
and without the addition of 50µM H2O2.  
 
Next, I examined whether NAC had an effect on AML disease progression in vivo. 
I injected the AML cell line OCI-AML3 (containing a luciferase construct) into NSG 
mice and administered NAC into their drinking water at a concentration of 2g/L, 
as per previous studies (343). However, no difference in disease progression was 
observed between NAC treated and control animals (Figure 3.16A). In addition, 
there was no difference in overall animal survival (Figure 3.16B). 
 
 
Figure 3.16. NAC has no effect on AML disease progression in vivo. 
OCI-AML3 cells (with luciferase construct) were injected into the tail vein of NSG mice and AML 
disease progression was monitored by bioluminescence (A). At signs of disease animals were 
sacrificed and survival data is presented in (B). 
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3.2.5 AML derived NOX2 superoxide drives mitochondrial transfer  
 
From the pharmacological screen, it was found that the NOX2 inhibitor 
Diphenyleneiodium chloride (DPI) had a similar effect on mitochondrial transfer 
as per NAC and GSH. NOX2 is elevated on AML blasts and converts molecular 
oxygen to superoxide, which increases oxidative stress. To examine the effect of 
DPI further the MitoTracker based mitochondrial transfer was repeated on an 
increased number of primary AML blast samples (n=11). Approximately a 2-fold 
reduction in mitochondrial transfer was observed (Figure 3.17).  
 
 
Figure 3.17. DPI inhibits the transfer of mitochondria from BMSC to AML. 
Mitochondrial levels were assessed between AML blasts (n=11) and BMSC upon the addition of 
1µM DPI, which inhibits NOX2 on AML.  
 
 
The effect of DPI on AML blast survival was next tested, DPI was added to the 
co-culture between AML blasts and BMSC and levels of apoptosis were 
measured in AML blasts after co-culture. DPI was seen to increase the level of 
apoptosis from 20 to 80% in AML blasts (Figure 3.18A), whereas no change in 
apoptosis levels were found in CD34+ cells (Figure 3.18B). This highlights the 
possibility of a specific therapeutic window for targeting NOX2 on AML blasts.  
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Figure 3.18. DPI induces apoptosis in AML blasts but not in CD34+ cells. 
AML blasts (A) or CD34+ cells (B) were cultured with BMSC and treated with either DMSO or 1µM 
DPI. Levels of apoptosis were determined using Annexin/PI and flow cytometry.   
 
Next, I made a lentivirus encoding shRNA specifically targeted to NOX2 mRNA. 
Four AML blast populations were transduced with this lentivirus (or lentivirus 
containing an empty construct) and mitochondrial transfer levels were assessed 
in these cells when cultured with BMSC. NOX2 was successfully knocked down 
in AML on average by 70% (Figure 3.19A) and this resulted in reduced 
mitochondrial transfer by approximately 2-fold (Figure 3.19B). In addition, NOX2 
KD AML blasts had a significantly reduced OCR compared with control KD cells 
after culture with BMSC (Figure 3.20). There was no change in OCR between 
control KD and NOX2 KD AML blasts when cultured alone (Figure 3.20).  
 
 
Figure 3.19. NOX2 KD in AML blasts reduces mitochondrial transfer. 
Four AML blast populations were transduced with a lentivirus encoding shRNA specific to NOX2 
or an empty construct. qPCR was used to confirm the level of knockdown presented in (A). These 
NOX2 KD and control KD cells were cultured with BMSC, levels of mitochondrial transfer were 
assessed using the MitoTracker based assay (B). 
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Figure 3.20. OCR levels are reduced in NOX2 KD AML blasts. 
Basal and maximum OCRs were determined (along with OCR post oligomycin (Post-O) and spare 
capacity (S.C)) using the Seahorse extracellular flux assay. Control KD and NOX2 KD cells were 
analysed after co-culture with BMSC and when cultured alone. All OCRs are presented as % 
relative OCR and have had non-mitochondrial respiration (post rotenone/antimycin A treatment) 
subtracted.  
 
As NOX2 is known to produce extracellular superoxide, the levels of these 
superoxides were next measured in control KD and NOX2 KD AML blasts. As 
expected there was a reduction in NOX2 derived superoxide from 700nM in 
control KD cells to 400nM in NOX2 KD cells (Figure 3.21).  
 
Figure 3.21. NOX2 KD AML blasts secrete lower levels of superoxide. 
NOX2 production in control KD and NOX2 KD AML blasts (n=4) was measured using the Amplex 
Red superoxide detection assay. The level of superoxide is presented as a concentration in nM. 
 
Next, I assessed whether the superoxide secreted by AML blasts caused a 
change in oxidative stress levels in BMSC. Primary AML blasts were cultured with 
BMSC (n=10) and ROS levels were analysed - using the DCF assay. ROS levels 
were significantly elevated in BMSC (n=10) cultured with AML blasts compared 
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to BMSC cultured alone (Figure 3.22A). This was specific to AML culture as when 
CD34+ cells were cultured with the BMSC (n=5) there was no change in ROS 
levels (Figure 3.22B).  
 
 
Figure 3.22. AML blasts, but not CD34+ cells, stimulate ROS in BMSC. 
BMSC were cultured with AML blasts (A) or CD34+ cells (B). ROS levels in co-cultured BMSC 
were assessed using the DCF assay compared to BMSC cultured alone. ROS levels are 
presented as DCF MFI.  
 
 
To assess whether increased ROS in BMSC was dependant on AML contact, I 
repeated the assay with AML blasts cultured in a transwell system. ROS levels 
remained elevated in BMSC when AML blasts were cultured in 0.4µM transwells 
(Figure 3.23A), therefore cell-cell contact is not necessary for this observation. To 
determine whether NOX2 derived superoxide caused the oxidative stress in 
BMSC I repeated the ROS detection assay in BMSC cultured with control KD and 
NOX2 KD AML blasts. ROS levels were reduced 2-fold in BMSC cultured with 
NOX2 KD cells compared with control KD cells (Figure 3.23B), which suggests 
that AML derived NOX2 superoxide contributes to the stimulation of oxidative 
stress in BMSC. 
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Figure 3.23. NOX2 derived superoxide is responsible for oxidative stress in BMSC. 
ROS levels were assessed using the DCF assay in BMSC when AML blasts were cultured in 
direct contact and when cultured in 0.4µm transwells (A). ROS levels were also determined in 
BMSC when cultured with control KD and NOX2 KD AML blasts (B).  
 
3.2.6 AML stimulates PGC-1α driven mitochondrial biogenesis in BMSC  
 
Next, I examined the consequence of AML-induced oxidative stress in BMSC and 
how this resulted in enhanced mitochondrial transfer. BMSC appeared unaffected 
by the loss of mitochondria to AML blasts, therefore I first examined mitochondrial 
levels in BMSC (n=8) after culture with AML blasts. A 3-fold increase in 
mitochondrial mass was observed in BMSC after AML culture (Figure 3.24A), 
suggesting that AML promotes mitochondrial biogenesis in BMSC. In addition, 
this increase in mitochondria caused BMSC to have elevated OCR compared 
when BMSC were cultured alone (Figure 3.24B).  
 
Figure 3.24. AML stimulates BMSC to increase mitochondrial mass and OCR. 
Mitochondrial levels in BMSC (n=8) were assessed with and without co-culture with AML blasts, 
using MitoTracker Green staining (A). (B) OCR in BMSC were determined, with and without AML, 
using the Seahorse extracellular flux analyser. Relative basal and maximum OCR are presented 
(along with post oligomycin (Post-O) OCR and spare capacity (S.C)) – all values have non-
mitochondrial respiration (after rotenone/antimycin A injection) subtracted. 
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Figure 3.25. PGC-1α is activated in BMSC after co-culture with AML blasts. 
PGC-1α mRNA levels were determined in BMSC (n=5) using qPCR with and without culture with 
AML blasts (A). Nuclear, cytosolic and total PGC-1α protein levels were determined in BMSC 
(n=2) using Western Blot analysis (B). Densitometries are presented between the Western blots. 
 
Mitochondrial biogenesis is regulated through the transcription factor PGC-1α, 
which has been shown to be activated by oxidative stress (344). Therefore, I 
assessed whether PGC-1α is activated in BMSC after culture with AML blasts. 
PGC-1α mRNA was increased 3-fold in BMSC (n=5) cultured with AML blasts 
(Figure 3.25A). PGC-1α was activated in BMSC (n=2) cultured with AML blasts, 
shown through an increased nuclear accumulation of the protein by western 
blotting (Figure 3.25B). This nuclear accumulation in BMSC (n=2) was reduced 
upon the addition of NAC (Figure 3.26), which suggests that PGC-1α activation 
and subsequent mitochondrial biogenesis is through AML-induced oxidative 
stress.  
 
Figure 3.26. Elevated PGC-1α nuclear accumulation in BMSC was reduced by NAC. 
Nuclear PGC-1α protein levels in BMSC (n=2) cultured alone and with AML blasts +/- NAC were 
determined by Western blotting. Densitometries are presented between the Western blots, which 
were normalised to Sam68 loading control. Experiment carried out with the help of Dr Stuart 
Rushworth. 
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3.2.7 Silencing of PGC-1α in BMSC inhibits mitochondrial transfer  
 
In section 3.2.6 I have shown that AML blasts stimulate mitochondrial biogenesis 
in BMSC through the activation of PGC-1α. I next investigated whether PGC-1α 
activity in BMSC is essential for mitochondrial transfer to AML blasts. I made a 
lentivirus encoding shRNA specifically targeted to PGC-1α mRNA, I then 
transduced BMSC with this virus to knockdown PGC-1α. Figure 3.27A shows that 
PGC-1α mRNA expression was reduced by around 90% in BMSC transduced 
with lentivirus targeted to PGC-1α compared to control. Mitochondrial transfer 
levels were found to be reduced on average by 40% in cultures of PGC-1α KD 
BMSC and AML blasts – compared with control KD BMSC (Figure 3.27B). 
 
 
Figure 3.27. Mitochondrial transfer levels to AML are reduced from PGC-1α KD BMSC. 
BMSC were transduced with a lentivirus encoding shRNA targeted to PGC-1α, mRNA expression 
of PGC-1α was analysed using qPCR (A). (B) The MitoTracker based mitochondrial transfer 
assay was utilised to determine mitochondrial transfer levels between control KD or PGC-1α KD 
BMSC and AML blasts (n=4). Data is presented as relative ΔMitoTracker Green MFI. 
 
I next determined whether the reduction of mitochondrial transfer (through BMSC 
PGC-1α KD) impacted on AML disease progression. To do this I utilised a 
subcutaneous mouse model whereby AML cell lines OCI-AML3 or MV4-11 
(containing a luciferase construct) were injected into the hind flank of NSG mice, 
along with either PGC-1α KD or control KD BMSC. The advantage of this model 
is that two conditions can be compared in the same animal, as AML was injected 
with control KD BMSC on the left flank and with PGC-1α KD in the right flank 
(Figure 3.28A). Live animal imaging showed that AML disease progression was 
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reduced in the right flank of the animal where AML blasts were injected with PGC-
1α KD BMSC, this was the same for both AML cell lines tested (Figure 3.28B). 
Quantification of bioluminescence highlighted that AML disease progression was 
reduced with PGC-1α KD BMSC on average by 2.5-fold with OCI-AML3 and 4.5-
fold with MV4-11 (Figure 3.28C).  
 
Taken together, the results in this section show that PGC-1α activation in BMSC 
plays a role in mitochondrial transfer between BMSC and AML blasts. 
 
 
Figure 3.28. AML disease progression is reduced in vivo through PGC-1α KD in BMSC. 
(A) Schematic representation of the subcutaneous in vivo model used to determine AML disease 
progression when PGC-1α was knocked down in BMSC. (B) Bioluminescent live animal imaging 
of OCI-AML3/MV4-11 cells containing a luciferase construct, which was enabled by the 
administration of D-luciferin prior to imaging. (C) Quantification of bioluminescence observed in 
(B) presented as tumour densitometry x103 (Bioluminescence arbitrary unit (BLI AU)). 
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3.2.8 Pre-clinical in vivo model of NOX2 KD in AML disease progression 
 
In section 3.2.5 I described that NOX2 on AML is responsible for stimulating 
mitochondrial transfer from BMSC - next I aimed to translate this idea in vivo. 
NOX2 was knocked down in the AML cell line OCI-AML3 using a lentivirus 
targeted to NOX2 mRNA, which reduced NOX2 levels by 75% compared to 
control KD cells (Figure 3.29A). NSG mice were administered with either control 
KD or NOX2 KD cells (containing a luciferase construct) and AML disease 
progression was monitored. It is important to note there was no difference in the 
growth capacity of control KD and NOX2 KD OCI-AML3 blasts grown in vitro prior 
to injection into mice (Figure 3.29B).  
 
Figure 3.29. The growth capacity of control and NOX2 KD OCI-AML3 cells is un-changed. 
OCI-AML3 cells were transduced with a lentivirus encoding shRNA which targeted NOX2 or 
control. (A) qPCR was used to determine NOX2 mRNA levels in these cells. (B) Growth capacity 
of control or NOX2 KD OCI-AML3 cells was measured by Trypan blue exclusion cell counts (B).  
 
AML disease progression was measured by live animal bioluminescent imaging 
over a 5-week period. It was found that AML homed to the bone marrow and 
progression was reduced in animals injected with NOX2 KD cells (Figure 3.30A). 
This corresponded with overall animal survival, where mice injected with NOX2 
KD OCI-AML3 cells outlived their control KD counterparts (Figure 3.30B).  
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Figure 3.30. AML disease progression is severely reduced upon knockdown of NOX2. 
Mice injected with either control or NOX2 KD OCI-AML3 cells were monitored by live animal 
bioluminescent imaging, through the activation of luciferase construct within AML blasts using D-
luciferin (A). Survival of animals in this experiment is presented in a Kaplan-Meier plot (B). 
 
 
Taking this further, control KD and NOX2 KD OCI-AML3 cells were isolated from 
mouse bone marrow using MACS with human CD45+ microbeads. Mitochondrial 
levels in the isolated AML cell population was determined using MitoTracker 
Green staining and flow cytometry. It was found that NOX2 KD OCI-AML3 cells 
had approximately half the mitochondrial content than control KD OCI-AML3 cells 
- there was no change in the mitochondrial content of these cells prior to 
administration into mice (Figure 3.31). The reduced mitochondrial mass in NOX2 
KD cells may therefore be in part due to in vivo intercellular mitochondrial transfer, 
however there still may be a range of other explanations for this observation. 
 
 
Figure 3.31. Mitochondrial levels are reduced in vivo in NOX2 KD OCI-AML3 cells.  
Control and NOX2 KD OCI-AML3 cells were isolated from mouse bone marrow by MACS. 
Mitochondrial levels were measured using MitoTracker Green staining and flow cytometry. 
Mitochondrial levels are presented as MitoTracker MFI. 
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Overall this in vivo model shows that NOX2 contributes to AML disease 
progression, in part through the stimulation of mitochondrial transfer in the BMM. 
Therefore, they may be a therapeutic intervention opportunity whereby NOX2 is 
targeted on AML blasts.  
 
3.3 Summary 
 
In this chapter of my thesis I have shown that mitochondrial transfer occurred 
from BMSC to AML blasts, which enhanced OCR. Mitochondria can move 
through TNTs and is stimulated by NOX2 superoxide, which caused oxidative 
stress in BMSC. This enhancement of oxidative stress in BMSC promoted PGC-
1α driven mitochondrial biogenesis - which facilitated mitochondrial movement to 
AML blasts. Finally, I have presented NOX2 as a novel therapeutic target in AML. 
NOX2 reduction on AML blasts increases animal survival. The data presented in 
this chapter is summarised schematically below (Figure 3.32). 
 
Figure 3.32. Schematic representation of mitochondrial transfer in AML. 
(1) NOX2 on AML blasts generate superoxide. (2) NOX2 superoxide causes oxidative stress in 
BMSC. (3) Oxidative stress in BMSC activates PGC-1α. (4) Activation of PGC-1α stimulates 
mitochondrial biogenesis. (5) AML acquires mitochondria from BMSC through TNTs. (6) 
Mitochondrial transfer results in increased mitochondrial levels in AML blasts which increases 
OCR and ATP generation. This process ultimately leads to AML proliferation and survival.  
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4 CD38 mediated mitochondrial transfer promotes bio-
energetic flexibility in multiple myeloma cells. 
 
4.1 Introduction 
 
It is becoming apparent that not all cancers utilise the Warburg hypothesis to 
generate ATP required for proliferation and survival. Multiple myeloma has been 
shown to be a “Warburg Cancer” as MM cells are susceptible to glycolysis 
inhibitors (316) and have been shown to have a glycolytic gene signature (317). 
However, these studies were carried out on MM cells alone and didn’t take into 
account the effect of the BMM. In the second chapter of my thesis I will examine 
the effect the microenvironment has on metabolism within MM cells and if (like 
AML) intercellular mitochondrial transfer occurs between BMSC and MM cells. 
 
4.2 Results 
 
4.2.1 Multiple myeloma cells enhance mitochondrial respiration in the 
presence of their BMM. 
 
First, I examined the metabolism within primary MM cells isolated from patients. 
To achieve this, I used the Seahorse Extracellular flux analyser to determine OCR 
and glycolysis in patient MM cells immediately after isolation from the bone 
marrow. Primary MM cells (n=4; from independent patient bone marrow samples) 
were found to have an increased OCR compared to four MM cell lines (Figure 
4.1A and B), in addition to having reduced levels of glycolysis (Figure 4.1C). This 
shows the BMM of primary MM cells can influence malignant cell metabolism. 
 
To assess how the mouse BMM influences metabolism within MM cell lines, I 
engrafted the MM cell line MM1S into NSG mice. After 3 weeks I sacrificed the 
mice and isolated MM1S cells using MACS with human CD45+ microbeads. OCR 
and glycolysis levels were examined in the isolated MM cells immediately 
compared to MM1S cells cultured in vitro. Increased OCR were found in MM1S 
cells analysed ex vivo (Figure 4.2A and B), with no change observed in glycolysis 
levels (Figure 4.2C).  
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Figure 4.1. Primary MM cells have increased OCR compared to MM cell lines. 
Primary MM cells were isolated from four independent patient bone marrows and analysed 
immediately using the Seahorse extracellular flux analyser compared to four MM cell lines (MM1S, 
U266, RPMI and H929). (A) Representative OCR plot (with injections of oligomycin, FCCP and 
rotenone/antimycin A) is shown which contains 2 primary MM and 2 MM cell lines. (B) Relative 
OCR in 4 primary MM cells and 4 MM cell lines – presenting the basal and maximum OCR along 
with post oligomycin (Post-O) OCR and spare capacity (S.C). All OCRs have had the non-
mitochondrial respiration (after rotenone/antimycin A treatment) subtracted. (C) Relative 
glycolysis rates in these cells is presented. 
 
 
Figure 4.2. MM1S cells isolated from NSG mice have increased OCR. 
MM1S cells were injected into the tail vein of NSG mice (n=5), after 3 weeks the mice were 
sacrificed and MM1S cells were isolated. These cells, along with MM1S cells grown in vitro, were 
immediately analysed using the Seahorse extracellular flux assay. (A) Shows a representative 
OCR plot with all data accumulated in the bar chart presented in (B). Basal and maximum OCR, 
along with post oligomycin (Post-O) OCR and spare capacity (S.C), are presented - all values 
have non-mitochondrial respiration (after rotenone/antimycin A treatment) subtracted. Relative 
glycolysis levels in the MM1S cells is shown in (C).  
 
Taking this further, I co-cultured three MM cell lines (MM1S, U266 and RPMI) 
alone and with BMSC for 72 hours. After culture, I analysed OCR and glycolysis 
using the Seahorse extracellular flux analyser. MM cell lines grown with BMSC 
were found to have increased OCR (Figure 4.3A and B). A large increase is seen 
in maximum OCR (after FCCP injection) which suggests an enhancement of the 
respiratory chain, however this may not be necessarily due to an increase in ATP 
synthase activity. No change in glycolysis was observed in 2/3 of the cell lines 
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tested, with a reduction in glycolysis observed in the RPMI cell line (Figure 4.3C). 
Taken together these results suggest that the microenvironment of MM promotes 
a more mitochondrial based metabolism, which is contrary to the Warburg 
hypothesis and previously published literature.  
 
 
Figure 4.3. MM cell lines have increased OCR after culture with BMSC. 
OCR and glycolysis rates were determined in MM cells (MM1S, U266 and RPMI) cultured with 
and without BMSC. A representative OCR plot is shown in (A). (B) Relative basal (B) and 
maximum (M) OCR is presented along with post oligomycin (P.O) OCR and spare capacity (S.C) 
– all OCR values have non-mitochondrial respiration (post rotenone/antimycin A) subtracted. 
Relative glycolysis rates are presented in (C). 
 
The consequence of increased OCR in MM cell lines was next tested. ATP levels 
and the growth capacity of MM cell lines after culture with BMSC was assessed, 
using CellTitre-Glo and Trypan blue cell counts respectively. Increased ATP 
production and growth capacity was observed in MM cell lines cultured with 
BMSC compared to when they were cultured alone (Figure 4.4). Therefore, 
culture with BMSC promotes MM cell growth and proliferation through an 
enhancement of mitochondrial respiration. 
 
 
Figure 4.4. MM cells have increased growth and ATP production after BMSC culture. 
MM1S, U266 and RPMI cells were grown with BMSC or alone for 72 hours. After culture, the 
growth capacity and ATP production in MM cells was determined using Trypan blue cell counts 
and CellTitre-Glo respectively.   
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4.2.2 Mitochondria are transferred from BMSC to MM cells 
 
To determine the reason why MM cells have increased OCR after co-culture with 
BMSC, I next examined whether intercellular mitochondrial transfer took place 
between BMSC and MM cells. I utilised the three methods developed in the AML 
project to detect mitochondrial transfer. Using the MitoTracker Green based 
mitochondrial transfer assay, increased MitoTracker MFI was found after co-
culture with BMSC in all 10 primary MM cells and in 4/5 MM cell lines tested 
(Figure 4.5). This showed that MitoTracker labelled mitochondria move from 
BMSC to MM cells. 
 
 
Figure 4.5. Increased MitoTracker MFI is observed in MM cells post co-culture with BMSC. 
Primary MM cells (n=10) and MM cell lines (n=5) were stained with 200nM MitoTracker Green 
and cultured alone or with MitoTracker Green stained BMSC for 24 hours. MitoTracker Green MFI 
levels were analysed by flow cytometry. 
 
 
The rLV.EF1.mCherry-Mito-9 lentivirus method was next used. However, the 
method was optimised to include fixed cell microscopy which was carried out on 
cells mounted onto cover slips - with mounting solution containing DAPI. The un-
labelled MM1S cell line was seen to acquire mCherry fluorescence from 
rLV.EF1.mCherry-Mito-9 positive BMSC (Figure 4.6). This showed that mCherry 
labelled mitochondria from BMSC move to the MM1S cells.  
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Figure 4.6. mCherry labelled mitochondria move from BMSC to MM cells. 
Primary BMSC were transduced with a rLV.EF1.mCherry-Mito-9 lentivirus. These BMSC were 
cultured with MM1S cells for 72 hours, followed by fixation and mounting on cell culture slides. 
The slides were imaged using fluorescent microscopy and a representative image is shown in this 
figure. The scale bar represents a 10µm distance. 
 
The final method utilised to show mitochondrial transfer was the in vivo xenograft 
model. MM1S and U266 MM cell lines were injected into the tail vein of NSG 
mice. At humane end point animals were sacrificed and human MM cells were 
then sorted from mouse bone marrow using MACS. qPCR with species specific 
primers targeted to mtDNA and gDNA was carried out on extracted DNA, PCR 
products were then visualised using agarose gel electrophoresis. In MM cell lines 
grown in vitro no presence of mouse mtDNA or gDNA was detected, whereas 
murine mtDNA was detected in MM cell lines isolated from mouse bone marrow 
- with no gDNA detected (Figure 4.7). This showed that murine mitochondria 
moved from the mouse BMM to MM cells.  
 
Taken together, these three experiments show that mitochondria moved from 
BMSC to MM cells which contributed to the increased OCR, ATP production and 
growth capacity observed in 4.2.1.  
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Figure 4.7. Murine mitochondria move to human MM cells in vivo. 
MM1S and U266 were engrafted into NSG mice. After isolation, DNA from human MM cells was 
analysed using qPCR with species specific primers targeted to mtDNA and gDNA. PCR products 
were visualised on an agarose gel and is presented in this figure. 
 
In AML, the chemotherapy agent daunorubicin was seen to increase the level of 
transfer (Figure 3.13). I next examined whether chemotherapy used in the 
treatment of MM (Bortezomib) had the same effect in this mitochondrial transfer 
model. Bortezomib was seen to increase the levels of mitochondrial transfer from 
BMSC to both primary MM cells (Figure 4.8A) and MM cell lines (Figure 4.8B) by 
approximately 50%. Therefore, a common theme is emerging whereby current 
chemotherapeutics increase the level of mitochondrial transfer.   
 
 
Figure 4.8. Bortezomib increases mitochondrial transfer from BMSC to MM cells. 
Mitochondrial levels were analysed between BMSC and primary MM cells (n=7) or MM cell lines 
(n=4), using the MitoTracker Green based transfer assay upon the addition of 10nM Bortezomib. 
Mitochondrial transfer levels to primary MM cells (A) and MM cell lines (B) are presented as % 
mitochondrial transfer compared to DMSO treated control. 
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4.2.3 Mitochondria are transferred from BMSC to MM cells through TNTs 
 
To examine how mitochondria move from BMSC to MM cells, TNTs were once 
again analysed to determine whether mitochondrial transfer in MM occurred in a 
similar way to AML. I used the MitoTracker based mitochondrial transfer assay to 
quantify the level of transfer between BMSC and MM cells upon the addition of 
CytoB (TNT inhibitor) and Dansylcadavarine (Endocytosis/Microvesicle inhibitor). 
Mitochondrial transfer was reduced upon the addition of CytoB by 40%, whereas 
no change was observed upon the addition of Dansylcadavarine (Figure 4.9).  
 
Figure 4.9. CytoB reduces mitochondrial transfer from BMSC to MM cells. 
The MitoTracker based transfer assay was used to determine transfer levels upon the addition of 
CytoB (A) and Dansylcadavarine (B). Mitochondrial transfer levels were determined using the 
ΔMitoTracker Fluorescence (MFI) between co-cultured and mono-cultured MM cells and are 
presented as %mitochondrial transfer relative to non-treated controls. 
 
Next, I aimed to visualise TNT formations using the Vybrant DiI staining of MM 
cells and MitoTracker Green staining of BMSC. After co-culture, fixed cell 
confocal microscopy was carried out and TNTs were found between MM cells 
and BMSC (Figure 4.10). These TNTs were formed by the cancer cell and 
contained mitochondria of BMSC origin. This assay was optimised to enhance 
the quality of TNT images - the rLV.EF1.AcGFP1-Mem-9 lentivirus was 
purchased from Clontech which labelled the plasma membrane of MM cells with 
a GFP fluorophore. These cells were cultured with MitoTracker CMXRos stained 
BMSC for 24 hours and fixed cell confocal microscopy was carried out. GFP-
TNTs were visualised between BMSC and MM cells which contained 
mitochondria of BMSC origin (Figure 4.10). 
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Figure 4.10. TNTs are formed between MM and BMSC which contain BMSC mitochondria. 
TNTs were visualised by confocal microscopy using two methods. MM were stained with Vybrant 
DiI and cultured with MitoTracker Green stained BMSC. Also, MM were transduced with the 
rLV.EF1.AcGFP1-Mem-9 lentivirus and cultured with MitoTracker CMXRos stained BMSC. Both 
conditions were visualised by fixed cell confocal microscopy and individual microscope fields are 
presented, along with the merged field. The scale bar relates to a 10µm diameter. 
 
TAPs are formed on BMSC after co-culture with MM cells stained with Vybrant 
DiI, these were used again to quantify the number of TNT formations. On average 
around 250 TAPs are formed per confocal image (Figure 4.11) which is slightly 
less than the average number of TAPs found on BMSC after AML co-culture. 
 
 
Figure 4.11. TAPs are formed on BMSC after culture with Vybrant DiI labelled MM cells. 
Four MM cell lines were stained with Vybrant DiI and cultured with BMSC stained with MitoTracker 
Green. MM cells were removed and TAPs were quantified and presented as counts per confocal 
image.  
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Upon the addition of CytoB the number of TAPs formed on BMSC was reduced 
by approximately 75% (Figure 4.12). This shows that TAPs are a useful method 
of quantifying the number of TNT formations that occur during a co-culture of 
BMSC and MM cells. This will be important in Section 4.2.5. 
 
Figure 4.12. The addition of CytoB reduces the number of TAPs formed on BMSC. 
Four MM cell lines were stained with Vybrant DiI and cultured with MitoTracker Green stained 
BMSC (with and without the addition of CytoB). After co-culture MM cells were removed and 
BMSC were visualised by confocal microscopy, a representative image taken after U266 culture 
is presented. The number of TAPs per confocal image was determined with and without the 
addition of CytoB, data is presented as relative TAP formations per confocal image. 
 
The results in this section show that mitochondria can be transferred from BMSC 
to MM cells via TNTs, which is comparable with the AML mitochondrial transfer 
mechanism described in Chapter 3. 
 
4.2.4 CD38 on MM cells is crucial for the transfer of mitochondria from 
BMSC 
 
In the first part of this chapter I have shown that mitochondria are transferred from 
BMSC to MM cells through TNTs. Next, I wanted to delve deeper into the 
mechanism which controls mitochondrial transfer in MM. MM cells express high 
levels of the surface molecule CD38 (244) and this molecule has been recently 
shown to facilitate mitochondrial transfer from astrocytes to neurons after stroke 
(331). Therefore, I examined whether CD38 plays a role in mitochondrial transfer 
observed in MM. 
 
First, I correlated levels of mitochondrial transfer to levels of CD38 on the surface 
of primary MM cells and MM cell lines. There was a strong positive correlation 
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(R=0.8727) observed between the levels of CD38 expressed on MM cells and the 
quantity of mitochondria they acquired from BMSC (Figure 4.13).  
 
 
 
Figure 4.13. CD38 expression on MM cells correlates with mitochondrial transfer levels. 
Mitochondrial transfer levels were assessed in primary MM cells (n=7) and MM cell lines (n=5) 
using the MitoTracker Green based transfer assay. CD38 levels were also measured on MM cells 
using flow cytometry.  
 
Next, I made a lentivirus encoding shRNA which targets CD38 mRNA. CD38 
surface expression was reduced by approximately 80% in MM cell lines 
transduced with CD38 lentivirus compared to a control virus (Figure 4.14A). The 
levels of mitochondrial transfer between BMSC and control KD or CD38 KD MM 
cell lines was next assessed. Mitochondrial transfer was reduced by 40-50% in 
CD38 KD MM cell lines compared to control KD cells (Figure 4.14B).  
 
Figure 4.14. CD38 KD MM cells acquire reduced quantities of mitochondria from BMSC. 
MM cell lines (MM1S, U266, H929 and RPMI) were transduced with a lentivirus encoding shRNA 
targeted to CD38 or control. (A) CD38 surface protein levels are presented on control KD or CD38 
KD cells. (B) Mitochondrial transfer levels in control KD and CD38 KD cells were assessed using 
the MitoTracker Green based transfer assay. 
	 145	
To analyse the role of CD38 further, I next overexpressed CD38 on MM cells to 
assess levels of mitochondrial transfer. All-trans retinoic acid (ATRA) has recently 
been shown to increase CD38 expression on AML blasts (345), therefore this was 
utilised in MM cell lines. MM cell lines treated with 1µM ATRA for 16-hours were 
seen to increase their CD38 mRNA expression (Figure 4.15A) and their CD38 
surface protein levels (Figure 4.15B) - compared to DMSO treated controls. 
Mitochondrial transfer levels were increased from BMSC to MM cell lines treated 
with ATRA compared to DMSO by between 40 and 70% respectively (Figure 
4.15C). Overall, these results provide evidence that CD38 has a role in facilitating 
mitochondrial transfer between BMSC and MM cells. 
 
 
Figure 4.15. CD38 overexpression, using ATRA, causes increased mitochondrial transfer. 
Three MM cell lines (U266, RPMI and H929) were treated with 1µM ATRA or DMSO for 16-hours 
(overnight). CD38 mRNA and protein expression levels were determined using qPCR (A) and flow 
cytometry (B) respectively. Mitochondrial transfer levels were determined in ATRA/DMSO treated 
MM cell lines using the MitoTracker Green based transfer assay (C).  
 
 
 
4.2.5 CD38 forms the leading edge of a MM tunneling nanotube 
 
Next, I assessed how CD38 controls the transfer of mitochondria from BMSC to 
MM cells. As CD38 is a cell surface molecule it is likely that it is involved in the 
extracellular projection (TNT) that facilitates mitochondrial transfer. To examine 
this hypothesis first, I analysed the number of TAPs (TNT formations) that were 
present on BMSC after co-culture with ether control KD or CD38 KD MM cell lines. 
A severe reduction in the number of TAPs formed on BMSC was observed after 
co-culture with RPMI CD38 KD cells compared to control KD cells (Figure 4.16A). 
This was also the case with MM1S, U266 and H929 MM cell lines where there 
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was approximately an 80% reduction in the number of TAPs formed on BMSC 
after culture with CD38 KD cells (Figure 4.16B). Therefore, the knockdown of 
CD38 in MM cells reduces the number of TNTs formed between MM cells and 
BMSC - resulting in reduced levels of mitochondrial transfer. 
 
 
Figure 4.16. CD38 KD MM cell lines form less TNTs with BMSC. 
Control KD and CD38 KD MM cell lines (MM1S, U266, RPMI and H929) were stained with Vybrant 
DiI stain and cultured for 24-hours with MitoTracker Green stained BMSC. TAPs were visualised 
using fixed cell confocal microscopy and quantified per confocal microscope image. 
 
Next, I analysed in more detail the composition of the TAP and whether CD38 
could be present within this formation. First, I examined the expression levels of 
CD38 on MM cells after co-culture with BMSC. Reduced levels of CD38 were 
observed on the surface of MM1S and U266 MM cell lines after co-culture with 
BMSC (Figure 4.17A). BMSC do not express CD38, however after co-culture with 
MM cell lines they gain CD38 expression - albeit at low levels (Figure 4.17B). This 
shows that CD38 may be transferred to BMSC during co-culture with MM cells.  
 
 
Figure 4.17. CD38 is transferred from MM cells to BMSC during co-culture.  
MM1S and U266 cells were cultured with BMSC for 24-hours. CD38 expression on MM1S/U266 
cells (A) and BMSC (B) were assessed by flow cytometry. 
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I next determined the location of CD38 on BMSC that was transferred from MM 
cells. Using the TAP visualisation method, BMSC were probed with a CD38 
antibody conjugated to an Alexa Fluor 647 fluorophore. CD38 was found to be 
located on BMSC within TAPs formed by TNT contacts (Figure 4.18), therefore 
CD38 may contribute to the formation of TNTs and resultant TAPs.  
 
 
Figure 4.18. MM CD38 is located within the TAP on BMSC after co-culture. 
MM1S cells were stained with Vybrant DiI and cultured with BMSC (which were stained with 
MitoTracker Green) for 24-hours. After culture MM1S cells were removed, BMSC were fixed and 
probed with CD38 Alexa Fluor 647 antibody before imaging with confocal microscopy. Individual 
microscope channels are presented along with merged field for BMSC alone and after co-culture 
with MM1S cells. 
 
Next, I analysed the location of CD38 on TNTs formed by MM cells during co-
culture with BMSC. I cultured rLV.EF1.AcGFP1-Mem-9 MM1S cells with 
MitoTracker CMXRos for 24 hours, the culture was fixed and probed with the 
CD38 Alexa Fluor 647 antibody. Confocal microscopy highlighted the location of 
CD38 on a MM cell during TNT formation (Figure 4.19). CD38 was highly 
clustered at the point of TNT formation and projects down the TNT. 
 
Taken together, these results provide evidence that CD38 may form the leading 
edge of a TNT projection – which is then deposited on BMSC after dissociation. 
This mechanism plays a role in the transfer of mitochondria from BMSC to MM 
cells.  
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Figure 4.19. CD38 localises of the leading edge of a TNT formation. 
MM1S cells were transduced with the rLV.EF1.AcGFP1-Mem-9 lentivirus. These cells were 
cultured with MitoTracker CMXRos stained BMSC for 24 hours. Co-cultures were then fixed and 
CD38 was probed using an Alexa Fluor 647 antibody. CD38 location on TNTs was visualised 
using confocal microscopy, individual microscope channels and merged field are presented.  
 
Next, I tried to determine the binding partner on BMSC which CD38 binds to form 
a TNT. The only known binding partner of CD38 is CD31 (346), therefore I 
examined whether CD31 could be this binding molecule on BMSC. As CD31 is a 
surface receptor I used flow cytometry to first examine whether primary human 
BMSC expressed CD31. I found that BMSC (n=3) did not express CD31 (Figure 
4.20) therefore could not be the molecule that CD38 binds forming a TNT. It is 
likely there is a novel binding partner to CD38 expressed on BMSC or CD38 could 
bind un-specifically to BMSC in order to form the TNT. Unfortunately, I was unable 
to find out anything further during my PhD research and this remains an 
unanswered question. 
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Figure 4.20. BMSC do not express the CD38 binding partner CD31. 
Primary human BMSC (n=3) were incubated with a CD31-FITC antibody or isotype control for 15 
minutes. CD31 expression on BMSC was analysed using flow cytometry. 
 
4.2.6 Silencing of CD38 in vivo reduces MM disease progression. 
 
To determine the effect of CD38 mediated mitochondrial transfer on MM disease 
progression, I used an in vivo xenograft model to monitor the growth of MM. 
Control KD or CD38 KD MM1S cells (containing a luciferase construct) were 
injected into the tail vein of NSG mice. There was no difference in the growth 
capacity of these cells prior to administration into mice (Figure 4.21). MM disease 
progression in the bone marrow was monitored using live animal bioluminescent 
imaging, a reduced MM disease burden was found in animals injected with CD38 
KD MM cells compared to control KD cells (Figure 4.22A). This resulted in these 
animals outliving their control KD counterparts (Figure 4.22B). 
 
Figure 4.21. Growth capacity is unchanged between control KD and CD38 KD MM1S cells.  
Before injection into mice, the growth capacity of control KD and CD38 KD MM1S were analysed 
using Trypan blue exclusion cell counts. 
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Figure 4.22. MM disease progression is severely reduced upon the knockdown of CD38.  
Control KD or CD38 KD MM1S cells (containing luciferase construct) were injected into the tail 
vein of NSG mice. MM disease progression at day 14 and 21 was analysed using live animal 
bioluminescent imaging, through activation of the luciferase construct in MM cells using D-luciferin 
(A). Overall survival of animals in this experiment is presented in a Kaplan-Meier plot (B). 
 
Furthermore, control KD and CD38 KD MM1S cells were isolated from mouse 
bone marrow and mitochondrial levels were analysed using MitoTracker Green 
staining. A 2.5-fold decrease in mitochondrial levels was observed in CD38 KD 
MM1S cells compared to control KD cells (Figure 4.23A). No change in 
mitochondrial levels was observed in control KD and CD38 KD MM cells pre-
transplant into mice (Figure 4.23B). Taking these results together, it suggests that 
one way that CD38 promotes MM disease progression in vivo is through 
intercellular mitochondrial transfer levels. 
 
 
Figure 4.23. Ex vivo mitochondrial levels are reduced in CD38 KD MM1S cells. 
Mitochondrial content was analysed in control KD and CD38 KD MM1S cells isolated from NSG 
mice (A) and cultured in vitro (B). Mitochondrial levels were determined using MitoTracker Green 
staining and flow cytometry. Data is presented as MitoTracker Green MFI.  
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4.3 Summary 
 
In this chapter I have presented data which shows that in the presence of its 
microenvironment, multiple myeloma utilises a more mitochondrial based 
metabolism over glycolysis to generate ATP. This is due in part to intercellular 
mitochondrial transfer from BMSC which can be facilitated through TNTs. Taking 
this further, I have shown that CD38 expression on the surface of MM cells plays 
a role in the transfer of mitochondria. CD38 has the ability to form the leading 
edge of a TNT which docks with BMSC. MM disease progression is reduced in 
vivo through inhibition of CD38 which may be mediated in part by pro-tumoral 
mitochondrial transfer. Figure 4.24 presents schematically an overview of the 
results discussed in this chapter. 
 
 
Figure 4.24. Overview of mitochondrial transfer in Multiple Myeloma. 
(1) CD38 is highly expressed on the surface of MM cells. (2) CD38 forms the leading edge of a 
MM derived TNT formation. (3) CD38 binds to BMSC through a currently unknown BMSC 
molecule and facilitates mitochondrial transfer to MM cells. (4) The TNT dissociates leaving 
behind MM-CD38 protein on the surface of BMSC - which form TAPs. (5) The consequence of 
mitochondrial transfer is that MM cells enhance mitochondrial respiration and ATP production. 
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5 LPS mediated bacterial infection stimulates mitochondrial 
transfer to haematopoietic stem cells. 
 
5.1 Introduction 
 
In the first two results chapters I have described two haematological malignancies 
where intercellular mitochondrial transfer aids proliferation and survival. The 
transfer of mitochondria between cells has previously been shown to also occur 
in non-malignant systems. In chapter 3 I found under normal circumstances 
CD34+ cells (HSCs) do not acquire mitochondria from BMSC, however under 
oxidative stress these cells can be forced to acquire mitochondria. A major 
stimulus of oxidative stress in the human body is bacterial infection (347), 
therefore this may stimulate mitochondrial transfer to HSCs in a non-malignant 
haematological system. LPS is found on the surface of gram negative bacteria 
and has been shown to stimulate a bacterial-like infection response in mice (16). 
LPS has also been shown to promote intercellular mitochondrial transfer in vivo, 
where airway instilled BMSC transfer their mitochondria to lung epithelial cells 
(330). In the final chapter of my thesis I will examine whether mitochondrial 
transfer occurs from the BMM to HSCs in mouse models simulating bacterial 
infection. This will determine whether intercellular mitochondrial transfer is a 
process that AML and MM cells have hijacked to promote their proliferation and 
survival.  
 
5.2 Results 
 
5.2.1 LPS causes increased mitochondrial content in C57BL/6J ST-HSCs 
 
First, I analysed the effect of LPS on mitochondrial levels in different cell 
populations within the murine haematopoietic system including ST-HSCs, LT-
HSC and MPPs. This was achieved using 7-colour flow cytometry with 6 
antibodies targeted to cell surface markers (along with MitoTracker Green). This 
flow cytometry method was based on a similar method used by Walter and 
colleagues (16) and included all appropriate colour compensations. The gating 
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strategy to determine cell populations of interest was defined using FMO controls 
and is shown in Figure 5.1 Panel A. 
 
C57BL/6J were treated with either 1mg/kg LPS or PBS for 2 hours. This time point 
was chosen to try and specifically detect changes in mitochondrial levels due to 
intercellular transfer rather than mitochondrial biogenesis. LPS caused an 
expansion of haematopoietic cells (Figure 5.1 Panel D) as expected and is 
comparable to data published by Walter and colleagues (16). As an expansion of 
the haematopoietic system is a hallmark of the response to bacterial infection, in 
this experiment I have therefore successfully managed to induce the desired 
bacterial response in order to analyse mitochondrial levels.
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Figure 5.1. LPS induces an expansion of ST-HSCs in C57BL/6J bone marrow and an increase in mitochondrial content. 
C57BL/6J mice were treated with either PBS or 1mg/kg LPS for 2 hours, followed by sacrifice and BM isolation. Haematopoietic cell population 
numbers and mitochondrial content within these populations were analysed using 7-colour flow cytometry. Panel A presents the gating strategy 
used to specifically analyse haematopoietic cell populations. Panel B shows representative histogram plots of the defined populations presenting 
MitoTracker Green MFI and cell counts. Panel C presents mitochondrial levels (MitoTracker Green MFI) in specific populations of all animals 
examined (n=5), with Panel D showing the cell counts.  
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Figure 5.2. Salmonella enterica stimulates expansion of the BM haematopetic component through an increase in mitochondria.    
Salmonella enterica was administered to C57BL/6J mice, after 72 hours the animals were sacrificed and bone marrow was extracted. Specific 
haematopoietic cell components were determined using the same gating strategy as Figure 5.1. Panel A presents the mitochondrial content (relative 
MitoTracker Green MFI). Panel B presents the cell numbers of each specific haematopoietic cell population. 
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A significant increase in mitochondrial levels were found in the ST-HSC 
population (Lin-Sca+c-Kit+CD150+CD48-CD34+) but not LT-HSCs (Lin-Sca+c-
Kit+CD150+CD48-CD34-) (Figure 5.1 Panel D). Significant increases in 
mitochondrial levels were also found in Lin- and Lin-Sca+c-Kit+ (LSK) populations. 
In the other populations analysed (Lin+, MPPs and total HSCs) the levels of 
mitochondria are unchanged.  
 
To determine whether the same effect is observed upon a real bacterial infection, 
the experiment was repeated with animals administered with live Salmonella 
enterica. This gram-negative bacterium was administered through oral gavage 
with bacterial infection observed after 72 hours. Therefore, at 72 hours the mice 
were sacrificed and bone marrow analysis was carried out. As expected, an 
expansion of the haematopoietic component of the bone marrow was again 
observed in Salmonella treated mice (Figure 5.2 Panel A). Increased 
mitochondrial levels were observed again in ST-HSC and LSK cells and 
additionally in LT-HSC, Total HSCs and MPPs likely due to the increased time 
point used (72-hour vs 2-hours) compared to the LPS experiment. Taken 
together, the results from LPS and Salmonella experiments suggest that ST-
HSCs increase their mitochondrial levels in order to proliferate and expand the 
downstream haematopoietic cell component in response to pathogen exposure. 
 
5.2.2 LPS induces intercellular mitochondria transfer to HSCs 
 
Next, I aimed to examine how ST-HSCs increase their mitochondrial levels and 
whether this could be due to intercellular mitochondrial transfer. To do this I 
generated “humanised” mice, through the transplantation of umbilical cord blood 
CD34+ stem and progenitor cells into 3-4-week-old NSG mice. Engraftment was 
assessed through monthly peripheral blood analysis looking specifically for 
human CD45+ cells. Figure 5.3 shows that the percentage of human CD45+ cells 
in the bone marrow rose from around 3% to 40% from month 1 to month 3 - which 
confirms “humanisation” of the mice.  
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Figure 5.3. Human CD45+ cells are present in the bone marrow of humanised mice. 
Cord blood CD34+ stem and progenitor cells were transplanted into 3-4-week-old NSG mice, 
engraftment was determined through peripheral blood flow cytometry analysis. The percentage of 
human CD45+ cells is presented over a 3-month time period in 5 humanised NSG mice.  
 
Humanised mice generated were treated with PBS or 1mg/kg LPS for 2 hours, 
bone marrow was then extracted and haematopoietic cell populations were 
analysed using flow cytometry. A modified panel of antibodies was used to detect 
the human HSC population (murineCD45- humanCD38-CD34+CD45RA-
CD90+CD49f+), MPP (murineCD45- humanCD38-CD34+CD45RA-CD90-CD49f-), 
CMP (murineCD45- humanCD38+CD34+CD45RA-CD90-CD49f-) and GMP 
(murineCD45- humanCD38+CD34+CD45RA+CD90-CD49f-). Again, appropriate 
colour compensations were carried out and gating strategy (Figure 5.4) was 
determined using FMO controls.  
 
Figure 5.4. Gating strategy of HSC, MPP, CMP and GMP populations in humanised mice. 
After sacrifice, humanised NSG BM was isolated and stained with a panel of antibodies to analyse 
specific HSC, MPP, CMP and GMP populations. The gating strategy is presented.  
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In addition to the panel of antibodies, humanised mouse BM from PBS/LPS 
treated mice was stained with MitoTracker Green to determine mitochondrial 
levels. Increased mitochondrial levels were observed in HSC and MPP 
populations from LPS treated humanised mice, with no change observed in CMP 
and GMP populations (Figure 5.5). This result was comparable with results 
obtained from C57BL/6J mice. 
 
Figure 5.5. LPS increases mitochondria in human HSC and MPP from humanised mice.  
Mitochondrial levels were determined in HSC, MPP, CMP and GMP populations isolated from 
humanised mice after PBS/LPS treatment. These populations were determined using the gating 
strategy shown in Figure 5.4 and mitochondrial levels were determined using MitoTracker Green 
staining. 
 
Finally, I determined whether increased mitochondrial levels were in part due to 
intercellular mitochondrial transfer from the mouse BMM. The humanised NSG 
mouse model allows the specific analysis of two species mitochondrial transfer. 
The human HSC population was sorted from the bone marrow of humanised mice 
after treatment with PBS/LPS, using the gating strategy shown in Figure 5.4. 
qPCR was directly carried out on HSC cell lysate using duplex Taqman qPCR, 
with species specific probes targeted to the mitochondrial ND1 gene. A human 
Tert probe was also used for normalisation of Ct values. The HSC population from 
PBS treated humanised mice contained no mouse mitochondria. However, on 
average 3% of the total mitochondria in human HSCs from the LPS treated mice 
were of mouse origin (Figure 5.6A). There was no difference in the levels of 
human mitochondria in isolated HSCs, suggesting that mitochondrial biogenesis 
is not occurring (Figure 5.6B). This presents data which suggests that upon LPS 
treatment mitochondria are transferred from the BMM to HSCs which allows their 
expansion and proliferation.   
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Figure 5.6. Mouse mitochondria move from the BMM to human HSCs upon LPS 
treatment. 
The human HSC population was sorted from the BM of PBS/LPS treated “humanised” mice. qPCR 
was carried out with species specific Taqman probes targeted to ND1 and Tert. Mouse and human 
mitochondrial levels were determined using the ΔΔCt normalising the human/mouse 
mitochondrial Ct to human Tert. (A) The percentage of mouse mitochondria detected in isolated 
HSC. (B) The relative quantity of human mitochondria in HSCs isolated from PBS/LPS treated 
mice is presented.  
 
5.3 Summary 
 
In the final results chapter of my thesis I have explored the possibility of 
intercellular mitochondrial transfer occurring in a non-malignant haematological 
system. I utilised LPS to simulate bacterial infection in C57BL/6J mice and found 
that ST-HSCs had increased mitochondrial levels compared to PBS treatment. 
This result was also observed after the administration of the “real” bacterium 
Salmonella enterica. Through the use of humanised NSG mice, I found that 
increased mitochondrial levels in HSCs were in part due to intercellular 
mitochondrial transfer from the BMM. This transfer of mitochondria resulted in the 
expansion and proliferation of the HSC compartment, which will mount an attack 
against the foreign pathogen. Results in this chapter show that mitochondrial 
transfer in the bone marrow is not specific to haematological malignancies and 
that it’s a fundamental process in which AML and MM cells are able to hijack to 
gain a survival advantage.  
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6 Discussion and Conclusions 
 
6.1 General Discussion 
 
Acute myeloid leukaemia and multiple myeloma are devastating haematological 
malignancies which are presently incurable. Current treatments targeting the 
malignant cell are effective at removing the bulk of the tumour, however disease 
relapse is very common and ultimately leads to mortality. Small numbers of 
AML/MM cells remain in bone marrow niches, where they are protected from 
chemotherapeutics and have the ability to proliferate - leading to the repopulation 
of the malignancy. It is envisaged that the eradication of the malignant cells which 
remain within the bone marrow will provide a better prognostic outcome for 
patients diagnosed with these diseases. One of the ways in which malignant cells 
are protected is via their interactions with BMSC. A better understanding of the 
complex biological interactions between these two cell types will ultimately lead 
to novel therapeutics that will be used in combination with current 
chemotherapeutic regimens.  
 
In my thesis, I have highlighted the process of intercellular mitochondrial transfer 
which contributes to AML/MM survival and proliferation. In addition, I have 
dissected the key mechanisms that underpin this pro-tumoral process. It is hoped 
these mechanisms can be targeted therapeutically, which may increase the 
survival and prognostic outcome of patients diagnosed with these currently 
destructive diseases. 
 
6.2 Key findings  
 
6.2.1 Mitochondrial transfer in the bone marrow niche 
 
In my thesis, I have described two malignancies where intercellular mitochondrial 
transfer contributes to their survival and proliferation- which will contribute to the 
literature describing mitochondrial transfer.  
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AML blasts have previously been shown to be anti-Warburg - relying on 
mitochondria for ATP production (311) whilst having increased mitochondrial 
levels (314). I have shown that intercellular mitochondrial transfer from BMSC 
contributes to the accumulation of mitochondria within AML blasts, resulting in 
increased ATP production through an enhancement of mitochondrial respiration 
(Section 3.2.1 – 3.2.3). There may be other factors which contribute to 
mitochondrial accumulation in AML blasts, one example being defects in the 
mitochondrial degradation process mitophagy. However, this process has 
however been shown to be functional in AML stem cells and is required for cellular 
survival (348). It is therefore unlikely that this process contributes to the observed 
phenotype. A second study by Moschoi and colleagues also described 
mitochondrial transfer from BMSC to AML blasts (349). Ergo, the accumulation of 
mitochondria in AML blasts is most likely due to intercellular mitochondrial 
transfer.  
 
I have shown that an increase in mitochondrial levels subsequently enhances 
OCR in AML blasts (Section 3.2.3). The process of FAO is also able to generate 
ATP from free fatty acids, through OXPHOS (350). AML have been shown to 
import free fatty acids via the FABP4 transporter protein (273), therefore the 
increased mitochondria acquired from BMSC may provide extra machinery to 
metabolise these fatty acids. The combination of OXPHOS and FAO have the 
ability to provide AML blasts with huge amounts of ATP which can be utilised for 
rapid proliferation within the bone marrow.  
 
To date, there has been no study comparing mitochondrial levels in MM cells with 
their non-malignant counterparts. In my thesis, I showed that mitochondrial 
transfer was also present between MM and BMSC – a highly surprising result 
(Figure 4.2.2 and 4.2.3). This is because (unlike AML blasts) MM cells have been 
shown to be a “Warburg Cancer” relying on aerobic glycolysis to generate ATP 
(316, 317). However, after analysing the effect the MM microenvironment has on 
metabolism within the malignant cell it becomes apparent why the transfer of 
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mitochondria occurs. The BMM allows MM cells to switch their metabolism to 
utilise mitochondria, which contributes to growth capacity and ATP production 
(Section 4.2.1). Studies showing MM utilised aerobic glycolysis only analysed MM 
cells in mono-culture and not in the context of their microenvironment. Therefore, 
it is of paramount importance to study metabolism of malignant cells within their 
supportive microenvironment as they would be in the human body.  
 
In the final chapter of my thesis I described mitochondrial transfer in a non-
malignant haematological system - where HSCs acquire mitochondria from the 
BMM under LPS induced bacterial infection (Section 5.2). Therefore, I believe 
mitochondrial transfer is a normal physiological process that malignant 
haematopoietic cells can hijack to favour their proliferation and survival. Recently 
HSCs have been shown to transfer mitochondria to BMSC (351). This process 
occurred through connexin-43 mediated gap junctions and was shown to regulate 
ROS levels within the HSC. However, only limited conclusions can be drawn as 
this research was presented as a conference abstract and the full paper has not 
been published yet. Nevertheless, it can be seen that mitochondrial transfer plays 
an important role in the regulation of normal haematopoiesis as well as in the 
malignant bone marrow. 
 
It is becoming ever more apparent that malignant haematopoietic cells can modify 
their protective microenvironment and utilise normal processes to promote their 
survival and proliferation (352, 353). My results contribute to the evidence where 
this is the case; I have shown in my thesis that AML blasts can induce 
mitochondrial biogenesis in BMSC in order to “steal” these mitochondria to aid its 
proliferative advantage (Section 3.2.6). The mechanism utilised by AML blasts 
can not only acquire mitochondria, but also ensures BMSC remain viable to 
safeguard a constant mitochondrial source. Although not examined in thesis due 
to time constraints, I believe there will be a similar process exploited in MM to 
ensure BMSC remain viable. This mechanism will need to be independent of 
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NOX2 (as MM cells do not express this enzyme) but is likely to be still through 
PGC-1α activation. 
 
The number of cancers in which intercellular mitochondrial transfer occurs from 
supporting microenvironment cells is rapidly increasing. These cancers include 
Breast (326), Lung (323), Ovarian (326) and now AML and MM. It is highly likely 
that this biological process will also occur in other cancers that are known to have 
a strong association with their microenvironment such as prostate (354) and 
colorectal cancer (355). Therefore, I believe that in the not too distance future 
there will be literature describing mitochondrial transfer in these malignancies.  
 
As mitochondrial transfer appears to be part of the malignant phenotype, it is 
becoming apparent that the Warburg hypothesis may not be universally 
applicable. PET scans are a useful tool in diagnosing cancer as malignant cells 
have increased glucose consumption due to the Warburg hypothesis. Even 
though MM cells rely on mitochondrial metabolism in their BMM, PET scans are 
used in the diagnosis of MM and increased glucose consumption is associated 
with a poor prognosis (356, 357). Warburg stated that cancers generate ATP 
through glycolysis and this process produces lactate. Recent studies have shown 
that circulating lactate can feed the TCA cycle in lung cancer (358), which is the 
case in both human and mouse tumours (359). Therefore, in the context of MM I 
hypothesise that glucose does feed glycolysis as Warburg hypothesised. 
However, lactate generated is then fed into the TCA cycle of functional 
mitochondria (acquired from the BMM) and ATP is generated through OXPHOS. 
This may be the case for other “Warburg Cancers” where the transfer of 
mitochondria occurs and may re-define metabolism within tumour cells.  
 
6.2.2 Tunneling nanotubes: The mitochondrial transporter 
 
Mitochondria have been shown to primarily be transferred between cells by TNTs 
(323, 326, 327, 329) as well as microvesicles (331) and connexion-43 gap 
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junctions (330). In both AML and MM, I found that mitochondria can be transferred 
by TNTs which were of malignant cell origin (Section 3.2.2 and 4.2.3). The TNT 
inhibitor CytoB was found to reduce mitochondrial transfer between BMSC and 
AML/MM cells. TNTs were visualised using fixed cell confocal microscopy and 
contained BMSC mitochondria. As the TNTs were of malignant cell origin, this 
shows that mitochondrial transfer is an active process in which AML/MM cells 
steal mitochondria from BMSC. As mentioned in section 6.2.1, a second paper 
has described the transfer of mitochondria from BMSC to AML blasts (349). 
However, in this paper the authors concluded that mitochondria were transferred 
via an endocytosis mechanism due to a reduction in mitochondrial transfer 
observed upon the addition of Dansylcadavarine. The authors didn’t assess the 
effect of CytoB or analyse the formation of TNTs. In my mitochondrial transfer 
assays, I found Dansylcadavarine had no effect on mitochondrial transfer levels 
however CytoB caused a reduction in mitochondrial trafficking (Figure 3.8 and 
3.10). As a result of these two publications, it suggests that mitochondria move 
from BMSC to AML blasts by a combination of TNT and endocytosis mechanisms. 
 
Mitochondria are not the only cellular component transported via TNTs. There 
have been a number of studies describing the movement of endosomes (360), 
lysosomes (361), autophagosomes (362), endoplasmic reticulum (363), 
microRNAs (364) and pro-survival cytokines (365). This poses the question - what 
else is moving between BMSC to AML/MM cells as well as the mitochondria? 
Malignant haematopoietic cells have the tendency to act as parasites and I 
believe once they dock with BMSC they will acquire anything that will aid their 
survival. It is therefore highly important to determine the extent of TNT material 
transfer between BMSC and AML/MM cells. Unfortunately, this was outside the 
scope of my PhD thesis but will hopefully be determined in the future.  
 
A recent study also showed that mitochondria can be transferred in the opposite 
direction from T-ALL (Jurkat) cells to BMSC, which also occurs through TNTs 
(366). This was shown to reduce ROS levels in the malignant cell, a result that is 
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in agreement with a study by Golan and colleagues which presented the transfer 
of mitochondria from HSCs to BMSC (351). This study also showed the transfer 
of mitochondria from HSCs to BMSC, although in this study the mitochondria were 
transferred via gap junctions. Mitochondria are a large source of intercellular ROS 
levels (367) and these levels are increased when mitochondria are dysfunctional 
(368). Therefore, mitochondria which are transferred to BMSC may be 
dysfunctional and their transfer may result in reduced ROS levels in the donor 
cell. It would be interesting to study whether AML/MM cells have the ability to 
transfer mitochondria to BMSC and whether these mitochondria are 
dysfunctional. This process may present a dysfunctional mitochondria recycling 
system which may aid malignant cell survival. 
 
6.2.3 Control mechanisms of mitochondrial transfer in AML/MM 
 
Mitochondrial transfer is becoming a critical part of the malignant phenotype. A 
full understanding of the mechanisms which underpin this biological phenomenon 
is therefore very important if this process is to be exploited therapeutically. In my 
thesis, I have presented controlling mechanisms of intercellular mitochondrial 
transfer from BMSC to both AML blasts and MM cells.  
 
Firstly, in AML I have shown that NOX2 located on the malignant cell stimulates 
mitochondrial transfer (Section 3.2.5 and 3.2.6). Superoxide generated by NOX2 
can increase oxidative stress in BMSC, causing the activation of PGC-1α and 
subsequent mitochondrial biogenesis. This process has been shown to be 
specific to AML cells as oxidative stress is not induced in BMSC cultured with 
non-malignant CD34+ cells. Mitochondrial transfer was reduced upon the addition 
of the NOX2 inhibitor DPI (in addition to knocking NOX2 down on AML blasts), 
which also induced apoptosis in AML blasts. NOX2 is most commonly found on 
professional phagocytes and is a transmembrane protein that transports 
electrons across plasma membranes reducing oxygen to superoxide (369). There 
are six other members of the NOX family (NOX1, 3, 4, 5 and DUOX1 and 2) which 
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are located on other cell types such as the colon, endothelium, kidney and thyroid 
cells (370). All seven members have a similar structure based around six 
transmembrane domains, two haem groups and a NADPH binding site on the 
COOH terminal (seen Figure 6.1). The crystal structure was only recently 
determined in 2017 (371) and is very similar to the long accepted predicted 
structure (369). Although the involvement of NOX2 in malignant mitochondrial 
transfer is most likely confined to AML (or CML if it occurs), other members of the 
NOX family could contribute to other mitochondrial transfer systems. For example 
NOX1 is highly expressed on colon cells (372) and colon cancers are known to 
have a high association with their microenvironment (355). This highlights a 
potential role for NOX1 in any intercellular mitochondrial transfer that may occur 
in this malignancy.  
 
Figure 6.1. The structure of NADPH oxidase family of enzymes. 
The predicted (left) (369) and the X-ray crystal structure (right) (371) of the NOX family of 
enzymes. The two structures are very similar with 6 transmembrane domains 2 haem groups. 
Electrons pass from NADPH to the haem groups (through FAD) and then reduce oxygen to 
superoxide. 
 
NOX2 may also play a role in the mechanism behind mitochondrial transfer from 
the BMM to HSCs under bacterial infection. NOX2 on monocytes/macrophages 
is crucial in the defence from bacterial infections and inactivity of this enzyme can 
lead to chronic granulomatous disease (CGD) (373). Superoxide generated by 
NOX2 monocytes/macrophages may also induce oxidative stress and 
mitochondrial biogenesis in BMSC. This may result in the trafficking of 
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mitochondria to HSCs, inducing cycling and the expansion of blood cells needed 
to fight the pathogen. However, this is still very much a hypothesis which requires 
further work. 
 
In addition to elucidating the mechanism behind mitochondrial transfer in AML, I 
have also determined the mechanism which can cause the transfer of 
mitochondria to MM cells. I have shown that CD38 located on the surface of MM 
cells form TNTs which dock with BMSC facilitating the movement of mitochondria 
(Section 4.2.4 and 4.2.5). CD38 is left behind on BMSC after the dissociation of 
the TNT and CD38 knockdown reduces the number of TNTs formed. CD38 has 
two known functions firstly, as an ectozyme catalysing the metabolism of the 
calcium messengers cyclic ADP-ribose and nicotinic acid adenine dinucleotide 
phosphate (374). Secondly CD38 functions as a cell surface receptor – the likely 
mechanism utilised in mitochondrial transfer. The X-ray crystallography structure 
of CD38 (375) is shown in Figure 6.2.  
 
 
 
Figure 6.2. X-Ray Crystallography structure of CD38. 
The structure of CD38 was determined in 2005 (375) and is presented in this figure. The left and 
red images are a 90˚ rotation of each other in the vertical axis. CD38 is made up of 8 alpha helices 
and 6 beta sheets. The C-terminal binds to the plasma membrane anchoring the protein.  
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As CD38 is found on the leading edge of the TNT and is deposited on the surface 
of BMSC after TNT dissociation, I believe that its role in mitochondrial transfer is 
as a receptor. However, in my thesis I was unable to determine the binding partner 
of CD38 on the surface of BMSC. CD38 has one known binding partner CD31 
(346), however CD31 is not expressed on BMSC (Figure 4.20) and is a known 
negative marker in the characterisation of BMSC (376). Therefore, there may be 
an unknown binding partner of CD38 present on the surface of BMSC. BMSC do 
express CD157 which is a homologue of CD38 (377), therefore there may be an 
association of CD38 with CD157 leading to TNT docking. Unfortunately, there 
was no time to assess CD157 and other possible factors as part of my thesis. 
 
The discovery of the role of CD38 in the MM mitochondrial transfer mechanism 
has highlighted an unknown role of this molecule. CD38 was initially thought to 
be only expressed on haematopoietic cells (378), however CD38 is known today 
to be expressed on a range of different tissues like brain, prostate, pancreas and 
kidney (377).  This opens up the possibility that CD38 may be involved in other 
mitochondrial transfer systems in other malignancies as well as non-malignant 
systems. CD38 has already been shown to mediate mitochondrial transfer from 
astrocytes to neurons after stroke (331). AML blasts have been shown to express 
CD38, albeit at lower levels than MM (379). It would be very interesting to test 
whether CD38 plays a role in the TNT formation shown between AML blasts and 
BMSC. If this were the case, it may pave the way for the use of the CD38 
monoclonal antibody Daratumumab to treat patients with AML.  
 
A common observation between the two malignant mitochondrial transfer 
systems described in my thesis is that chemotherapy drugs increase the level of 
mitochondrial transfer. Daunorubicin and Bortezomib, used in the treatment of 
AML and MM respectively, were shown to increase the level of mitochondrial 
transfer from BMSC by on average 2-fold (Figure 3.13 and 4.8). This presents a 
system where malignant cells can adapt to treatments they encounter in order to 
survive.  This is extremely interesting in the context of minimal residual disease, 
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where mitochondrial transfer may contribute to the survival of a small number of 
AML/MM cells in close proximity to BMSC within the bone marrow. This 
mechanism may lead to the patient relapse which is currently responsible for the 
current poor survival rates of AML and MM. Chemotherapeutics have been shown 
to induce oxidative stress in the bone marrow (380), which suggests that this 
stimulates mitochondrial transfer as per NOX2. In my results, I did not analyse 
the effect of oxidative stress in the mitochondrial transfer to MM cells. The effect 
of Bortezomib suggests that oxidative stress is also involved in this mechanism, 
albeit in an independent process to NOX2.  
 
Taken together, these malignant mitochondrial transfer mechanisms describe 
biological molecules that may be therapeutically targetable in the context of AML 
and MM. In addition, the mechanisms described may provide a molecular basis 
for the elucidation of other transfer systems where the trafficking of mitochondria 
has already been or will be described in the future. 
 
6.2.4 Therapeutically targeting mitochondrial transfer  
 
The overall aim of any cancer research project is to determine key biological 
processes and molecules which can be targeted therapeutically for the benefit of 
the patient. In my thesis, I have shown that in both AML and MM intercellular 
mitochondrial transfer from the BMM is a process that contributes to the survival 
and proliferation of these malignancies. Furthermore, I have highlighted the 
biological role of NOX2, PGC-1α and CD38 in the mitochondrial transfer process 
and present these as novel biological targets in the treatment of AML and MM - 
which may stop the flow of mitochondria. I have shown that current chemotherapy 
treatments increase the level of mitochondrial transfer (Figure 3.13 and 4.8), it is 
therefore apparent that treatments targeting mitochondrial transfer could be used 
in conjunction with lower doses of the current chemotherapy regimens to provide 
a more effective therapy. 
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In the AML mitochondrial transfer system, I have highlighted NOX2 and PGC-1α 
as molecules that contribute to the trafficking of mitochondria from BMSC (Section 
3.2.5 and 3.2.6). There may be a novel opportunity to target these therapeutically 
to treat AML and hopefully increase patient survival. In my thesis, I have used the 
commercially available DPI to inhibit NOX2 on the surface of AML and shown that 
induction of apoptosis is specific to malignant cells over non-malignant cells 
(Figure 3.18). However, DPI and the other commercially available inhibitor 
Apocymin are not isoform specific as they also inhibit NOX1, 3, 4 and 5 (381). 
Therefore, these compounds would be unsuitable to be used in the clinic. The 
only known NOX2 specific inhibitor is the small peptide NOX2-ds-tat, which has 
an IC50 for NOX2 inhibition of 0.74µM (382). However currently there are no 
clinical trials which use this compound in any disease, the only NOX inhibitor in 
clinical trials is the NOX1/4 inhibitor GKT137831 used to the treat primary biliary 
cholangitis (NCT03226067) and type 2 diabetes (NCT02010242). It would be very 
interestingly to test NOX2-ds-tat in in vitro and in vivo models of AML, specifically 
focussing on mitochondrial transfer. 
 
The second molecule that could be targeted in the AML mitochondrial transfer 
system is PGC-1α in BMSC. In my thesis, I specifically inhibited PGC-1α using 
shRNA (Section 3.2.7) however there is a chemical inhibitor of PGC-1α (SR-
18292) which was not tested (383). The clinical efficacy of this drug has not been 
examined and SR-18292 has currently not been used in any clinical trials to date. 
As PGC-1α is crucial to normal bodily homeostasis (through mitochondrial 
biogenesis) any treatments targeting PGC-1α in BMSC must be specific to avoid 
any of target effects. In addition, PGC-1α inhibition in BMSC may interfere and 
alter normal haematopoiesis disrupting the bone marrow further. For these 
reasons, I believe that NOX2 is the more favourable target in AML to inhibit the 
transfer of mitochondria from the BMM. 
 
Elucidation of the mitochondrial transfer system in MM highlighted the role of 
CD38 in the formation of the TNT (Section 4.2.4 – 4.2.6). Targeting CD38 may 
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reduce the levels of mitochondrial transfer, which could potentially lead to 
increased patient survival. Contrary to treating AML with NOX2 inhibitors, a 
specific CD38 antibody Daratumumab has been shown to induce MM apoptosis 
in the presence of the protective BMM (249). Early clinical trials using 
Daratumumab targeting CD38 have been shown to be well tolerated and clinically 
efficacious in early phase studies of the treatment of relapsed refractory MM 
(251). In addition, phase 3 clinical trials of anti-CD38 antibodies in MM therapy 
have demonstrated improvements in overall response rates and progression free 
survival when combined with chemotherapy (384). Further to this, Daratumumab 
has been FDA approved for the treatment of refractory MM in combination with 
bortezomib and lenalidomide (252). Although I didn’t use Daratumumab, my 
thesis results provide a further insight into potential mechanisms of action of 
CD38 antibodies in the treatment of MM - where pro-tumoral mitochondrial 
transfer is also inhibited. Therefore, the data I have presented here shows that 
CD38 inhibition in MM (using Daratumumab) also has the ability to inhibit 
mitochondrial transfer for clinical benefit.  
 
I have shown in my third results chapter that mitochondrial transfer can occur to 
non-malignant HSCs under stress stimuli (Section 5.2). It is therefore very 
important to consider this process when designing treatments targeting malignant 
mitochondrial transfer. Although I have not determined the control mechanisms 
in non-malignant transfer, there are likely to be similarities between the 
processes. Therefore, targeting specific mechanisms such as the NOX2 oxidative 
stress mechanism may also impair non-malignant mitochondrial transfer to HSCs 
which could make patients more susceptible to bacterial infections. 
 
6.3 Limitations of the Study and Further Work 
 
Despite the results obtained, as with any study there are limitations which should 
be considered. The number of primary patient samples in some experiments is 
limited, this is due to sample availability and sharing samples around a highly 
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active research group. However, I believe experiments using small numbers of 
primary cells outweighs equivalent experiments using cell lines. Likewise, in 
animal experimentation increased numbers of mice would give more statistically 
significant results. However, I chose to refine animal experimentations to use the 
minimum number of mice to generate a statistically significant result. 
 
Ideally, the isolation of primary BMSC could have been more specific. I cultured 
and expanded all adherent cells from the mononuclear cell fraction and 
characterised them as CD73, CD90 and CD105 positive BMSC - this population 
was therefore very heterogeneous. Different cells within the BMSC population 
could have transferred varying levels of mitochondria to malignant AML/MM cells. 
Enhanced characterisation of stromal cells within the bone marrow has led to the 
discovery of specific subtypes like CAR and Nestin GFP+ cells (discussed in my 
introduction section 1.2.3). It would be of interest to isolate these cells specifically 
and analyse mitochondrial transfer levels from these to malignant AML/MM cells.  
 
In the MM mitochondrial transfer system, I have shown that CD38 is crucial for 
the process and CD38 KD in MM xenograft models increases animal survival 
(Section 4.2.6). As discussed in section 6.2.4, the CD38 monoclonal antibody 
Daratumumab has been FDA approved for the treatment of refractory MM. 
Unfortunately, I was unable to obtain Daratumumab from Janssen during my PhD 
and was therefore unable to test the role of this drug in mitochondrial transfer. If 
in the future my research group could obtain Daratumumab, I would suggest 
further work should examine the effect of Daratumumab on the intercellular 
mitochondrial transfer which occurs in MM. In addition, I would examine whether 
CD38 is involved in the AML mitochondrial transfer system to determine whether 
Daratumumab could be a viable therapeutic to treat AML.  
 
Although I have elucidated parts of the mitochondrial transfer mechanisms in MM, 
there is still further work needed to fully understand this system. I was unable to 
determine the molecule on BMSC which CD38 binds to anchor the TNT formation. 
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The obvious candidate was CD31, however this is not expressed on the surface 
of BMSC. Therefore, there is either a novel binding partner of CD38 on the surface 
on BMSC or CD38 binds un-specifically with BMSC to facilitate the transfer of 
mitochondria. Further work is needed to address this issue.   
 
Finally, I have shown that LPS induced bacterial infections stimulates 
mitochondrial transfer from the BMM to non-malignant HSCs. Due to time 
constraints, I was unable to determine the mechanism behind this but hypothesise 
that NOX2 may play a part due to its essential role to bacterial infection. Hopefully, 
future work will determine if NOX2 is involved in the non-malignant mitochondrial 
transfer mechanism which I have shown to occur between the BMM and HSCs 
under bacterial infection. 
 
6.4 Concluding remarks 
 
Overall in my thesis I have shown that intercellular mitochondrial transfer occurs 
from BMSC to both AML and MM cells and this transfer can occur via TNTs. AML 
NOX2 superoxide stimulates PGC-1α in BMSC, which results in increased 
mitochondrial biogenesis and contributes to the pro-tumoral trafficking of 
mitochondria. In MM, CD38 on the surface of the malignant cell has the ability to 
form TNTs which dock with BMSC and allows the transfer of mitochondria. 
Inhibition of both these processes has been shown to induce apoptosis and 
increase the survival of mice which have been injected with AML/MM cells. In 
addition, I have shown that mitochondrial transfer is an already established 
process that can be hijacked by malignant haematopoietic cells. My work 
highlights the nature of mitochondrial transfer in the progression and survival of 
AML and MM. My thesis presents novel biological molecules which underpin pro-
tumoral mitochondrial transfer, which could be targeted therapeutically in the 
clinic to improve the survival of patients who are affected by AML and MM. 
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